# Peptpedia — Research Peptide Encyclopedia (Full Content) > Peptpedia is a comprehensive, citation-backed research peptide encyclopedia covering 42+ compounds with mechanisms of action, pharmacokinetics, peer-reviewed studies, and head-to-head comparisons — for educational and research purposes only. ## About This File This is the full-content version of the Peptpedia llms.txt index, intended for AI language models and automated research tools that benefit from rich context. For a curated index with short descriptions, see [/llms.txt](https://peptpedia.org/llms.txt). All content on Peptpedia is for educational and research purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment. --- ## Core Pages - [Browse All Peptides](https://peptpedia.org/browse): Full searchable directory of 42+ research peptides with filtering by category - [Peptide Comparisons](https://peptpedia.org/compare): Head-to-head comparison articles for peptide pairs - [Research Articles](https://peptpedia.org/research): In-depth mechanism and pharmacology research articles - [Peptide Categories](https://peptpedia.org/categories): Peptides organized by research application - [Peptide Classes](https://peptpedia.org/peptide-classes): Pharmacological class guides (GLP-1, GH secretagogues, etc.) - [Medical Review Board](https://peptpedia.org/medical-board): Credentialed expert reviewers - [Editorial Policy](https://peptpedia.org/editorial-policy): Content standards and review process - [Research Methodology](https://peptpedia.org/methodology): How data is sourced, cited, and rated --- ## Peptide Class Guides ### [GLP-1 Receptor Agonists & Incretin Mimetics](https://peptpedia.org/peptide-class/glp-1) Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of peptides and small molecules that mimic the incretin hormone GLP-1, which is secreted by intestinal L-cells in response to nutrient ingestion. The class has evolved from first-generation GLP-1-only agonists (Liraglutide, Semaglutide) to dual and triple receptor agonists (Tirzepatide, Retatrutide) and now small molecule oral agonists (Orforglipron). These agents represent the fastest-growing therapeutic peptide class in clinical development. **Peptides in this class:** - Semaglutide: Once-weekly GLP-1 agonist; Ozempic/Wegovy - Liraglutide: Once-daily GLP-1 agonist; Victoza/Saxenda - Tirzepatide: Dual GIP/GLP-1 agonist; Mounjaro/Zepbound - Retatrutide: Triple GIP/GLP-1/glucagon agonist; Phase 3 - Orforglipron: Oral non-peptide GLP-1 agonist; Eli Lilly - Survodutide: Dual glucagon/GLP-1 agonist for MASH - Cagrilintide: Long-acting amylin analog for CagriSema - Mazdutide: Dual GLP-1/glucagon agonist; China NDA accepted ### [Growth Hormone Secretagogues (GHRP & GHRH)](https://peptpedia.org/peptide-class/ghrp-secretagogues) Growth hormone secretagogues (GHS) are a class of peptides that stimulate the pituitary gland to release endogenous growth hormone (GH). The class is divided into two mechanistic subgroups: growth hormone-releasing hormone analogs (GHRH analogs), which act on GHRH receptors on somatotroph cells, and growth hormone-releasing peptides (GHRPs), which act on ghrelin receptors (GHSR-1a) to amplify GH pulse amplitude. Both subgroups work synergistically when combined, producing a supra-additive GH release. **Peptides in this class:** - Ipamorelin: Selective GHRP with minimal off-target hormone release - CJC-1295: Long-acting GHRH analog with DAC modification - Sermorelin: First 29 amino acids of GHRH; clinical GH secretagogue - GHRP-2: Potent synthetic GHRP; strong GH pulse stimulator - GHRP-6: Classic GHRP; notable appetite stimulation - Hexarelin: Potent GHRP with additional cardiac receptor activity - Tesamorelin: FDA-approved GHRH analog for HIV lipodystrophy ### [BPC Family & Tissue Repair Peptides](https://peptpedia.org/peptide-class/bpc-family) The BPC family and tissue repair peptide class encompasses endogenous and synthetic peptide sequences that promote healing of musculoskeletal structures, skin, mucosa, and neural tissue through mechanisms including angiogenesis stimulation, collagen synthesis, anti-inflammatory signaling, and stem cell mobilization. Key members include BPC-157 (derived from gastric juice), TB-500 (Thymosin Beta-4 fragment), and GHK-Cu (a tripeptide copper complex). These compounds are broadly studied in animal models for tendon, ligament, muscle, and gut repair. **Peptides in this class:** - BPC-157: Gastric peptide sequence; tendon and gut repair research - TB-500: Thymosin Beta-4 fragment; actin regulation and angiogenesis - GHK-Cu: Copper tripeptide; collagen synthesis and skin repair - LL-37: Human cathelicidin; antimicrobial and wound healing - KPV: Alpha-MSH tripeptide; anti-inflammatory gut research - TB-4 Fragment: N-terminal TB4 peptide; actin-binding focus ### [Thymosin Family & Immune-Modulating Peptides](https://peptpedia.org/peptide-class/thymosin-family) The thymosin family encompasses thymic peptides and related immune-modulating sequences that regulate components of the innate and adaptive immune system. The class includes thymic peptides (Thymosin Alpha-1, Thymulin) that promote T-cell differentiation, antimicrobial peptides (LL-37) that provide direct microbial killing and immunomodulatory signaling, and anti-inflammatory peptides (KPV, BPC-157) that suppress pathological inflammation through melanocortin and nitric oxide pathways. Many members are derived from endogenous proteins and decline in concentration with age. **Peptides in this class:** - Thymosin Alpha-1: Thymic peptide; T-cell maturation and antiviral immunity - Thymulin: Zinc-dependent thymic nonapeptide; T-cell differentiation - LL-37: Human cathelicidin; antimicrobial and immune signaling - KPV: Alpha-MSH tripeptide; anti-inflammatory and gut immunity - BPC-157: Gastric peptide; anti-inflammatory and organ protection ### [Melanocortin Receptor Peptides (MC1R–MC5R)](https://peptpedia.org/peptide-class/melanocortin) Melanocortin peptides are a class of endogenous and synthetic ligands that activate the five melanocortin receptor subtypes (MC1R–MC5R). Endogenous melanocortins include alpha-MSH, beta-MSH, and ACTH, all derived from the POMC precursor. Research peptides in this class—PT-141, Melanotan II, and KPV—were developed to achieve selective receptor activation for specific physiological effects: sexual function (MC3R/MC4R), skin pigmentation (MC1R), and anti-inflammatory activity (MC1R/MC3R). The class represents one of the most pharmacologically diverse peptide families. **Peptides in this class:** - PT-141: FDA-approved MC3R/MC4R agonist; Vyleesi for HSDD - Melanotan II: Broad melanocortin agonist; tanning, sexual function research - KPV: Alpha-MSH C-terminal tripeptide; anti-inflammatory ### [TRH Analogs & Neuroendocrine Regulatory Peptides](https://peptpedia.org/peptide-class/trh-analogs) TRH analogs and neuroendocrine regulatory peptides are a class of hypothalamic and pituitary-derived sequences that regulate the major endocrine axes: thyroid (TRH), reproductive (GnRH/Kisspeptin), and social-stress (Oxytocin). This class also includes neuropeptides with specialized regulatory roles—DSIP for sleep architecture regulation, and Semax as an ACTH-derived cognitive modulator. Members of this class are characterized by their small size, central nervous system activity, and roles as master regulatory molecules governing downstream hormonal cascades. **Peptides in this class:** - Kisspeptin: Master GnRH trigger; reproductive axis research - Oxytocin: Social bonding neuropeptide; FDA-approved for obstetrics - DSIP: Delta sleep-inducing peptide; sleep architecture research - Semax: ACTH analog; BDNF upregulation and neuroprotection (Russia) ### [Nootropic & Neurotropic Peptides](https://peptpedia.org/peptide-class/nootropic-peptides) Nootropic peptides are a loosely defined class of peptide sequences investigated for effects on cognition, anxiety, and neuronal survival. The class spans ACTH-derived fragments (Semax), immunomodulatory analogs repurposed as anxiolytics (Selank), angiogenesis-pathway potentiators (Dihexa), and complex brain-derived peptide mixtures (Cerebrolysin), with Oxytocin studied for social cognition. What unifies the class is not a shared receptor but a shared objective: modulating central nervous system function with peptide structures. The clinical evidence base is unusually stratified, ranging from drugs registered for decades in Russia (Semax, Selank) to compounds with only animal data (Dihexa). **Peptides in this class:** - Semax: ACTH analog; BDNF/TrkB upregulation and neuroprotection - Selank: Tuftsin analog; GABA-A modulation and anxiolytic research - Dihexa: HGF/c-Met potentiator; preclinical synaptogenesis research - Cerebrolysin: Brain-derived neurotrophic peptide mixture; stroke research - Oxytocin: Neuropeptide; social cognition and intranasal research ### [Mitochondrial & Longevity-Targeted Peptides](https://peptpedia.org/peptide-class/mitochondrial-peptides) Mitochondrial peptides represent a distinct frontier in peptide pharmacology: rather than targeting cell-surface receptors, these compounds act on the organelle that governs cellular energy production, oxidative stress, and apoptosis. The class includes mitochondria-derived peptides encoded in the mitochondrial genome itself (MOTS-c), inner-membrane-targeted tetrapeptides (SS-31/elamipretide), telomerase-modulating geroprotectors (Epithalon), and senolytic peptides that selectively clear senescent cells (FOXO4-DRI). In 2025, this class produced its first FDA approval, establishing mitochondrial medicine as a validated drug development direction. **Peptides in this class:** - MOTS-c: Mitochondria-derived peptide; AMPK activation and metabolism - SS-31: Cardiolipin-targeting elamipretide; FDA-approved as Forzinity - Epithalon: Pineal tetrapeptide; telomerase and geroprotection research - FOXO4-DRI: Senolytic peptide; disrupts FOXO4-p53 in senescent cells ### [Gut Health & Mucosal Repair Peptides](https://peptpedia.org/peptide-class/gut-health-peptides) Gastrointestinal peptides are a class defined by their site of action: the gut lumen, mucosa, and enteric signaling systems. The class spans gastric-juice-derived sequences with unusual stability in the GI environment (BPC-157), minimal anti-inflammatory melanocortin fragments studied in inflammatory bowel disease models (KPV), FDA-approved intestinotrophic hormones (Teduglutide), and endogenous antimicrobial effectors of mucosal immunity (LL-37). Adjacent compounds such as Larazotide, a tight-junction modulator evaluated in celiac disease trials, share this mucosal focus. The gut is also the one compartment where orally administered peptides can act locally without surviving systemic absorption, giving this class a distinct pharmacokinetic logic. **Peptides in this class:** - BPC-157: Gastric-stable pentadecapeptide; mucosal and gut repair research - KPV: Alpha-MSH tripeptide; PepT1-transported IBD anti-inflammatory - Teduglutide (GLP-2): FDA-approved GLP-2 analog; Gattex for short bowel syndrome - LL-37: Human cathelicidin; mucosal antimicrobial defense --- ## Peptide Profiles ### [BPC-157](https://peptpedia.org/peptide/bpc-157) BPC-157 is a synthetic pentadecapeptide derived from a protective protein found in gastric juice. It has been extensively studied for its potential regenerative and protective properties in various tissue types. **Key Findings:** - BPC-157 is cleared from circulation in approximately 15 minutes, yet its tissue repair signals persist for weeks, suggesting a hit-and-run pharmacological mechanism. - BPC-157 is one of very few peptides that remains stable in human gastric juice, giving it meaningful oral bioavailability in preclinical models. - BPC-157 promotes organized blood vessel formation through the Egr-1/NAB2 pathway, which acts as both an accelerator and a brake to prevent aberrant vessel growth. - Over 100 published preclinical studies have demonstrated protective and reparative effects of BPC-157 across tendon, muscle, bone, and gastrointestinal tissue. **Frequently Asked Questions:** - Q: What is BPC-157 and where does it come from? A: BPC-157 (Body Protection Compound-157) is a synthetic 15-amino-acid peptide derived from a protective protein found in human gastric juice. It was first characterized by Professor Predrag Sikiric and colleagues at the University of Zagreb in the early 1990s. The peptide does not occur naturally in… - Q: What makes BPC-157 unusual among research peptides? A: BPC-157's most distinctive property is its exceptional stability in gastric acid and resistance to enzymatic degradation. This stability allows it to be administered orally in animal models and retain bioactivity—a property almost unique among research peptides. Most peptides are degraded rapidly i… - Q: What are the primary research applications for BPC-157? A: The bulk of BPC-157 research has focused on tissue repair (tendon, muscle, ligament, bone), gastrointestinal protection (ulcer models, IBD models, gut-brain axis), wound healing acceleration, and neuroprotection. Secondary areas include cardiovascular protection and organ protection in toxicity mod… - Q: How does BPC-157 promote tissue repair? A: The most studied mechanisms include: upregulation of growth hormone receptors in fibroblasts (increasing sensitivity to healing signals), activation of the FAK-paxillin pathway (promoting cell adhesion and migration), modulation of the nitric oxide system through Src-Caveolin-1-eNOS phosphorylation… - Q: What is the 'Gene Expression Paradox' in BPC-157 research? A: The Gene Expression Paradox refers to the observation that BPC-157 is cleared from systemic circulation in approximately 15 minutes (mean elimination half-life in rats), yet its reparative effects persist for weeks. Researchers propose that the peptide's brief presence is sufficient to trigger a ca… ### [TB-500](https://peptpedia.org/peptide/tb-500) TB-500 is the N-terminally acetylated 17-23 fragment of thymosin beta-4 (Ac-LKKTETQ, CAS 885340-08-9), identified analytically in TB-500 product by HPLC/high-resolution MS (PMID 22962027). It is studied for tissue repair, cell migration, and blood vessel formation. Product content is not reliable: a 2023 analysis of TB500/TB1000 sold online found contents inconsistent with the label, including full-length 43-residue thymosin beta-4 in place of the heptapeptide (PMID 36482504). **Key Findings:** - TB-500 is one of the few peptides whose low molecular weight allows it to travel long distances through tissues and potentially affect injury sites far from the injection location. - A landmark Nature study showed TB-500 reduces heart attack damage by activating integrin-linked kinase, a survival pathway previously unconnected to healing peptides. - TB-500 works by sequestering G-actin monomers, effectively reprogramming cells to migrate toward wounds rather than simply dividing in place. - Research demonstrates TB-500 shifts macrophages from the inflammatory M1 type to the regenerative M2 type, accelerating the transition from damage control to tissue rebuilding. **Frequently Asked Questions:** - Q: What is TB-500? A: TB-500 is a synthetic peptide corresponding to a key fragment of Thymosin Beta-4 (Tβ4), a 43-amino-acid protein naturally present in nearly all nucleated cells. TB-500 contains the actin-binding domain of Tβ4 that drives the peptide's effects on cell migration and wound healing. The full Tβ4 protei… - Q: How does TB-500 promote tissue repair at the molecular level? A: TB-500's primary mechanism is sequestration of G-actin monomers—the building blocks of actin filaments. By binding to free G-actin, TB-500 modulates actin polymerization dynamics, which directly enables cell migration toward injury sites. Additionally, TB-500 activates integrin-linked kinase (ILK),… - Q: What is TB-500's cardioprotective mechanism? A: A landmark 2004 Nature study (PMID: 15565145) established that TB-500 activates integrin-linked kinase (ILK) in cardiac cells, which triggers downstream pro-survival signaling including Akt phosphorylation. In mouse myocardial infarction models, TB-500 reduced infarct size, decreased fibrosis, and… - Q: Why can TB-500 affect injury sites far from the injection point? A: TB-500's relatively low molecular weight and structural properties allow it to diffuse extensively through connective tissue and cross tissue planes more readily than larger proteins. Research has documented responses at anatomical sites distant from the injection location. This systemic distributi… - Q: What animal studies support TB-500's wound healing effects? A: A foundational 1999 study (PMID: 10469335) demonstrated Thymosin Beta-4 increases keratinocyte migration by 42% in scratch assays and enhances angiogenesis in wound beds. Subsequent studies showed improved wound closure, collagen organization, and reduced scarring. Research in cardiac models (Natur… ### [Ipamorelin](https://peptpedia.org/peptide/ipamorelin) Ipamorelin is a selective growth hormone secretagogue and ghrelin receptor agonist. It stimulates the release of growth hormone from the pituitary gland without significantly affecting cortisol or prolactin levels. **Key Findings:** - Ipamorelin is called the first truly selective growth hormone secretagogue because it stimulates GH release without measurably raising cortisol, prolactin, or ACTH at therapeutic doses. - Unlike most GHRPs, Ipamorelin preserves the natural pulsatile rhythm of growth hormone release rather than forcing a continuous elevation, maintaining normal feedback regulation. - Ipamorelin has only a handful of human studies, primarily pharmacokinetic trials and a discontinued Phase II for postoperative ileus, making its widespread popularity largely based on animal data. - In glucocorticoid-treated rats mimicking osteoporosis, Ipamorelin counteracted steroid-induced bone loss by enhancing bone formation without changing bone mineral density markers. **Frequently Asked Questions:** - Q: What makes Ipamorelin selective compared to other GHRPs? A: In the rat and swine characterization program (Raun 1998, PMID: 9849822), Ipamorelin released GH without the ACTH and cortisol rise that GHRP-6 and GHRP-2 produced in the same model; prolactin was unchanged by every secretagogue tested, so that part is not specific to Ipamorelin. No human study has… - Q: What human clinical data exists for Ipamorelin? A: Ipamorelin's human data is limited to two published pharmacokinetic/pharmacodynamic studies: a 1999 PK/PD study (PMID: 10496658) that documented dose-response relationships and peak GH at 30-40 minutes post-injection in human volunteers, and a completed Phase II clinical trial for postoperative ile… - Q: How does Ipamorelin preserve the natural pulsatility of GH secretion? A: Ipamorelin stimulates GH release in discrete pulses that clear from circulation relatively quickly (plasma half-life approximately 2 hours), allowing the pituitary to return to baseline between doses. This mirrors the natural pattern of GH secretion, which occurs in 4-6 pulses per day—predominantly… - Q: What's the difference between Ipamorelin and CJC-1295? A: They are not substitutes. Ipamorelin is a selective GHRP: it starts a GH pulse at the ghrelin receptor (GHSR-1a) and has a ~2-hour half-life. In the study that introduced it (Raun 1998, PMID: 9849822 — rat and swine, not human), ipamorelin released GH without the ACTH and cortisol rise seen with GH… - Q: What bone research has been done with Ipamorelin? A: Ipamorelin has been studied in two bone-related rodent models. A 1999 study (PMID: 10373343) showed increased longitudinal bone growth (tibial length) with no significant change in bone turnover markers (osteocalcin, BSAP)—suggesting growth through increased bone volume rather than remodeling. A 20… ### [CJC-1295](https://peptpedia.org/peptide/cjc-1295) CJC-1295 is a synthetic analog of growth hormone releasing hormone (GHRH) with a Drug Affinity Complex that extends its half-life significantly compared to native GHRH. **Key Findings:** - The Drug Affinity Complex modification allows CJC-1295 to covalently bond to serum albumin after injection, extending its half-life from minutes to 6 to 8 days. - A single injection of CJC-1295 with DAC can elevate IGF-1 levels for up to two weeks, a duration unmatched by any other GHRH analog studied in clinical settings. - CJC-1295 combined with a GHRP such as Ipamorelin or GHRP-6 produces 2 to 5 times more growth hormone than either peptide alone, due to activation of complementary pituitary pathways. - CJC-1295 exists in two distinct forms with vastly different pharmacokinetics: the DAC version acts for days, while Modified GRF 1-29 without DAC has a half-life of only 30 minutes. **Frequently Asked Questions:** - Q: What is the difference between CJC-1295 with DAC and without DAC? A: CJC-1295 with DAC (Drug Affinity Complex) has a lysine modification that covalently binds to serum albumin, extending its biological half-life from minutes to 6–8 days. This allows once-weekly dosing and creates sustained GH/IGF-1 elevation. Without DAC (Modified GRF 1-29), CJC-1295 behaves like na… - Q: What does the clinical evidence show for CJC-1295? A: A published Phase I/II dose-escalation study in healthy adults (PMID: 16352683; JCEM 2006) found a single CJC-1295 with DAC injection produced dose-dependent GH increases (up to 2–10× baseline) and IGF-1 increases (up to 1.5–3× baseline) lasting 6–7 days in 66 subjects. This is one of the few GHRH… - Q: How does CJC-1295 compare to Sermorelin? A: Both are GHRH analogs activating the same pituitary GHRHR, but with different pharmacokinetics. Sermorelin uses only the first 29 amino acids of GHRH without stability modifications, giving it a ~10-minute half-life requiring nightly injection to leverage peak nocturnal GH release. CJC-1295 with DA… - Q: What's the difference between CJC-1295 and Ipamorelin? A: They are not substitutes. CJC-1295 is a GHRH analog that amplifies GH at the GHRH receptor — about 30 minutes without DAC, 6–8 days with DAC. Ipamorelin is a selective GHRP that starts a GH pulse at the ghrelin receptor (GHSR-1a), with a ~2-hour half-life. In the study that introduced it (Raun 1998… - Q: Why is CJC-1295 often combined with Ipamorelin? A: CJC-1295 and Ipamorelin activate complementary receptor pathways. CJC-1295 acts on the GHRH receptor, while Ipamorelin acts on the ghrelin receptor (GHSR-1a)—both on the same pituitary somatotroph cells. These pathways synergize: activation of one primes the cell to respond more strongly to the oth… ### [Semax](https://peptpedia.org/peptide/semax) Semax is a synthetic peptide derived from adrenocorticotropic hormone (ACTH). It was developed in Russia as a nootropic and neuroprotective agent with applications in cognitive enhancement research. **Key Findings:** - Semax is derived from ACTH but has been engineered to retain cognitive effects while completely eliminating the steroidogenic activity of its parent hormone. - Semax has been approved in Russia as a prescription medication since the 1990s for stroke recovery and cognitive disorders, giving it more real-world clinical data than most research peptides. - Semax upregulates both BDNF and NGF simultaneously, a dual neurotrophic effect that is uncommon among nootropic compounds and may explain its broad cognitive benefits. - Unlike stimulant-based cognitive enhancers, Semax builds its nootropic effects over days to weeks through neuroplasticity mechanisms rather than acute neurotransmitter manipulation. **Frequently Asked Questions:** - Q: What is Semax and how is it related to ACTH? A: Semax is a synthetic heptapeptide derived from the ACTH(4-10) fragment, which is a region of adrenocorticotropic hormone known to influence memory and attention. Unlike parent ACTH, Semax has been modified (with an added Pro-Gly-Pro extension) to increase stability and to eliminate the adrenal-stim… - Q: Is Semax approved as a medicine anywhere? A: Yes. Semax has been registered as a pharmaceutical drug in Russia since 1994, where it is available as a nasal spray for indications including ischemic stroke recovery, cognitive impairment, optic nerve atrophy, and attention deficit. It is also approved in Ukraine. Outside Russia and Ukraine, it i… - Q: How does Semax cross the blood-brain barrier? A: Intranasal administration bypasses the blood-brain barrier via the olfactory nerve and trigeminal pathways, allowing direct delivery to the CNS within minutes. This is the primary route used in Russian clinical protocols. When administered subcutaneously, Semax must cross the blood-brain barrier th… - Q: What is BDNF and why does Semax's effect on it matter? A: Brain-Derived Neurotrophic Factor (BDNF) is a protein that supports the survival, growth, and differentiation of neurons and synapses. Low BDNF levels are associated with depression, cognitive decline, Alzheimer's disease, and poor neurological recovery after injury. Semax upregulates both BDNF and… - Q: How does Semax compare to Selank? A: Both Semax and Selank are Russian-developed neuropeptides approved domestically, but they differ in their primary focus. Semax is primarily nootropic/neuroprotective—enhancing cognition, BDNF, and protecting against brain injury. Selank is primarily anxiolytic—reducing anxiety and normalizing stres… ### [Selank](https://peptpedia.org/peptide/selank) Selank is a synthetic peptide analog of the endogenous tetrapeptide tuftsin. It was developed in Russia for its anxiolytic and nootropic properties and has been studied for effects on stress response and cognitive function. **Key Findings:** - Selank is a synthetic analog of the immune peptide tuftsin with an added Pro-Gly-Pro sequence that dramatically increases its stability and half-life in the body. - Selank is approved in Russia as an anxiolytic medication, making it one of very few peptides prescribed specifically for anxiety disorders in any country. - Research shows Selank modulates the expression of over 50 genes related to inflammation and immune response, suggesting effects far beyond simple anxiety reduction. - Selank influences GABA-ergic neurotransmission without the sedation, tolerance, or dependence typically seen with conventional GABA-enhancing anxiolytics like benzodiazepines. **Frequently Asked Questions:** - Q: What is Selank and where does it come from? A: Selank is a synthetic heptapeptide developed at the Institute of Molecular Genetics, Russian Academy of Sciences. It was created by extending the naturally occurring immune peptide tuftsin (Thr-Lys-Pro-Arg) with a Pro-Gly-Pro tripeptide sequence, which increases plasma stability and adds anxiolytic… - Q: How does Selank compare to benzodiazepines for anxiety? A: Selank and benzodiazepines both reduce anxiety, but through different mechanisms. Benzodiazepines act directly on GABA-A receptors, producing rapid sedation, muscle relaxation, and anxiolysis—but with dose-dependent cognitive impairment, tolerance, dependence, and withdrawal. Selank modulates GABA… - Q: What is tuftsin and why is it relevant to Selank? A: Tuftsin is a naturally occurring tetrapeptide (Thr-Lys-Pro-Arg) produced by the spleen and found on immunoglobulin G. It stimulates phagocytic activity of monocytes, macrophages, and granulocytes. Selank was created by adding Pro-Gly-Pro to tuftsin's C-terminus, which dramatically increases its pla… - Q: Is Selank approved as a medicine anywhere? A: Yes. Selank has been registered in Russia as an anxiolytic nasal spray (under the trade name 'Selank') for generalized anxiety disorder, neurasthenia, and adjustment disorders with anxiety since 2009. It is also registered in Ukraine. Outside these countries, it is not approved for any clinical use… - Q: What does Selank research show for immune function? A: Because Selank retains tuftsin's structural foundation, it maintains tuftsin-receptor interactions on immune cells. Studies show enhanced phagocytic activity in monocytes and macrophages, increased natural killer cell cytotoxicity, and modulation of cytokine production (notably IL-6). Research has… ### [GHRP-6](https://peptpedia.org/peptide/ghrp-6) GHRP-6 is a synthetic hexapeptide that stimulates growth hormone release through the ghrelin receptor. It was one of the first growth hormone releasing peptides developed. **Key Findings:** - GHRP-6 causes near-universal appetite stimulation through potent ghrelin receptor activation in the hypothalamus, an effect strong enough to confound metabolic research designs. - GHRP-6 was the first synthetic growth hormone secretagogue discovered, paving the way for the entire GHRP family including GHRP-2, Hexarelin, and Ipamorelin. - GHRP-6 raises cortisol and prolactin levels in addition to growth hormone, distinguishing it from more selective secretagogues and limiting its utility in isolated GH research. - Research shows GHRP-6 has cytoprotective effects on gastric mucosa independent of its GH-releasing activity, sharing unexpected overlap with gut-protective peptides like BPC-157. **Frequently Asked Questions:** - Q: What makes GHRP-6 unique compared to Ipamorelin and GHRP-2? A: GHRP-6 was one of the earliest synthetic GH secretagogues and is notable for producing the most pronounced appetite stimulation of any GHRP. This is because GHRP-6 has the highest intrinsic activity at hypothalamic ghrelin receptors controlling orexigenic (appetite-stimulating) neuropeptide release… - Q: Why does GHRP-6 increase appetite? A: GHRP-6 mimics ghrelin's action at the GHSR-1a receptor in the hypothalamus, specifically at neurons in the arcuate nucleus that release NPY (neuropeptide Y) and AgRP (agouti-related peptide)—powerful appetite-stimulating signals. Natural ghrelin rises before meals and triggers hunger through this e… - Q: Does GHRP-6 have cardioprotective effects? A: Preclinical evidence suggests yes. Studies in rodent ischemia-reperfusion models show GHRP-6 reduces infarct size by approximately 40%, improves left ventricular function, and activates cardioprotective PI3K/Akt signaling pathways—effects observed at doses not significantly elevating systemic GH. T… - Q: How does GHRP-6 compare to GHRP-2? A: Both are GHSR-1a agonists, but GHRP-2 produces greater GH release per microgram with less appetite stimulation and less cortisol/prolactin elevation compared to GHRP-6. GHRP-2 is generally preferred when maximum GH stimulation is desired with fewer off-target effects. GHRP-6 is preferred when appet… - Q: Does GHRP-6 affect the gastrointestinal tract? A: Yes. GHRP-6 activates ghrelin receptors in the gastrointestinal tract, accelerating gastric emptying, stimulating the migrating motor complex, and increasing gastric acid secretion. Research shows 30–50% improvement in gastric emptying in gastroparesis models. Additionally, GHRP-6 has been shown to… ### [GHRP-2](https://peptpedia.org/peptide/ghrp-2) GHRP-2 is a synthetic growth hormone secretagogue that stimulates GH release through the ghrelin receptor. It is considered one of the most potent GHRPs for GH stimulation. **Key Findings:** - GHRP-2 is among the most potent GHRPs for growth hormone stimulation on a per-microgram basis while producing substantially less appetite stimulation than GHRP-6. - Despite frequent claims that GHRP-2 deepens sleep, a placebo-controlled study found evidence against a role for the GHRP axis in human slow-wave sleep, even though deep sleep and the nocturnal GH pulse naturally coincide. - GHRP-2 maintains its GH-releasing effectiveness in elderly subjects, with only modest age-related decline compared to the dramatic reduction in natural GH secretion seen with aging. - GHRP-2 has been formally studied as a diagnostic tool for assessing pituitary GH reserve, giving it a clinical validation path distinct from most research peptides. **Frequently Asked Questions:** - Q: Is GHRP-2 more potent than GHRP-6? A: Yes, GHRP-2 produces greater GH release per microgram compared to GHRP-6 in most published studies—clinical data show 10–15× baseline GH elevations. Additionally, GHRP-2 produces less appetite stimulation than GHRP-6 (a moderate vs. near-universal hunger response) and has less cortisol and prolacti… - Q: Has GHRP-2 been approved for any medical use? A: Yes. GHRP-2 (under the pharmaceutical name Pralmorelin) is approved in Japan as a diagnostic agent for assessing pituitary GH reserve in adults suspected of GH deficiency. This makes GHRP-2 one of the few GHRPs with actual regulatory approval in any country. It is not approved for therapeutic GH re… - Q: How does GHRP-2 affect sleep quality? A: Despite popular claims that GHRP-2 deepens sleep, the controlled evidence does not support this. A placebo-controlled polysomnography study (PMID: 9612233) found evidence against a role for the growth-hormone-releasing peptide axis in human slow-wave sleep—GHRP administration did not meaningfully i… - Q: How does GHRP-2 compare to Hexarelin? A: Both are highly potent GHRPs, but Hexarelin tends to produce more cortisol and prolactin elevation, and more receptor desensitization (tachyphylaxis) with repeated dosing. GHRP-2 maintains more consistent GH response across repeated administrations and has less pronounced cortisol effects, making i… - Q: Can GHRP-2 be used to test pituitary function? A: Yes. In Japan, Pralmorelin (GHRP-2) is used as a pituitary function test—intravenous administration allows clinicians to measure peak GH response and assess the pituitary's GH reserve capacity. A robust GH response (typically > 9 ng/mL) suggests an intact somatotroph population, while a blunted res… ### [Hexarelin](https://peptpedia.org/peptide/hexarelin) Hexarelin is a synthetic growth hormone secretagogue and one of the most potent GHRPs. It has been studied for cardioprotective effects in addition to GH release properties. **Key Findings:** - Hexarelin protects heart tissue from ischemia damage through the CD36 receptor, a mechanism entirely independent of its growth hormone releasing activity. - Hexarelin is the most potent GHRP for GH release but uniquely suffers from significant desensitization after 4 to 6 weeks of continuous use, requiring cycling protocols. - In CD36 knockout mice, Hexarelin's cardioprotective effect is completely abolished, definitively proving its heart benefits depend on this scavenger receptor rather than GH elevation. - Hexarelin produces peak GH concentrations 20 to 30 percent higher than GHRP-2 and 40 to 50 percent higher than GHRP-6 at equivalent doses in comparative human studies. **Frequently Asked Questions:** - Q: What makes Hexarelin unique among GHRPs? A: Hexarelin is unique for two reasons: it is the most potent GHRP for GH release (producing 20–30% more GH than GHRP-2 at equivalent doses), and it has cardioprotective effects mediated through CD36 receptor activation in cardiac tissue—completely independent of GH release. A landmark study (PMID: 11… - Q: What is tachyphylaxis and why does Hexarelin cause it? A: Tachyphylaxis is a rapid decrease in response to a drug with repeated dosing. Hexarelin causes significant GH response diminishment after 4–6 weeks of continuous daily use—more pronounced than any other GHRP. The mechanism involves GHSR-1a receptor downregulation and increased hypothalamic somatost… - Q: How does Hexarelin protect the heart? A: Hexarelin activates the CD36 scavenger receptor on cardiac myocytes, triggering a pro-survival signaling cascade including PI3K/Akt activation, increased Bcl-2 (anti-apoptotic protein), and reduced caspase-3 activity. In mouse ischemia-reperfusion models, this produces approximately 50% reduction i… - Q: Does Hexarelin elevate cortisol? A: Yes, more so than other GHRPs. Hexarelin produces modest but measurable cortisol and prolactin elevations at standard research doses, mediated through ACTH and hypothalamic mechanisms. This is less pronounced than the full GHRP-6 hormonal profile but more than Ipamorelin or GHRP-2 at equivalent dos… - Q: How does Hexarelin compare to other GHRPs in potency? A: Published comparative studies rank Hexarelin as the most potent GHRP for GH stimulation, achieving peak GH concentrations 20–30% higher than GHRP-2 and 40–50% higher than GHRP-6 at equivalent doses. However, this potency advantage comes with the trade-off of more rapid tachyphylaxis and greater cor… ### [Sermorelin](https://peptpedia.org/peptide/sermorelin) Sermorelin is a synthetic analog of growth hormone releasing hormone (GHRH) containing the first 29 amino acids, which represent the active portion of the natural hormone. **Key Findings:** - Sermorelin held FDA approval as Geref for diagnosing and treating pediatric growth hormone deficiency from 1997 until the manufacturer discontinued it in 2008; the FDA determined it was not withdrawn for safety or effectiveness reasons. - Unlike exogenous growth hormone injections that suppress natural production, Sermorelin preserves pituitary function and the natural IGF-1 feedback loop, reducing the risk of excessive GH levels. - Sermorelin contains only the first 29 amino acids of the 44 amino acid GHRH molecule, yet this fragment retains full biological activity at the GHRH receptor. - Research shows Sermorelin can actually restore youthful GH secretion patterns in older adults over time, suggesting it may rejuvenate pituitary responsiveness rather than simply override it. **Frequently Asked Questions:** - Q: How does Sermorelin differ from synthetic (exogenous) GH? A: Synthetic GH directly replaces the hormone, bypasses the pituitary, and suppresses natural GH production via negative feedback—prolonged use can cause the pituitary to reduce its own GH output. Sermorelin stimulates the pituitary to produce GH through the natural GHRH receptor pathway, preserving t… - Q: Was Sermorelin actually FDA approved? A: Yes. Sermorelin (brand name Geref) received FDA approval for diagnosing and treating idiopathic growth hormone deficiency in children with short stature. It was commercially available in the United States from the 1990s until approximately 2008, when the manufacturer (Serono) withdrew it from the U… - Q: Why should Sermorelin be administered at bedtime? A: Endogenous GH secretion follows a circadian rhythm, with the largest pulse occurring during the first cycle of slow-wave (deep) sleep, approximately 60–90 minutes after sleep onset. By administering Sermorelin at bedtime, the GHRH receptor stimulation coincides with this natural peak, amplifying ra… - Q: How does Sermorelin compare to CJC-1295? A: Both are GHRH analogs activating the same pituitary receptor, but with very different pharmacokinetics. Sermorelin has a ~10–20 minute half-life, requiring daily injection and producing acute GH pulses. CJC-1295 with DAC has a 6–8 day half-life (due to albumin binding), enabling weekly dosing and s… - Q: Can Sermorelin restore pituitary function in older adults? A: Research suggests yes, partially. A 1993 JCEM study by Corpas et al. (PMID: 8421077) found that continuous GHRH infusion increased overall GH and IGF-I levels in elderly men, demonstrating the aging pituitary retains capacity to respond to sustained GHRH stimulation. This supports a 'pituitary exer… ### [PT-141](https://peptpedia.org/peptide/pt-141) PT-141 (Bremelanotide) is a synthetic peptide that acts on melanocortin receptors. It was developed from the tanning peptide Melanotan II and has been studied for sexual dysfunction. **Key Findings:** - PT-141 is the only FDA-approved peptide for sexual dysfunction, marketed as Vyleesi for treating hypoactive sexual desire disorder in premenopausal women. - PT-141 works through melanocortin-4 receptors in the brain rather than through vascular mechanisms, making it fundamentally different from PDE5 inhibitors like sildenafil. - PT-141 was originally discovered as a side effect during Melanotan II tanning research, when male subjects unexpectedly reported spontaneous erections during clinical trials. - Because PT-141 acts centrally on desire pathways rather than on blood flow, it is effective in populations where vascular-based treatments fail, including some forms of psychogenic dysfunction. **Frequently Asked Questions:** - Q: What is PT-141 (Bremelanotide) and how does it differ from Viagra? A: PT-141 (brand name Vyleesi) is an FDA-approved cyclic peptide that activates melanocortin-3 and melanocortin-4 receptors in the hypothalamus and limbic system—the brain regions governing desire and arousal. Viagra (sildenafil) and Cialis (tadalafil) inhibit PDE5 to enhance blood flow in peripheral… - Q: Was PT-141 actually FDA approved? A: Yes. Bremelanotide (PT-141) received FDA approval in June 2019 under the brand name Vyleesi for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. It is the second FDA-approved treatment for HSDD (after flibanserin/Addyi, approved in 2015) and the only one administere… - Q: How does PT-141 differ from Melanotan II? A: PT-141 was derived from Melanotan II by removing an amide group from the C-terminus, converting the parent cyclic structure into a metabolite that retains MC3R/MC4R activity while reducing the transient hypertension seen with Melanotan II. Both activate the same receptor pathways, but PT-141 has a… - Q: What were the Phase 3 trial results for PT-141 (Vyleesi)? A: Two Phase 3 randomized, double-blind, placebo-controlled trials (RECONNECT studies) enrolled 1,267 premenopausal women with HSDD. At the approved 1.75 mg subcutaneous dose, participants showed statistically significant improvements in satisfying sexual events per month (+0.5 events vs. +0.2 for pla… - Q: Does PT-141 work in men? A: Early Phase 1/2 studies examined PT-141 in men with psychogenic erectile dysfunction. Results showed significant improvement in erectile response at doses of 4–6 mg, suggesting MC3R/MC4R pathways contribute to male sexual function as well. However, PT-141 development in men was not pursued to regul… ### [Melanotan II](https://peptpedia.org/peptide/melanotan-ii) Melanotan II is a synthetic analog of alpha-melanocyte stimulating hormone. It was developed for research into tanning, sexual function, and appetite regulation. **Key Findings:** - Melanotan II is a non-selective melanocortin receptor agonist that simultaneously affects pigmentation, sexual function, appetite, and inflammation through MC1R through MC5R activation. - Melanotan II produces UV-independent tanning by directly stimulating melanocytes to produce eumelanin, the protective dark pigment, without requiring sun exposure. - The sexual arousal effects observed with Melanotan II directly led to the development of PT-141, a more targeted derivative that became the first FDA-approved peptide for sexual dysfunction. - Melanotan II has a notably broad side effect profile including nausea and facial flushing precisely because it lacks selectivity and activates all five melanocortin receptor subtypes. **Frequently Asked Questions:** - Q: What is the difference between Melanotan I and Melanotan II? A: Melanotan I (afamelanotide) is a linear peptide with MC1R selectivity, primarily affecting pigmentation. It has FDA/EMA approval (as Scenesse) for erythropoietic protoporphyria (EPP), a photosensitivity disorder. Melanotan II is a cyclic peptide with non-selective agonism across MC1R–MC5R, producin… - Q: How was PT-141 discovered from Melanotan II research? A: During Phase 1 tanning trials with Melanotan II at the University of Arizona in the 1990s, male subjects reported unexpected spontaneous erections and sexual arousal as a side effect. Researchers recognized this as evidence that MC3R/MC4R activation mediates sexual response. This serendipitous find… - Q: Is Melanotan II legal or approved for use? A: Melanotan II is not approved by the FDA, EMA, or any major regulatory agency for any clinical indication. It is classified as a research chemical in most jurisdictions. Its sale for human use is prohibited in many countries including the UK, Australia, Canada, and the European Union. The FDA has is… - Q: What side effects does Melanotan II cause? A: Due to its non-selective agonism across all five melanocortin receptors, Melanotan II has a broad side effect profile: nausea and vomiting (common, especially at higher doses), facial flushing, spontaneous erections/arousal regardless of intent, transient increases in blood pressure, appetite suppr… - Q: Can Melanotan II actually produce a tan without sun exposure? A: Yes, in research settings, subcutaneous Melanotan II administration has produced visible skin darkening without UV exposure by directly stimulating MC1R on melanocytes to increase eumelanin production. Studies document measurable melanin index increases within 2–4 weeks. However, the tanning produc… ### [GHK-Cu](https://peptpedia.org/peptide/ghk-cu) GHK-Cu is a naturally occurring copper complex of the tripeptide glycyl-L-histidyl-L-lysine. It has been extensively studied for wound healing, skin rejuvenation, and tissue remodeling. **Key Findings:** - A Broad Institute gene array analysis revealed that GHK-Cu modulates 4,128 genes representing roughly 32 percent of the entire human genome, making it one of the most broadly active signaling molecules known. - GHK-Cu simultaneously upregulates tissue repair genes while suppressing 54 genes linked to the metastatic phenotype in cancer cells, suggesting a programmed restoration of healthy gene expression. - GHK-Cu occurs naturally in human plasma but its concentration declines dramatically with age, dropping from approximately 200 ng/mL at age 20 to about 80 ng/mL by age 60. - The copper ion in GHK-Cu is not merely structural; it is essential for the peptide's enzymatic and gene-regulatory activity, and the free peptide without copper has significantly reduced biological function. **Frequently Asked Questions:** - Q: Why is copper essential for GHK peptide activity? A: The copper ion (Cu²⁺) in GHK-Cu is not merely structural—it is essential for the peptide's biological activity. Copper participates in multiple enzymatic processes including lysyl oxidase (collagen and elastin crosslinking), cytochrome C oxidase (energy metabolism), and superoxide dismutase (antiox… - Q: What is the significance of GHK-Cu modulating 4,128 genes? A: A 2012 study in Oxidative Medicine and Cellular Longevity (PMID: 22666519) used the Broad Institute's Connectivity Map database to analyze GHK-Cu's effects on human gene expression. The analysis found modulation of thousands of genes relevant to tissue repair, antioxidant defense, and neuroprotecti… - Q: Does GHK-Cu decline with age and does this matter? A: Yes. GHK-Cu plasma concentrations in humans are approximately 200 ng/mL at age 20 but decline to roughly 80 ng/mL by age 60—a ~60% reduction over adult life. This age-related decline parallels declining tissue repair capacity, reduced skin collagen density, and increased inflammatory gene expressio… - Q: Is GHK-Cu effective for skin aging when applied topically? A: In-vivo research has demonstrated GHK-Cu's wound healing effects. A 1993 study in the Journal of Clinical Investigation (PMID: 8227353) showed that GHK-Cu stimulated connective tissue accumulation in rat wounds, with approximately 70% increases in collagen deposition. Additionally, the 1988 FEBS Le… - Q: How does GHK-Cu compare to other regenerative peptides like BPC-157? A: GHK-Cu and BPC-157 are both regenerative peptides but with distinct mechanisms. GHK-Cu is naturally occurring in human plasma, primarily works through copper-mediated gene expression modulation, and has its strongest evidence in skin (topical) applications. BPC-157 is synthetic, works through the n… ### [Epithalon](https://peptpedia.org/peptide/epithalon) Epithalon is a synthetic tetrapeptide based on the natural peptide Epithalamin produced by the pineal gland. It has been studied for effects on telomerase activity and longevity. **Key Findings:** - Epithalon is one of the only known compounds to activate telomerase in human somatic cells, producing 2 to 3 fold increases in telomerase expression and measurable telomere elongation in vitro. - Rodent lifespan studies spanning decades at the St. Petersburg Institute showed Epithalon-treated animals lived 10 to 25 percent longer while exhibiting delayed onset of tumors and immune decline. - Epithalon restores pineal gland melatonin production in aging organisms by up to 100 percent toward youthful levels, potentially counteracting age-related circadian rhythm disruption. - Despite being just four amino acids long, Epithalon has been shown to overcome the Hayflick limit in treated fibroblast cultures, allowing cells to divide beyond their normal replicative threshold. **Frequently Asked Questions:** - Q: What is the relationship between Epithalon and telomeres? A: A 2003 Bulletin of Experimental Biology and Medicine study (PMID: 12937682) found that Epithalon treatment produced 2.4-fold increases in telomerase activity (measured via TRAP assay) and approximately 33% longer telomeres in human fetal fibroblast cultures. Treated cells also exceeded the Hayflick… - Q: What is Epithalamin and how does Epithalon relate to it? A: Epithalamin is a natural polypeptide complex extracted from bovine pineal glands, studied extensively by Professor Khavinson's group for anti-aging properties. Epithalon is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) designed to represent the minimal active sequence of Epithalamin. Because Epithalam… - Q: What lifespan research has been done with Epithalon? A: Multiple animal studies from the St. Petersburg Institute of Bioregulation and Gerontology document lifespan extension with Epithalon treatment. Mouse studies showed 11–25% lifespan increase, with delayed tumor development and preserved immune function. Drosophila melanogaster studies showed approx… - Q: How does Epithalon affect melatonin levels? A: Studies in aging animals show Epithalon can restore nocturnal melatonin secretion by 50–100% toward levels seen in younger organisms. The mechanism involves restoration of pinealocyte function—the cells responsible for melatonin synthesis—through gene expression normalization and reduction of age-r… - Q: Is Epithalon safe for human use? A: No formal phase I safety trials have been published in peer-reviewed Western journals as of 2026. The published safety data comes from the same Russian research group that developed the compound. Short-term use in animal studies did not document significant toxicity, and the tetrapeptide's small si… ### [LL-37](https://peptpedia.org/peptide/ll-37) LL-37 is a human cathelicidin antimicrobial peptide that plays a crucial role in innate immunity. It has broad-spectrum antimicrobial activity and immunomodulatory properties. **Key Findings:** - LL-37 is the only cathelicidin antimicrobial peptide produced by humans, making it a cornerstone of the innate immune system's first line of defense against pathogens. - LL-37 kills bacteria by physically disrupting their cell membranes through electrostatic attraction, a mechanism so fundamental that bacteria have extreme difficulty developing resistance to it. - LL-37 can penetrate and destroy established bacterial biofilms that are impervious to conventional antibiotics, reducing biofilm mass by 50 to 80 percent in laboratory models. - Beyond antimicrobial activity, LL-37 serves as a bridge between innate and adaptive immunity by promoting dendritic cell maturation and enhancing antigen presentation to T cells. **Frequently Asked Questions:** - Q: How does LL-37 kill bacteria without causing the same resistance problems as antibiotics? A: LL-37 kills bacteria by physically disrupting their cell membranes through electrostatic attraction—the peptide's positive charges bind to negatively charged phospholipids in bacterial membranes, causing pore formation and cell lysis. This mechanism targets the fundamental physical structure of bac… - Q: Why does vitamin D affect LL-37 levels? A: The LL-37/hCAP18 gene has a vitamin D response element (VDRE) in its promoter region, meaning it is directly transcriptionally regulated by the active form of vitamin D (1,25-dihydroxyvitamin D3). When vitamin D binds to the vitamin D receptor (VDR) in immune cells and epithelial cells, it upregula… - Q: What role does LL-37 play in wound healing? A: LL-37 promotes wound healing through multiple mechanisms: it stimulates keratinocyte migration via EGFR (epidermal growth factor receptor) transactivation, accelerating re-epithelialization of wounds; promotes angiogenesis through VEGF upregulation and endothelial cell proliferation; and attracts m… - Q: Is there a relationship between low LL-37 and skin conditions? A: Yes. LL-37 expression is significantly dysregulated in several skin conditions. In rosacea, LL-37 is overexpressed and abnormally processed into fragments that trigger inflammation and vascular changes. In atopic dermatitis (eczema), LL-37 is underexpressed, contributing to increased bacterial colo… - Q: Can LL-37 address antibiotic-resistant bacteria? A: LL-37 demonstrates antimicrobial activity against drug-resistant organisms including MRSA (methicillin-resistant Staphylococcus aureus) and multidrug-resistant Gram-negative bacteria in vitro and in animal models. Because its mechanism (membrane disruption) differs fundamentally from antibiotics, i… ### [Thymosin Alpha-1](https://peptpedia.org/peptide/thymosin-alpha-1) Thymosin Alpha-1 is a peptide originally isolated from thymic tissue that modulates immune function. It is approved in several countries for immune deficiency conditions and as an adjuvant therapy. **Key Findings:** - Thymosin Alpha-1 is approved in over 35 countries for treating hepatitis B and C and as an immune enhancer, giving it one of the broadest regulatory footprints of any peptide worldwide. - Thymosin Alpha-1 enhances vaccine efficacy in immunocompromised populations including the elderly and HIV patients, where standard vaccines often produce inadequate immune responses. - Thymosin Alpha-1 simultaneously activates dendritic cells, natural killer cells, and both CD4+ and CD8+ T cells, orchestrating a coordinated immune response rather than boosting a single pathway. - Unlike most immunostimulants, Thymosin Alpha-1 also promotes immune tolerance through regulatory T cell induction, reducing the risk of autoimmune overactivation. **Frequently Asked Questions:** - Q: How does Thymosin Alpha-1 differ from Thymosin Beta-4? A: Despite the similar name, these are completely distinct peptides. Thymosin Alpha-1 (28 amino acids) is a thymic hormone involved in T-cell maturation and immune activation—its primary applications are infectious disease and immune modulation. Thymosin Beta-4 (TB-500; 43 amino acids) is an actin-seq… - Q: In which countries is Thymosin Alpha-1 approved and for what? A: Thymalfasin (synthetic Thymosin Alpha-1; brand name Zadaxin, manufactured by SciClone Pharmaceuticals) is approved in 35+ countries. In China—the largest market—it is approved for chronic hepatitis B, chronic hepatitis C, lung cancer adjuvant, and as a vaccine adjuvant in immunocompromised patients… - Q: What is the evidence for Thymosin Alpha-1 in chronic hepatitis B? A: Meta-analysis of multiple RCTs shows that Thymosin Alpha-1 (1.6 mg SC twice weekly for 6–12 months) achieves HBeAg seroconversion in 36% of patients versus 19% in controls. Combination with interferon-alpha increases seroconversion to approximately 45–50%. The effect is mediated through restoration… - Q: How was Thymosin Alpha-1 evaluated during COVID-19? A: During COVID-19, several Chinese hospitals used Thymosin Alpha-1 as adjuvant therapy for severe COVID-19 based on its established immunomodulatory profile. A 2020 study in Clinical Infectious Diseases reported that Thymosin Alpha-1 treatment in severe COVID-19 patients reduced 28-day mortality from… - Q: How does Thymosin Alpha-1 work through Toll-like receptors? A: Thymosin Alpha-1 activates dendritic cells via TLR2 and TLR9 (Toll-like receptors 2 and 9) engagement. TLR9 normally recognizes bacterial and viral CpG-DNA motifs as 'danger signals.' TA1-induced TLR9 activation triggers MyD88-dependent signaling that produces IL-12, IFN-α, and TNF-α—cytokines esse… ### [DSIP](https://peptpedia.org/peptide/dsip) DSIP is a neuropeptide that was originally isolated from rabbit brain during slow-wave sleep. It has been studied for effects on sleep, stress response, and hormonal regulation. **Key Findings:** - DSIP crosses the blood-brain barrier through a saturable transport system, confirming it is actively transported into the brain rather than passively diffusing across. - Despite its name, DSIP does not simply induce sleep but rather normalizes disrupted sleep architecture, increasing slow-wave sleep in insomniacs while having minimal effect on normal sleepers. - DSIP demonstrates remarkable stress-protective properties by modulating the hypothalamic-pituitary-adrenal axis, reducing ACTH and cortisol responses to both physical and psychological stress. - DSIP has paradoxical stability characteristics: it is rapidly degraded by blood enzymes with a half-life of minutes, yet its sleep-normalizing effects persist for days to weeks after administration. **Frequently Asked Questions:** - Q: Does DSIP actually induce sleep? A: Despite its name, the evidence is nuanced. The original 1977 Monnier study showed that dialysate from sleeping rabbit brains (containing DSIP) could induce delta-wave sleep when infused into waking rabbits. However, subsequent controlled studies showed variable results. The current understanding is… - Q: What is delta sleep and why does it matter? A: Delta sleep (Stage 3 NREM sleep, also called slow-wave sleep) is the deepest phase of non-REM sleep, characterized by 0.5–2 Hz delta waves on EEG. It is the most physically restorative sleep phase: during delta sleep, growth hormone secretion peaks (~70% of daily secretion), tissue repair processes… - Q: How does DSIP have long-lasting effects despite a very short half-life? A: DSIP has a plasma half-life of only a few minutes due to rapid degradation by blood peptidases—yet behavioral effects in sleep normalization and HPA axis modulation persist for days to weeks after a single administration. This paradox is not fully explained. Proposed mechanisms include: DSIP-induce… - Q: What effect does DSIP have on cortisol and stress hormones? A: The controlled human evidence is weaker than often claimed. A controlled study (PMID: 7777652) found that DSIP did not significantly affect CRH- or meal-induced ACTH and cortisol secretion—indicating DSIP does not measurably blunt the human cortisol response, contrary to stress-protective effects s… - Q: What conditions might DSIP research be most relevant to? A: Based on its mechanism profile, DSIP research is most directly relevant to: insomnia characterized by reduced delta sleep; conditions with HPA axis dysregulation (burnout, chronic stress, PTSD); neuroendocrine disorders involving GH secretion rhythm disruption; and potentially pain conditions given… ### [AOD-9604](https://peptpedia.org/peptide/aod-9604) AOD-9604 is a modified fragment of human growth hormone (amino acids 176-191) that has been studied for its effects on fat metabolism without the growth-promoting effects of full GH. **Key Findings:** - AOD-9604 is the fat-metabolizing fragment of growth hormone containing only amino acids 176 to 191, engineered to stimulate lipolysis without any of GH's growth-promoting or diabetogenic effects. - AOD-9604 stimulates fat breakdown through beta-3 adrenergic receptor pathways rather than the growth hormone receptor, explaining why it does not raise IGF-1 or blood sugar levels. - AOD-9604 has never received drug approval in any country; its only regulatory recognition is an FDA GRAS designation as a food ingredient. Research interest has shifted to cartilage repair following a 2015 rabbit osteoarthritis study showing enhanced regeneration with intra-articular injection. - Clinical obesity trials of AOD-9604 showed statistically significant fat loss but the effect size was deemed insufficient for regulatory approval, despite confirming its safety and mechanism. **Frequently Asked Questions:** - Q: How does AOD-9604 differ from growth hormone? A: AOD-9604 contains only amino acids 176–191 of the 191-amino-acid human GH molecule—the C-terminal region associated with lipolytic activity. Full-length GH activates the GH receptor (GHR) and produces IGF-1 elevation, insulin resistance, tissue growth, and sodium retention. AOD-9604 acts through be… - Q: Is AOD-9604 approved anywhere? A: No. AOD-9604 has never received drug approval in any country — its only regulatory recognition is an FDA GRAS designation as a food ingredient. In Australia it is Schedule 4 (prescription-only, compounded), not TGA-approved. The obesity-targeted Phase 2b clinical trials (Monash University/Metabolic… - Q: What happened in the AOD-9604 obesity clinical trials? A: Several Phase 1 and Phase 2 trials were conducted in Australia and globally between 2001–2008. A 24-week Phase 2b trial enrolling over 500 obese subjects showed statistically significant reductions in body weight (~3–4 kg greater than placebo) and preferential visceral fat loss versus subcutaneous… - Q: Why is AOD-9604 classified as a GRAS ingredient in some contexts? A: AOD-9604 received 'Generally Recognized as Safe' (GRAS) status determination from a US FDA GRAS notification (GRN 000237) for use as a food ingredient at specified levels. This designation was based on its amino acid composition and the extensive safety data from clinical trials. However, the GRAS… - Q: How does AOD-9604 promote cartilage repair? A: The chondroprotective effects of AOD-9604 appear to be independent of its lipolytic mechanism. In vitro studies show AOD-9604 promotes chondrocyte proteoglycan synthesis (type II collagen and aggrecan production) and reduces MMP (matrix metalloproteinase) activity that degrades cartilage. In sheep… ### [Tesamorelin](https://peptpedia.org/peptide/tesamorelin) Tesamorelin is a synthetic growth hormone releasing hormone analog. It is FDA-approved for reducing excess abdominal fat in HIV-infected patients with lipodystrophy. **Key Findings:** - Tesamorelin is the only FDA-approved GHRH analog, specifically indicated for reducing excess abdominal fat in HIV patients with lipodystrophy and marketed as Egrifta. - Tesamorelin selectively reduces visceral fat by 15 to 18 percent while preserving subcutaneous fat, a targeted redistribution not achievable through caloric restriction alone. - Beyond fat reduction, Tesamorelin significantly lowers liver fat content and improves NAFLD markers, expanding its research relevance to hepatic steatosis treatment. - Unlike direct growth hormone injection, Tesamorelin stimulates the pituitary to produce GH naturally, maintaining physiological feedback regulation and avoiding supraphysiological hormone levels. **Frequently Asked Questions:** - Q: What is HIV-associated lipodystrophy and why does Tesamorelin help? A: HIV-associated lipodystrophy (HAL) occurs in approximately 40–50% of HIV patients on long-term antiretroviral therapy (ART), particularly protease inhibitors. It is characterized by visceral fat accumulation (often with visible abdominal protrusion), subcutaneous fat wasting from the face and extre… - Q: How is Tesamorelin different from synthetic GH? A: Tesamorelin is a GHRH (the hypothalamic hormone that tells the pituitary to make GH), not GH itself. It works upstream in the endocrine axis. This distinction matters clinically: Tesamorelin triggers natural pulsatile GH release governed by the pituitary's own feedback regulation, so GH levels rise… - Q: Is Tesamorelin being researched for non-HIV conditions? A: Yes. Researchers at Massachusetts General Hospital and elsewhere have investigated Tesamorelin for: (1) Non-alcoholic fatty liver disease (NAFLD)—a 2018 Lancet HIV study showed 35% reduction in liver fat fraction; (2) Mild cognitive impairment (MCI)—a 2018 JAMA Neurology trial showed preserved func… - Q: What are the side effects and limitations of Tesamorelin? A: Common side effects in clinical trials include injection site reactions (~25%), fluid retention/edema (~10%), and arthralgia (~10%). Because it elevates IGF-1 (within normal range), it is contraindicated in patients with active malignancies due to theoretical IGF-1-mediated tumor growth promotion.… - Q: Why is Tesamorelin significant compared to other GH secretagogues? A: Tesamorelin is unique because it has Phase 3 human clinical trial data and FDA approval—an evidence standard that separates it from most GH secretagogues in the research space. Unlike GHRP-based secretagogues (ipamorelin, GHRP-6, sermorelin), Tesamorelin's clinical evidence base comes from multiple… ### [Dihexa](https://peptpedia.org/peptide/dihexa) Dihexa is a synthetic peptide derivative of angiotensin IV that has been studied for potent nootropic and neuroprotective effects. It is reported to be extremely potent in promoting cognitive function. **Key Findings:** - Dihexa shows cognitive enhancement at picomolar concentrations, making it approximately ten million times more potent than brain-derived neurotrophic factor in some synaptogenesis assays. - Dihexa works through an entirely novel mechanism by potentiating hepatocyte growth factor at the c-Met receptor, a pathway involved in synapse formation rather than traditional neurotransmitter modulation. - In aged rats with induced cognitive deficits, Dihexa restored memory performance to levels comparable to healthy young animals through structural increases in dendritic spine density. - Dihexa increases dendritic spine density by 40 to 60 percent in treated brain regions, with electrophysiology confirming these new spines form functional synaptic connections. **Frequently Asked Questions:** - Q: How potent is Dihexa compared to other nootropics? A: Dihexa is reported to be active at picomolar concentrations in synaptogenesis assays—approximately 10,000–10,000,000-fold more potent than BDNF (brain-derived neurotrophic factor) in some in vitro measures, though this comparison involves different assay conditions and should not be taken as a dire… - Q: What is the HGF/c-Met pathway and why is it relevant to cognition? A: Hepatocyte Growth Factor (HGF) is a pleotropic cytokine that activates the c-Met tyrosine kinase receptor. In the brain, HGF/c-Met signaling promotes: dendritic spine formation and synaptogenesis; neuronal survival through PI3K/Akt and Ras/MEK/ERK pathways; hippocampal long-term potentiation (the c… - Q: Is Dihexa safe for human use? A: Safety data for human use does not exist in peer-reviewed form as of 2026. Animal studies at effective doses showed no overt toxicity, but this cannot be extrapolated to human safety. An important theoretical concern exists: c-Met is overexpressed in multiple human cancers (gastric, lung, colorecta… - Q: What is Dihexa's chemical classification? A: Dihexa (full name: N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) is technically a peptidomimetic—a small molecule designed to mimic peptide binding activity while having improved stability and bioavailability compared to peptides. Unlike true peptides, Dihexa is not degraded by peptidases, has a rela… - Q: How does Dihexa compare to other cognitive enhancement peptides like Semax? A: Dihexa and Semax both target neuroplasticity but through entirely different mechanisms. Semax works primarily through BDNF receptor (TrkB) modulation and immediate neurotransmitter effects (particularly dopamine and serotonin)—it has human clinical trial data from Russian studies and rapid-onset co… ### [SNAP-8](https://peptpedia.org/peptide/snap-8) SNAP-8 is a synthetic peptide designed to reduce wrinkles by modulating neuromuscular junction activity. It is an extension of the hexapeptide Argireline. **Key Findings:** - SNAP-8 is an octapeptide that mimics the N-terminal end of the SNAP-25 protein, competitively blocking the SNARE complex assembly needed for neuromuscular signal transmission. - Clinical studies show SNAP-8 reduces expression wrinkle depth by up to 63 percent over 28 days of topical application, offering a needle-free alternative to botulinum toxin. - Unlike botulinum toxin which requires injection and cleaves SNARE proteins enzymatically, SNAP-8 works topically through competitive inhibition without destroying the signaling machinery. - SNAP-8 specifically targets expression wrinkles caused by repetitive muscle contraction and has no effect on wrinkles caused by photoaging, gravity, or loss of skin elasticity. **Frequently Asked Questions:** - Q: How does SNAP-8 compare to Argireline? A: SNAP-8 (Acetyl Octapeptide-3) extends Argireline (Acetyl Hexapeptide-3) by two additional C-terminal amino acids. Structurally, the extra amino acids increase its binding specificity to the SNAP-25 region of the SNARE complex and improve molecular stability in cosmetic formulations. Manufacturer (L… - Q: Is SNAP-8 a 'topical Botox'? A: This comparison is common marketing but overstates the equivalence. Both SNAP-8 and botulinum toxin target neuromuscular transmission through SNARE complex interference, but the mechanism and magnitude differ significantly. Botulinum toxin is enzymatically active—it permanently cleaves SNAP-25, pro… - Q: How does the SNARE complex relate to wrinkle formation? A: The SNARE complex (comprising SNAP-25, syntaxin, and VAMP/synaptobrevin) is the molecular machinery that fuses synaptic vesicles to the neuromuscular junction membrane, releasing acetylcholine to trigger muscle contraction. Facial expression muscles contract repetitively throughout the day, and ove… - Q: What are the evidence limitations of SNAP-8 research? A: The SNAP-8 evidence base has important limitations researchers should understand. The most-cited clinical data comes from studies conducted or commissioned by Lipotec (the manufacturer)—creating potential bias. Study populations are typically small (10–50 subjects), mostly female, without placebo c… - Q: How long does it take SNAP-8 to show effects? A: The most referenced clinical study (28-day protocol, twice-daily application of 10% solution) showed measurable wrinkle depth reduction beginning at day 14, with maximal effects at day 28 (63% reduction in crow's feet depth). Effects are not permanent—they are maintained only with continued applica… ### [FOXO4-DRI](https://peptpedia.org/peptide/foxo4-dri) FOXO4-DRI is a senolytic peptide designed to selectively induce apoptosis in senescent cells by disrupting the FOXO4-p53 interaction. **Key Findings:** - FOXO4-DRI is a D-retro-inverso peptide, meaning its amino acid sequence is reversed and uses mirror-image D-amino acids, making it resistant to enzymatic degradation while maintaining binding activity. - FOXO4-DRI selectively induces apoptosis in senescent cells by disrupting the FOXO4-p53 interaction that keeps these damaged zombie cells alive, without harming healthy cells. - In aged mice, FOXO4-DRI treatment restored fur density, improved renal function, and increased physical activity levels, demonstrating functional rejuvenation through targeted senescent cell clearance. - FOXO4-DRI represents a peptide-based senolytic approach that is more targeted than small-molecule senolytics like dasatinib plus quercetin, which affect broader cellular pathways. **Frequently Asked Questions:** - Q: What are senescent cells and why target them? A: Senescent cells are cells that have permanently halted their cell cycle ('replicative arrest') but resist apoptosis—sometimes called 'zombie cells.' They accumulate with age in multiple tissues and secrete a pro-inflammatory cocktail called the Senescence-Associated Secretory Phenotype (SASP), cont… - Q: What is a D-Retro-Inverso peptide and why does it matter? A: Conventional L-amino acid peptides are rapidly degraded by proteases (half-life of minutes in biological fluids). D-Retro-Inverso (DRI) modification addresses this by: using D-amino acids (mirror images of natural L-amino acids) and reversing the sequence. The resulting peptide has a nearly identic… - Q: How does FOXO4-DRI differ from other senolytics like dasatinib + quercetin? A: FOXO4-DRI and dasatinib+quercetin (D+Q) are both senolytic strategies but with different mechanism specificity. D+Q works by inhibiting pro-survival pathways (tyrosine kinases and Bcl-2 family) broadly—these pathways are also present in non-senescent cells, creating off-target effects. FOXO4-DRI th… - Q: Has FOXO4-DRI been studied in humans? A: As of 2026, no peer-reviewed human clinical trials on FOXO4-DRI have been published. The primary evidence comes from the 2017 Cell paper using aged and chemotherapy-treated mice, and subsequent mechanistic studies. The translation from mouse to human senolytic therapy has proven challenging for sev… - Q: What is the theoretical concern about senolytics and cancer? A: Senescent cells, despite their pro-inflammatory SASP, also suppress tumor progression in some contexts through 'senescence surveillance'—nearby immune cells recognize and destroy newly senescent cells, including pre-malignant cells undergoing oncogene-induced senescence. There is a theoretical conc… ### [MOTS-c](https://peptpedia.org/peptide/mots-c) MOTS-c is a mitochondria-derived peptide that plays a role in metabolic homeostasis. It is encoded in the mitochondrial genome and affects insulin sensitivity and cellular metabolism. **Key Findings:** - MOTS-c is one of the first peptides discovered to be encoded by mitochondrial DNA rather than nuclear DNA, revealing that mitochondria actively communicate with the rest of the cell through signaling molecules. - MOTS-c activates the AMPK pathway and enhances glucose uptake into skeletal muscle, closely mimicking the metabolic effects of physical exercise and earning it the label of exercise mimetic. - Circulating MOTS-c levels increase during exercise in humans, suggesting the peptide may naturally mediate some of the metabolic benefits attributed to physical activity. - MOTS-c has demonstrated the ability to prevent diet-induced obesity in animal models even without changes in food intake, by increasing energy expenditure and improving insulin sensitivity. **Frequently Asked Questions:** - Q: What makes MOTS-c unique among peptides? A: MOTS-c is the first identified peptide encoded in the mitochondrial genome (rather than nuclear DNA) that can translocate to the cell nucleus and regulate gene expression. This represents a fundamentally new type of intracellular signaling pathway: retrograde mitochondria-to-nucleus communication.… - Q: How does MOTS-c relate to exercise? A: A 2020 study found that circulating MOTS-c levels increase significantly during both aerobic and resistance exercise in humans, with levels correlating with exercise intensity. MOTS-c appears to be secreted by contracting muscle mitochondria in response to metabolic stress, and may mediate some of… - Q: How does MOTS-c activate AMPK and what does that mean? A: AMPK (AMP-activated protein kinase) is the cell's master energy sensor—activated when cellular energy (ATP) is low relative to AMP, it shifts metabolism toward energy production and away from energy storage. MOTS-c activates AMPK indirectly by inhibiting the folate-methionine cycle, which depletes… - Q: Does MOTS-c decline with age? A: Yes. A study measuring circulating MOTS-c in 781 individuals found that serum MOTS-c levels decline significantly with age, with older individuals having approximately 40% lower MOTS-c concentrations than young adults. The decline correlates with reduced muscle mass, impaired insulin sensitivity, a… - Q: What are the limitations of current MOTS-c research? A: MOTS-c research has several critical limitations. First, the peptide was only discovered in 2015, so the research base is less than 10 years old. Second, all efficacy data comes from mouse studies—no human clinical trials have been completed or published. Third, the pharmacokinetics of exogenous MO… ### [Kisspeptin](https://peptpedia.org/peptide/kisspeptin) Kisspeptin is a neuropeptide that plays a central role in regulating the reproductive hormone axis. It is the endogenous ligand for the GPR54 receptor. **Key Findings:** - Kisspeptin is the master switch for human puberty, and loss-of-function mutations in either the KISS1 gene or its GPR54 receptor cause a complete absence of sexual maturation. - Intravenous kisspeptin produces up to 50 fold increases in luteinizing hormone, making it the most potent known stimulator of the human reproductive hormone axis. - In IVF clinical trials, kisspeptin triggers final egg maturation with a significantly lower risk of ovarian hyperstimulation syndrome compared to the standard hCG trigger protocol. - Kisspeptin neurons integrate metabolic signals such as leptin and energy status with reproductive function, explaining why extreme dieting or intense athletic training can suppress fertility. **Frequently Asked Questions:** - Q: Why is Kisspeptin important for reproduction? A: Kisspeptin is the master switch for human reproduction at the hypothalamic level. Loss-of-function mutations in the KISS1 gene or the GPR54/KISS1R receptor cause a complete failure of puberty (idiopathic hypogonadotropic hypogonadism) and sterility. Kisspeptin neurons in the arcuate nucleus generat… - Q: What are the clinical applications of Kisspeptin? A: Current clinical and near-clinical applications include: (1) IVF triggering—Kisspeptin-54 (9.6 nmol/kg SC) achieves 91% oocyte maturation with reduced OHSS risk in high-risk IVF patients (PMID: 26030227); (2) Diagnostic testing for hypogonadotropic hypogonadism—Kisspeptin stimulation tests can diff… - Q: How does Kisspeptin regulate LH pulsatility? A: LH is secreted in pulses (approximately every 90–120 minutes in normally cycling adults) rather than continuously. This pulsatility is essential—continuous GnRH/LH stimulation actually causes receptor downregulation and gonadal suppression (the basis of GnRH agonist treatments for endometriosis and… - Q: What is the connection between Kisspeptin and sexual attraction? A: fMRI studies by Dhillo et al. at Imperial College London found that intravenous Kisspeptin administration in healthy men enhanced brain activation in limbic regions (amygdala, cingulate cortex) in response to sexual images, while simultaneously increasing positive emotional responses to non-sexual… - Q: How does body weight and nutrition affect Kisspeptin? A: Kisspeptin neurons directly receive inputs from leptin receptors (the adiposity signal). Adequate leptin levels are required for normal Kisspeptin neuron activity—leptin deficiency (from starvation or extreme weight loss) dramatically reduces Kisspeptin expression in the arcuate nucleus, suppressin… ### [TB4-FRAG](https://peptpedia.org/peptide/tb4-frag) TB4-FRAG (Ac-SDKP) is a tetrapeptide fragment of Thymosin Beta-4. It has been studied for anti-fibrotic and cardioprotective effects. **Key Findings:** - TB4-FRAG is naturally degraded by angiotensin-converting enzyme, which means ACE inhibitor medications unexpectedly raise its levels, potentially contributing to those drugs' cardioprotective benefits. - TB4-FRAG protects bone marrow stem cells during chemotherapy by inducing reversible cell cycle arrest in the quiescent G0 phase, shielding them from cytotoxic drugs that target dividing cells. - In cardiac fibrosis models, TB4-FRAG reduces collagen deposition by 40 to 60 percent through direct suppression of TGF-beta signaling, the master driver of pathological scarring. - Despite being only four amino acids derived from the 43 amino acid Thymosin Beta-4, TB4-FRAG has distinct anti-fibrotic and hematopoietic activities not shared by its parent molecule. **Frequently Asked Questions:** - Q: How is TB4-FRAG different from TB-500? A: TB4-FRAG (Ac-SDKP; 4 amino acids, ~446 Da) and TB-500 (the Ac-LKKTETQ actin-binding fragment, ~889 Da) are derived from the same parent protein but act through completely different mechanisms. Ac-SDKP is cleaved from the N-terminus of TB-4 by prolyl oligopeptidase; it acts primarily as an anti-fibr… - Q: Why do ACE inhibitors increase Ac-SDKP levels? A: ACE (angiotensin-converting enzyme) is the principal enzyme that degrades Ac-SDKP, cleaving it at the Asp-Lys bond. When ACE is pharmacologically inhibited by medications like lisinopril or enalapril, Ac-SDKP plasma levels rise 4–5-fold. This accumulation is now considered a potentially significant… - Q: How does Ac-SDKP protect bone marrow during chemotherapy? A: Ac-SDKP selectively induces G0 (quiescent) cell cycle arrest in pluripotent hematopoietic stem cells (HSCs)—the most primitive bone marrow progenitors. In G0, cells are not synthesizing DNA, making them resistant to S-phase-active chemotherapy agents (alkylating agents, antimetabolites). More diffe… - Q: What fibrotic conditions is Ac-SDKP being studied for? A: Ac-SDKP has demonstrated anti-fibrotic efficacy across multiple organ systems in preclinical models: cardiac fibrosis (post-MI remodeling and hypertensive cardiac fibrosis—40–60% collagen reduction), pulmonary fibrosis (bleomycin-induced lung fibrosis models), renal fibrosis (unilateral ureteral ob… - Q: What is the clinical evidence for TB4-FRAG (Ac-SDKP) in human cardiovascular disease? A: TB4-FRAG (Ac-SDKP) has indirect human evidence through the ACE inhibitor observation: ACE inhibitors that raise Ac-SDKP 4–5-fold produce well-documented reductions in cardiac fibrosis and left ventricular hypertrophy in hypertensive heart disease patients—effects that exceed what angiotensin II red… ### [Semaglutide (GLP-1)](https://peptpedia.org/peptide/semaglutide) Semaglutide is a long-acting GLP-1 (glucagon-like peptide-1) receptor agonist that mimics the incretin hormone GLP-1, regulating blood glucose levels, appetite, and body weight through multiple metabolic pathways. **Key Findings:** - Semaglutide features an engineered C18 fatty acid chain that binds to serum albumin, extending its half-life from the 2 minutes of native GLP-1 to approximately 7 days for once-weekly dosing. - The SELECT cardiovascular outcomes trial demonstrated semaglutide reduces major adverse cardiac events by 20 percent in overweight patients without diabetes, establishing cardiometabolic benefits independent of glucose control. - Semaglutide is the first GLP-1 receptor agonist available as both a weekly injection and a daily oral tablet, with the oral form requiring a specialized absorption enhancer called SNAC to survive stomach acid. - At the highest approved dose for obesity, semaglutide produces average weight loss of approximately 15 percent of body weight, rivaling the results of some bariatric surgical procedures. **Frequently Asked Questions:** - Q: What is the difference between Ozempic, Wegovy, and Rybelsus? A: All three contain semaglutide but differ in dose, formulation, and FDA-approved indication. Ozempic (0.25–2 mg SC weekly) is approved for type 2 diabetes and cardiovascular risk reduction in T2D patients. Wegovy (0.25–2.4 mg SC weekly) is approved for chronic weight management in obesity or overwei… - Q: How does semaglutide compare to tirzepatide for weight loss? A: Head-to-head data: The SURMOUNT-5 trial (2025) compared semaglutide 2.4 mg vs tirzepatide 10–15 mg in people with obesity—tirzepatide produced approximately 47% greater weight loss (20.2% vs 13.7% from baseline). Both are effective, but tirzepatide appears superior in direct comparison at maximum a… - Q: What does the SELECT cardiovascular trial mean for semaglutide? A: The SELECT trial (2023; PMID: 37952131) enrolled 17,604 adults with obesity/overweight without diabetes who had established cardiovascular disease. Semaglutide 2.4 mg weekly reduced major adverse cardiovascular events (MACE: CV death, MI, stroke) by 20% versus placebo over 3.3 years (HR 0.80, 95% C… - Q: Why does semaglutide cause nausea? A: GLP-1 receptors are expressed in the dorsal vagal complex (area postrema) in the brainstem—a region involved in nausea and vomiting control, and where the blood-brain barrier is incomplete. Semaglutide activation of these receptors is believed to cause nausea, vomiting, and decreased appetite simul… - Q: What is the current research status of semaglutide for neurological conditions? A: Semaglutide for neurological conditions is an active research frontier. GLP-1 receptors are expressed in the brain's substantia nigra, hippocampus, and cortex. Retrospective data shows patients on semaglutide for diabetes have lower rates of Parkinson's disease onset. Dedicated semaglutide trials i… ### [Liraglutide (GLP-1)](https://peptpedia.org/peptide/liraglutide) Liraglutide is a GLP-1 receptor agonist with 97% amino acid sequence homology to native GLP-1, modified with a palmitic acid chain for extended duration of action, used in research for diabetes and obesity. **Key Findings:** - Liraglutide was one of the first long-acting GLP-1 receptor agonists developed and paved the way for the entire therapeutic class now transforming diabetes and obesity treatment. - The LEADER cardiovascular outcomes trial demonstrated liraglutide reduces cardiovascular death by 22 percent in high-risk type 2 diabetes patients, establishing the cardioprotective class effect for GLP-1 agonists. - Liraglutide is approved for pediatric obesity in children aged 12 and older, making it one of the very few anti-obesity medications cleared for use in adolescents. - Liraglutide uses a C16 palmitic acid modification to bind albumin non-covalently, achieving a 13 hour half-life that requires daily dosing compared to semaglutide's weekly schedule. **Frequently Asked Questions:** - Q: How does liraglutide differ from semaglutide? A: Both are GLP-1 receptor agonists but differ in duration, efficacy, and dosing. Liraglutide (C16 palmitate modification) achieves 13-hour half-life requiring daily injection. Semaglutide (C18 fatty diacid modification) achieves 7-day half-life allowing weekly injection. For weight loss: semaglutide… - Q: What is the difference between Victoza and Saxenda? A: Both contain liraglutide but are dose-optimized for different indications. Victoza (0.6–1.8 mg/day SC) is FDA-approved for type 2 diabetes and cardiovascular risk reduction in T2D—at these doses the primary effects are glycemic control with modest weight loss (~3–5 kg). Saxenda (3.0 mg/day SC) is a… - Q: What was the significance of the LEADER trial for liraglutide? A: LEADER (2016; PMID: 27295427; N=9,340; median follow-up 3.8 years) was the first large RCT to demonstrate cardiovascular mortality benefit from any GLP-1 agonist: 22% reduction in cardiovascular death (HR 0.78, 95% CI 0.66–0.93) and 13% reduction in 3-point MACE. LEADER also showed 22% reduction in… - Q: Is liraglutide still used given semaglutide's advantages? A: Yes, liraglutide retains several clinical niches. It has the longest post-market safety record (14+ years), which matters for long-term safety comparisons. It is the only GLP-1 agonist with pediatric obesity approval for ages 12+. Some patients who cannot tolerate semaglutide's GI side effects tole… - Q: What renal benefits has liraglutide demonstrated? A: The LEADER trial included pre-specified renal outcomes and showed liraglutide reduced composite kidney disease progression (new macroalbuminuria, doubling of serum creatinine, ESRD, or renal death) by 22% vs. placebo. Renal benefits are attributed to: hemodynamic effects (renal vasodilation, reduce… ### [Teduglutide (GLP-2)](https://peptpedia.org/peptide/teduglutide) Teduglutide is a GLP-2 (glucagon-like peptide-2) analog that promotes intestinal mucosal growth and function, FDA-approved for short bowel syndrome research and treatment. **Key Findings:** - Teduglutide is the only GLP-2 receptor agonist approved by the FDA, specifically indicated for short bowel syndrome where it can reduce or eliminate the need for intravenous nutrition. - Unlike GLP-1 peptides that suppress appetite and promote weight loss, teduglutide promotes intestinal villus growth and increases the absorptive surface area of the remaining gut. - A single amino acid substitution from alanine to glycine at position 2 makes teduglutide resistant to DPP-4 enzyme degradation, extending its half-life from 7 minutes to about 2 hours. - Teduglutide has demonstrated the ability to reduce parenteral nutrition requirements by 20 percent or more in clinical trials, fundamentally improving quality of life for short bowel syndrome patients. **Frequently Asked Questions:** - Q: How does GLP-2 differ from GLP-1? A: GLP-1 and GLP-2 are both cleaved from proglucagon in intestinal L-cells and released postprandially, but activate completely different receptors with organ-specific distribution. GLP-1 receptors (GLP1R) are in the pancreas, brain, heart, kidneys, and GI tract—GLP-1 primarily controls glucose, appet… - Q: What is short bowel syndrome and why is parenteral nutrition problematic? A: Short bowel syndrome (SBS) occurs when the functional intestinal length is insufficient for adequate nutrient absorption, typically following surgical resection leaving less than ~200 cm of small intestine. Parenteral nutrition (PN)—IV delivery of nutrients directly into the bloodstream—compensates… - Q: Can teduglutide be used for conditions other than short bowel syndrome? A: Teduglutide is FDA-approved only for SBS as of 2026, but research is active in: (1) Crohn's disease—GLP-2 receptors are expressed in inflamed bowel and GLP-2 promotes mucosal healing; (2) Chemotherapy-induced mucositis—the intestinotrophic effects may protect GI mucosa from cytotoxic drug damage; (… - Q: Is there a concern about teduglutide promoting cancer? A: Yes, this is a recognized safety consideration. GLP-2 stimulates intestinal proliferation, which raises a theoretical concern about accelerating growth of colorectal polyps or carcinomas in susceptible individuals. The FDA label requires colonoscopy within 6 months before starting teduglutide and a… - Q: How does teduglutide (Gattex/Revestive) work to reduce parenteral nutrition requirements? A: Teduglutide promotes intestinal adaptation—the bowel's natural ability to compensate for lost segments by increasing the absorptive capacity of remaining tissue. GLP-2 receptor activation in the intestine: (1) Increases villus height and crypt depth (enlarging the absorptive surface area); (2) Redu… ### [Tirzepatide (GLP-1/GIP)](https://peptpedia.org/peptide/tirzepatide) Tirzepatide is a first-in-class dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptor agonist, providing synergistic metabolic effects for diabetes and obesity research. **Key Findings:** - Tirzepatide is the first dual GIP and GLP-1 receptor agonist approved for clinical use, combining two incretin pathways that were previously only targeted individually. - In the SURMOUNT-1 trial, tirzepatide at the 15 mg dose produced average weight loss of 22.5 percent, with over one third of participants losing at least 25 percent of body weight. - Head-to-head trials showed tirzepatide achieves approximately double the weight loss of semaglutide and brings 46 percent of diabetic patients to a normal HbA1c below 5.7 percent versus 19 percent with semaglutide. - The SUMMIT trial demonstrated tirzepatide reduces heart failure events by 38 percent in patients with obesity-related heart failure with preserved ejection fraction, expanding its indications beyond metabolism. **Frequently Asked Questions:** - Q: How does tirzepatide differ from semaglutide? A: Tirzepatide is a dual GIP/GLP-1 receptor agonist; semaglutide is GLP-1 only. The GIP receptor addition is the key mechanistic difference and is believed responsible for tirzepatide's superior efficacy. In the SURPASS-2 head-to-head trial: tirzepatide 15 mg achieved mean HbA1c reduction of 2.30% vs… - Q: What is the difference between Mounjaro and Zepbound? A: Both contain identical tirzepatide at the same doses (2.5–15 mg weekly SC) but differ in FDA-approved indication. Mounjaro (2022): approved for type 2 diabetes management. Zepbound (2023): approved for chronic weight management in adults with BMI ≥30 or ≥27 with comorbidities, and for obstructive s… - Q: What role does GIP receptor activation play in tirzepatide's effects? A: The GIP (glucose-dependent insulinotropic polypeptide) receptor was historically underestimated because GIP infusion in people with T2D shows minimal insulinotropic effect—suggesting T2D causes GIP receptor downregulation. Tirzepatide appears to restore GIP receptor sensitivity (a 'priming' effect)… - Q: What did the SUMMIT trial demonstrate for tirzepatide? A: SUMMIT (2025; PMID: 39555826) enrolled 731 patients with heart failure with preserved ejection fraction (HFpEF) and obesity—a condition with previously limited treatment options. Tirzepatide reduced the composite endpoint of CV death or worsening heart failure by 38% (HR 0.62, 95% CI 0.41–0.95) ver… - Q: Does tirzepatide have any non-metabolic research applications? A: Active research areas beyond diabetes/obesity include: (1) Obstructive sleep apnea (OSA)—FDA approved in 2024; SURMOUNT-OSA showed 63–73% reduction in apnea-hypopnea index; (2) Non-alcoholic steatohepatitis (NASH/MASH)—SYNERGY-NASH trial showed 74% MASH resolution in biopsied patients; (3) Polycyst… ### [Retatrutide (Triple Agonist)](https://peptpedia.org/peptide/retatrutide) Retatrutide is a first-in-class triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously, producing the most profound metabolic effects seen in obesity research to date. **Key Findings:** - Retatrutide is the first triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously, adding a thermogenic component absent from prior incretin therapies. - Phase 2 trials showed retatrutide achieves 24.2 percent mean weight loss at 48 weeks, the most profound pharmacological weight loss ever recorded, with weight curves still declining at study end. - Despite activating the glucagon receptor, which normally raises blood sugar, retatrutide produces net glucose lowering because GLP-1 and GIP receptor effects overwhelm the glucagon component. - Retatrutide reduces liver fat by over 80 percent in NAFLD patients, exceeding the hepatic benefits seen with both semaglutide and tirzepatide and positioning it as a potential NASH breakthrough. **Frequently Asked Questions:** - Q: How does retatrutide differ from tirzepatide? A: Retatrutide (triple agonist: GLP-1 + GIP + glucagon) adds glucagon receptor agonism to tirzepatide's dual agonism (GLP-1 + GIP). The glucagon receptor component adds thermogenesis—glucagon directly activates brown adipose tissue to increase energy expenditure—that is absent from tirzepatide. Phase… - Q: Does the glucagon receptor activation cause hyperglycemia? A: This is the central pharmacological paradox of triple agonists. Glucagon normally signals hepatic glucose production and raises blood sugar. However, in clinical trials retatrutide produces robust glucose lowering despite glucagon receptor activation. The GLP-1 receptor activation suppresses glucag… - Q: What is retatrutide's current development status as of 2026? A: Retatrutide completed Phase 2 trials in 2023 demonstrating record weight loss (24.2% at 48 weeks in obesity; 16.9% weight loss + 2.02% HbA1c reduction in T2D). Phase 3 trials are underway (TRIUMPH program) evaluating retatrutide for obesity and T2D. FDA approval is not expected before 2026–2027. Th… - Q: Why is retatrutide particularly interesting for fatty liver disease? A: Retatrutide reduces liver fat by over 80% in NAFLD patients—exceeding the hepatic fat reduction seen with semaglutide (~50–60%) or tirzepatide (~65–75%) in comparable Phase 2 populations. The glucagon receptor component is key: glucagon directly stimulates hepatic fatty acid oxidation and promotes… - Q: What is retatrutide's dosing protocol in Phase 3 trials? A: Based on Phase 2 data, retatrutide Phase 3 trials use a multi-step titration: starting at 2 mg SC weekly for 4 weeks, then escalating to 4 mg, 8 mg, and 12 mg at 4-week intervals. This slower titration vs. tirzepatide is partly driven by the glucagon receptor component, which may cause greater GI e… ### [KPV](https://peptpedia.org/peptide/kpv) KPV is a naturally-occurring tripeptide derived from the C-terminus of alpha-melanocyte stimulating hormone (α-MSH), demonstrating potent anti-inflammatory effects independent of melanocortin receptor activation. **Key Findings:** - KPV is derived from the last three amino acids of alpha-MSH but retains the anti-inflammatory activity while completely lacking the tanning and appetite effects of its parent hormone. - KPV reduces NF-kB nuclear translocation by up to 80 percent in some models by directly entering cells and inhibiting IkB kinase, bypassing the need for any cell surface receptor. - KPV maintains oral bioavailability and has shown efficacy in colitis models when taken by mouth, a rare property for peptides that are typically destroyed in the digestive tract. - KPV produces anti-inflammatory effects comparable in magnitude to corticosteroids in some models but without the immunosuppression, metabolic disruption, or tolerance development associated with steroids. **Frequently Asked Questions:** - Q: How does KPV differ from alpha-MSH? A: Alpha-MSH (α-melanocyte stimulating hormone) is a 13-amino acid neuropeptide that activates MC1R through MC5R (melanocortin receptors), producing tanning (MC1R), anti-inflammatory effects, and appetite suppression (MC3R/MC4R). KPV is just the last 3 amino acids (Lys-Pro-Val) of α-MSH's C-terminus.… - Q: Can KPV be taken orally? A: Preclinical data shows KPV retains biological activity when administered orally in colitis models—unusual for peptides which are typically hydrolyzed by GI proteases. The mechanism of KPV's GI stability is not fully characterized but may relate to its small size (3 amino acids), resistance to stand… - Q: What is the current clinical status of KPV? A: As of 2026, KPV remains in preclinical and early research stages with no Phase 3 clinical trials. The most advanced clinical work involves topical and intranasal formulations for skin inflammatory conditions and allergic rhinitis respectively. KPV's oral delivery advantages for IBD are compelling b… - Q: How does KPV's anti-inflammatory mechanism compare to steroids or NSAIDs? A: KPV, steroids, and NSAIDs target inflammation through different mechanisms: Corticosteroids act on glucocorticoid receptors to broadly suppress immune gene transcription (powerful but causes immunosuppression, metabolic effects, HPA axis suppression). NSAIDs inhibit COX-1/COX-2 enzymes to block pro… - Q: What does KPV research show for wound healing? A: KPV has demonstrated accelerated wound closure in multiple preclinical models through mechanisms that include: (1) anti-inflammatory effects reducing wound-area inflammation that impedes healing; (2) promotion of keratinocyte migration and proliferation; (3) reduction of pro-fibrotic signaling, pot… ### [Orforglipron](https://peptpedia.org/peptide/orforglipron) Orforglipron is an oral, non-peptide GLP-1 receptor agonist developed by Eli Lilly and approved by the FDA in April 2026 as Foundayo for chronic weight management. It enables once-daily oral dosing of a small molecule that mimics incretin hormone activity, without the food and water restrictions of oral peptide GLP-1 drugs. **Key Findings:** - Orforglipron (Foundayo) is the first oral non-peptide small molecule GLP-1 receptor agonist approved by the FDA, approved in April 2026 for chronic weight management, giving an oral alternative to injectable GLP-1 therapies. - In the ATTAIN-1 Phase 3 trial, the 36 mg dose produced 11.2 percent mean body weight reduction at 72 weeks in adults with obesity, with 54.6 percent of participants achieving at least 10 percent weight loss. - The ACHIEVE-1 trial demonstrated HbA1c reductions of 1.48 percentage points with orforglipron 36 mg in early type 2 diabetes, significantly exceeding placebo at 40 weeks. - Unlike oral semaglutide which requires fasting and limited water intake for absorption, orforglipron can be taken as a daily tablet without dietary restrictions due to its non-peptide small molecule structure. **Frequently Asked Questions:** - Q: How does orforglipron differ from injectable GLP-1 receptor agonists like semaglutide? A: Orforglipron is a non-peptide small molecule (not a large peptide like semaglutide), which means it can be taken as a simple daily oral tablet with no meal-timing restrictions, no fasting requirement, and no absorption enhancers. Oral semaglutide (Rybelsus) requires 30+ minutes fasted with only 4 o… - Q: What are the main side effects of orforglipron in clinical trials? A: GI side effects dominate (consistent with all GLP-1 agonists): nausea (38–45%), diarrhea (20–30%), vomiting (15–20%), and constipation (10–15%) at maintenance doses. The gradual 4-step titration (3→12→24→36 mg over 12+ weeks) is designed to allow GI receptor accommodation and substantially reduces… - Q: Is orforglipron approved for clinical use? A: Yes. On April 1, 2026 the FDA approved orforglipron as Foundayo (Eli Lilly) for chronic weight management in adults with obesity, or overweight with at least one weight-related condition, used together with a reduced-calorie diet and increased physical activity. It is the first oral non-peptide GLP… - Q: What distinguishes orforglipron from other oral antidiabetic pills? A: Orforglipron is mechanistically distinct from all other oral antidiabetic pills. Metformin reduces hepatic glucose output. SGLT-2 inhibitors (empagliflozin, dapagliflozin) reduce renal glucose reabsorption. DPP-4 inhibitors (sitagliptin) extend native GLP-1's half-life with modest effect. Orforglip… - Q: What clinical programs is orforglipron being evaluated in? A: Eli Lilly is running two major orforglipron Phase 3 programs: ACHIEVE (type 2 diabetes; multiple trials evaluating HbA1c reduction and cardiovascular outcomes) and ATTAIN (obesity and overweight; evaluating weight loss, cardiometabolic parameters). ATTAIN-1 is the primary obesity trial showing 11.2… ### [Survodutide](https://peptpedia.org/peptide/survodutide) Survodutide is a dual glucagon and GLP-1 receptor agonist developed by Boehringer Ingelheim and Zealand Pharma, investigated for obesity, type 2 diabetes, and metabolic dysfunction-associated steatohepatitis (MASH). **Key Findings:** - Survodutide produced up to 14.9 percent mean weight loss at 46 weeks in Phase 2 obesity trials, with completers achieving 18.7 percent reduction, exceeding results typically seen with GLP-1-only agonists. - In a Phase 2 MASH trial published in NEJM, 62 percent of participants on survodutide 4.8 mg achieved MASH improvement without worsening fibrosis compared to 14 percent on placebo at 48 weeks. - The glucagon receptor component uniquely increases energy expenditure and directly reduces hepatic fat through enhanced lipid oxidation, providing mechanistic advantages over pure GLP-1 receptor agonists. - The Phase 3 SYNCHRONIZE program includes a cardiovascular outcomes trial enrolling nearly 5,000 participants to evaluate whether survodutide reduces major adverse cardiovascular events in people with obesity. **Frequently Asked Questions:** - Q: How does survodutide differ from semaglutide and other GLP-1 agonists? A: Survodutide activates both the glucagon receptor (GCGR) and GLP-1 receptor simultaneously; semaglutide is GLP-1 receptor-only. The glucagon receptor component produces two additional benefits: (1) thermogenesis—glucagon stimulates brown adipose tissue and hepatic energy expenditure, increasing basa… - Q: What is the SYNCHRONIZE clinical trial program? A: SYNCHRONIZE is Boehringer Ingelheim's Phase 3 program for survodutide: SYNCHRONIZE-1 (obesity without T2D, N≈2,700), SYNCHRONIZE-2 (obesity with T2D, N≈1,200), and SYNCHRONIZE-CVOT (cardiovascular outcomes trial, N≈4,935 with established CV disease or CKD). All three are 76-week, randomized, placeb… - Q: Why does survodutide show particularly strong effects on liver disease (MASH)? A: MASH (metabolic dysfunction-associated steatohepatitis) involves both hepatic fat accumulation and progressive inflammation with fibrosis. Survodutide addresses multiple MASH pathways: glucagon receptor activation drives hepatic lipid oxidation to directly reduce liver fat; GLP-1 receptor activatio… - Q: What is survodutide's current regulatory status? A: As of April 2026, survodutide is in Phase 3 trials (SYNCHRONIZE program) but is not yet approved in any jurisdiction. Boehringer Ingelheim is developing it both for obesity/T2D and MASH. A separate MASH Phase 3 program is in planning based on the strong Phase 2 NEJM data. Regulatory approval is ant… - Q: What are the main side effects of survodutide? A: Survodutide's side effect profile overlaps with other GLP-1 agonists (nausea, vomiting, diarrhea, constipation) with the addition of effects from glucagon receptor activation: increased heart rate and hepatic glucose output at higher doses. In the Phase 2 obesity trial, GI adverse events were the m… ### [Cagrilintide](https://peptpedia.org/peptide/cagrilintide) Cagrilintide is a long-acting acylated amylin analog developed by Novo Nordisk, designed for once-weekly subcutaneous administration and studied both as monotherapy and in combination with semaglutide (CagriSema) for obesity and type 2 diabetes management. **Key Findings:** - CagriSema (cagrilintide plus semaglutide) produced 20.4 percent mean weight loss at 68 weeks in the REDEFINE 1 trial, with 60 percent of participants losing at least 20 percent of body weight, approaching bariatric surgery outcomes. - Cagrilintide is the first long-acting amylin analog to reach Phase 3 trials, with fatty acid acylation enabling once-weekly dosing compared to the three-times-daily dosing required by the older amylin analog pramlintide. - In the REDEFINE 2 trial in adults with obesity and type 2 diabetes, 73.5 percent of CagriSema-treated participants achieved HbA1c of 6.5 percent or below compared to 15.9 percent with placebo. - The combination targets two distinct appetite pathways: amylin receptors controlling hedonic eating behavior and GLP-1 receptors regulating homeostatic energy balance, producing additive weight loss beyond either mechanism alone. **Frequently Asked Questions:** - Q: What is the difference between cagrilintide and CagriSema? A: Cagrilintide is a standalone long-acting amylin analog targeting amylin receptors (calcitonin receptor + RAMPs). CagriSema is the fixed combination of cagrilintide 2.4 mg plus semaglutide 2.4 mg administered as co-injected weekly doses—not yet a single fixed-dose pen. REDEFINE 1 Phase 3 results (20… - Q: How does amylin signaling differ from GLP-1 signaling for appetite control? A: GLP-1 and amylin suppress appetite through entirely different neural circuits. GLP-1 acts primarily on the hypothalamic arcuate nucleus (POMC/NPY neurons) to regulate energy homeostasis and metabolic set-point—it's the 'background thermostat' for caloric balance. Amylin acts on the area postrema (b… - Q: Is cagrilintide related to pramlintide (Symlin)? A: Both are amylin analogs engineered to be soluble and stable (native amylin aggregates). Pramlintide (approved 2005): three-amino-acid substitution enabling solubility, 2-3× daily dosing before meals, approximately 2–3% weight loss in T2D. Cagrilintide: fatty acid acylation (like semaglutide's engin… - Q: What does the REDEFINE 1 trial mean for obesity pharmacotherapy? A: REDEFINE 1 (2025; N=3,417; 68 weeks; PMID: 40544433) is potentially the most impactful obesity trial since the original STEP and SURMOUNT programs. CagriSema's 20.4% mean weight loss on ITT analysis (22.7% on-treatment) means: ~60% of participants lost ≥20% body weight; ~40% lost ≥25%—approaching b… - Q: What is cagrilintide's mechanism of action in detail? A: Cagrilintide binds to amylin receptors—heterodimeric complexes of the calcitonin receptor (CTR) with receptor activity-modifying proteins (RAMP1 or RAMP3). Three receptor subtypes exist (AMY1, AMY2, AMY3) based on which RAMP is associated. Amylin receptor signaling activates both cAMP/PKA and MAPK… ### [Mazdutide](https://peptpedia.org/peptide/mazdutide) Mazdutide is a dual GLP-1 and glucagon receptor agonist based on an oxyntomodulin analog, developed by Innovent Biologics in partnership with Eli Lilly, and the first drug of its class to receive regulatory acceptance for obesity in China. **Key Findings:** - The GLORY-1 Phase 3 trial demonstrated 14.0 percent mean weight loss with mazdutide 6 mg at 48 weeks, with 49.5 percent of participants achieving at least 15 percent weight loss versus 2.0 percent with placebo. - Mazdutide is the first dual GLP-1 and glucagon receptor agonist to complete a positive Phase 3 clinical trial for obesity and have its New Drug Application accepted by a regulatory authority. - Phase 1b data showed rapid weight loss of 11.7 percent in just 12 weeks with the 9 mg dose, suggesting dose-dependent efficacy that may increase at higher doses being evaluated in GLORY-2. - Exploratory analyses showed significant reductions in liver fat content and transaminases, suggesting potential utility for metabolic dysfunction-associated steatotic liver disease beyond weight management. **Frequently Asked Questions:** - Q: How does mazdutide compare to survodutide, since both are GLP-1/glucagon dual agonists? A: Mazdutide (oxyntomodulin-based; Innovent/Eli Lilly) and survodutide (Boehringer Ingelheim) both activate GLP-1 and glucagon receptors but differ in peptide structure, GLP-1:glucagon receptor activity ratio, and target markets. Mazdutide clinical development has been China-focused (GLORY program). S… - Q: Is mazdutide approved for clinical use? A: As of April 2026, mazdutide is under regulatory review by China's NMPA (New Drug Application accepted February 2024 for chronic weight management based on GLORY-1 data). NMPA approval is anticipated in 2025–2026. Mazdutide has not been submitted to FDA or EMA. Global expansion would require additio… - Q: What populations have been studied in mazdutide clinical trials? A: Mazdutide has been studied primarily in Chinese and Han Asian populations, using Asian-specific BMI thresholds: ≥24 kg/m² with comorbidity or ≥28 kg/m² (lower than Western thresholds of ≥27 or ≥30). This matters because Asian populations have higher cardiometabolic risk at lower BMI than European p… - Q: How does mazdutide relate to oxyntomodulin? A: Oxyntomodulin is a 37-amino acid endogenous hormone secreted by intestinal L-cells postprandially. It is derived from proglucagon and naturally acts as both a GLP-1 receptor and glucagon receptor agonist—the same dual mechanism mazdutide is designed to mimic and enhance. Native oxyntomodulin has a… - Q: What clinical trial data supports mazdutide's efficacy for weight loss? A: The GLORY program Phase 3 data (China, Asian populations): GLORY-1 (N=248) showed mazdutide 4.5 mg/week achieved 11.5% weight loss and mazdutide 6 mg/week achieved 14.7% weight loss vs. 2.2% with placebo at 36 weeks. HbA1c improved significantly in T2D participants. GLORY-3 evaluated mazdutide spec… ### [Cerebrolysin](https://peptpedia.org/peptide/cerebrolysin) Cerebrolysin is a neuropeptide preparation derived from purified porcine brain proteins, consisting of low-molecular-weight peptides and free amino acids that mimic the action of endogenous neurotrophic factors. **Key Findings:** - A meta-analysis of nine randomized trials including 1,879 stroke patients demonstrated Cerebrolysin superiority on NIHSS at day 30 with a number needed to treat of 7.7 for early neurological improvement. - In Alzheimer's disease, pooled analysis of six placebo-controlled trials showed significant cognitive improvement with standardized mean difference of -0.40 and odds ratio of 4.98 for global clinical change at 6 months. - Cerebrolysin is registered in over 50 countries and has been used clinically for more than 50 years for neurological conditions, though it is not FDA-approved in the United States. - The low-molecular-weight peptide fraction (below 10 kDa) crosses the blood-brain barrier and mimics the actions of BDNF, NGF, and GDNF, providing multimodal neurotrophic support that recombinant proteins cannot achieve due to their large molecular size. **Frequently Asked Questions:** - Q: Is Cerebrolysin approved by the FDA? A: No—Cerebrolysin is not FDA-approved and is not legally available as a pharmaceutical in the United States. It is registered and used clinically in 50+ countries, including: EU countries (Austria, Germany), Russia, China, Ukraine, and most of Southeast Asia, South America, and the Middle East. In Eu… - Q: How is Cerebrolysin different from synthetic neuropeptides like Semax? A: Cerebrolysin is a complex biological mixture (~85% free amino acids + ~15% low-MW peptides <10 kDa) derived from enzymatic proteolysis of porcine brain proteins—containing hundreds of components. Semax is a single defined synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro). Cerebrolysin works thro… - Q: What are the main safety concerns with Cerebrolysin? A: Meta-analyses in stroke and Alzheimer's consistently show adverse event rates comparable to placebo. Known contraindications: epilepsy (seizure threshold concerns), severe renal impairment, and hypersensitivity to porcine-derived products. The theoretical prion transmission risk is often raised giv… - Q: What does the Cochrane evidence say about Cerebrolysin? A: Cerebrolysin has been reviewed in multiple Cochrane and systematic reviews: For acute ischemic stroke (Bath 2012, updated): possible benefit on neurological recovery, particularly in severe stroke patients; evidence quality rated low-moderate. For dementia/Alzheimer's (Chen 2013): modest cognitive… - Q: What are the neurotrophic mechanisms by which Cerebrolysin may work? A: Cerebrolysin's peptide fraction mimics neurotrophic factors through multiple mechanisms: (1) NGF (nerve growth factor) pathway activation—enhancing cholinergic neuron survival and promoting acetylcholine synthesis; (2) BDNF (brain-derived neurotrophic factor) pathway stimulation—supporting synaptic… ### [Follistatin 344](https://peptpedia.org/peptide/follistatin-344) Follistatin 344 is a naturally occurring glycoprotein that functions as a potent inhibitor of myostatin, activin, and other members of the TGF-beta superfamily. It has been extensively studied for its role in promoting skeletal muscle growth and as a gene therapy candidate for muscular dystrophy. **Key Findings:** - Transgenic mice overexpressing follistatin show 194-327% increases in muscle mass, substantially exceeding the approximately 100% increase from myostatin knockout alone due to simultaneous activin A inhibition. - A Phase 1/2a clinical trial in Becker muscular dystrophy demonstrated an average 11.5% improvement in six-minute walk test at 6 months (p = 0.02) with AAV1-FS344 gene therapy. - In nonhuman primates, AAV1-FS344 produced durable muscle hypertrophy lasting over 15 months with no disruption to reproductive hormones or cardiac tissue. - The FS-344 isoform was selected for clinical development because it has approximately 10-fold lower affinity for pituitary activin compared to FS-288, minimizing reproductive hormone disruption. **Frequently Asked Questions:** - Q: What is the difference between Follistatin 344 and Follistatin 288? A: Both isoforms are generated from the same gene by alternative splicing, differing in the C-terminal domain. FS-288 has a high-affinity heparan sulfate binding domain that causes it to bind tightly to cell surface proteoglycans—making it locally acting with very high affinity for pituitary activin r… - Q: How does Follistatin 344 compare to direct myostatin inhibitors? A: Follistatin 344 is more potent than myostatin-specific inhibitors because it simultaneously blocks both myostatin (GDF-8) and activin A, which both signal through the ActRIIB receptor to suppress muscle growth via Smad2/3 phosphorylation. Transgenic data: follistatin overexpression → 194–327% muscl… - Q: What has clinical research shown about Follistatin 344 gene therapy? A: The NCT01519349 Phase 1/2a trial in 6 Becker muscular dystrophy patients showed: high-dose cohort 6MWT improvement of +108 m and +29 m in two patients; average 11.5% improvement in 6MWT at 6 months (p=0.02); fibrosis reduced to 35–43% of baseline on biopsy; no serious adverse events; normal reprodu… - Q: Is Follistatin 344 used in competitive sports research? A: Follistatin 344 injection has been reported as a performance-enhancing substance in some elite athletic circles, prompting anti-doping research. The World Anti-Doping Agency (WADA) includes follistatin-derived peptides on its Prohibited List (S2: Peptide Hormones, Growth Factors, Related Substances… - Q: Why has Follistatin 344 shown greater muscle effects than pure myostatin inhibitors in clinical trials? A: Myostatin-specific antibodies (e.g., landogrozumab, domagrozumab) have consistently disappointed in clinical trials for muscular dystrophy and sarcopenia—achieving only 2–5% muscle mass gains despite strong myostatin inhibition. The explanation is that myostatin blockade triggers compensatory upreg… ### [IGF-1 LR3](https://peptpedia.org/peptide/igf-1-lr3) IGF-1 LR3 is a modified form of insulin-like growth factor-1 with an arginine substitution at position 3 and a 13-amino acid N-terminal extension, designed to have reduced binding to IGF-binding proteins, which increases its free, biologically active fraction and potency. **Key Findings:** - IGF-1 LR3 has markedly reduced affinity for IGF-binding proteins compared to native IGF-1, resulting in roughly 1.5- to 2-fold greater biological potency in vivo (PMID 8708565); contrary to popular claims it has no extended half-life and is actually cleared substantially faster than native IGF-1 in animal models because it cannot bind the protective IGFBP-3 complex (PMID 7693845). - The PI3K/Akt/mTOR pathway activated by IGF-1 LR3 simultaneously increases protein synthesis through p70S6K and decreases protein degradation through FOXO1 suppression, creating a dual anabolic mechanism. - In cell culture studies, Long R3 IGF-1 at 10 ng/mL is sufficient to induce significant myotube hypertrophy through Akt-dependent signaling, with effects blocked by myostatin co-expression. - Systemic Long R3 IGF-1 infusion in animal models suppresses endogenous GH, IGF-1, and IGFBP-3 through hypothalamic-pituitary negative feedback, highlighting the distinction between local and systemic administration effects. **Frequently Asked Questions:** - Q: How does IGF-1 LR3 differ from native IGF-1? A: IGF-1 LR3 has two key structural modifications vs. native IGF-1: (1) an Arg3 substitution (Glu→Arg at position 3) reducing IGFBP-3 binding by approximately 100-fold; (2) a 13-amino acid N-terminal extension (MFPAMPLLSLFVNGPRTLCGAELV... truncated) that further disrupts IGFBP interactions. The net ef… - Q: What is the primary signaling pathway activated by IGF-1 LR3? A: IGF-1 LR3 activates IGF-1R (a receptor tyrosine kinase) → IRS-1 (insulin receptor substrate-1) → two parallel pathways: (1) PI3K/Akt/mTORC1: phosphorylates p70S6K and inhibits 4E-BP1, driving ribosomal protein synthesis and muscle hypertrophy; (2) PI3K/Akt/FOXO1: phosphorylates FOXO1 preventing nuc… - Q: Why is IGF-1 LR3 prohibited in competitive sports? A: IGF-1 LR3 appears on WADA's Prohibited List under S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) and is prohibited both in- and out-of-competition. The prohibition reflects its potent anabolic potential in skeletal muscle. Detection methodology: immunopurification + mass spe… - Q: How does IGF-1 LR3 relate to growth hormone and insulin in the anabolic axis? A: GH (growth hormone) and IGF-1 form the GH/IGF-1 axis: GH released by the pituitary → stimulates the liver to produce IGF-1 → IGF-1 exerts most of GH's anabolic effects systemically. IGF-1 LR3, being an IGF-1 analog, bypasses pituitary GH secretion to directly activate IGF-1 receptors, making it dow… - Q: What are the hypoglycemia risks of IGF-1 LR3? A: IGF-1 can cause hypoglycemia through two mechanisms: direct IGF-1 receptor activation on glucose-dependent tissues (reducing hepatic glucose output and increasing peripheral glucose uptake), and cross-activation of the insulin receptor (which has ~100-fold lower affinity for IGF-1 than insulin, but… ### [Thymulin](https://peptpedia.org/peptide/thymulin) Thymulin is a zinc-dependent nonapeptide hormone produced by thymic epithelial cells that plays a central role in T-cell differentiation, immune regulation, and the neuroendocrine-immune axis. **Key Findings:** - Thymulin is the only known peptide hormone whose biological activity is absolutely dependent on equimolar zinc binding, making it a unique biomarker at the intersection of nutritional status and immune function. - Circulating thymulin levels decline progressively after puberty in parallel with thymic involution, and zinc supplementation in elderly individuals can restore thymulin activity to near-youthful levels. - Gene therapy delivering synthetic thymulin genes to the hypothalamus of aged animals has demonstrated restoration of thymic function markers and improved neuroendocrine parameters. - Thymulin treatment prevents overproduction of pro-inflammatory cytokines (IL-1-beta, IL-6, TNF-alpha) through NF-kB and p38 MAPK inhibition, revealing anti-inflammatory properties independent of its T-cell maturation role. **Frequently Asked Questions:** - Q: Why does thymulin require zinc to function? A: Thymulin (Pyr-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn) is a nonapeptide with a zinc-binding site formed by specific side-chain interactions. Zinc (Zn²⁺) coordinates with the peptide backbone and induces a conformational change in the N-terminal pyroglutamyl residue and adjacent residues that is required fo… - Q: How does thymulin relate to aging and immune decline? A: Thymulin is one of the most sensitive biomarkers of thymic aging. Active (zinc-bound) thymulin peaks in mid-childhood, declines through adolescence and early adulthood, and is nearly undetectable in blood after age 60—paralleling thymic involution where thymic epithelial tissue is progressively rep… - Q: What is the difference between thymulin and other thymic peptides like Thymosin Alpha-1? A: Thymulin (FTS, 9 aa) and Thymosin Alpha-1 (Tα1, 28 aa) are both thymic peptides but differ substantially. Thymulin: produced exclusively by thymic epithelial cells; absolutely zinc-dependent for bioactivity; primary function is T-cell differentiation (promotes CD4/CD8 double-negative → single-posit… - Q: What is the research status of thymulin gene therapy? A: Thymulin gene therapy is an emerging approach—rather than administering thymulin peptide directly (short half-life, zinc requirement), researchers deliver a synthetic thymulin gene using AAV vectors to enable sustained local production. Studies in aged animals show hypothalamic AAV-thymulin deliver… - Q: How does thymulin deficiency impact immune function in measurable clinical terms? A: Thymulin deficiency (from thymic involution, zinc deficiency, or congenital thymic aplasia) produces characteristic immunological changes: reduced naïve CD4+ and CD8+ T-cell output from the thymus; skewed T-cell receptor repertoire diversity (fewer distinct TCR clones); impaired T-cell responsivene… ### [Oxytocin](https://peptpedia.org/peptide/oxytocin) Oxytocin is a cyclic nonapeptide neurohormone produced in the hypothalamus and released by the posterior pituitary, playing critical roles in social bonding, maternal behavior, and neuromodulation of emotional and cognitive processes. **Key Findings:** - A meta-analysis of 3,941 individuals from 11 independent samples demonstrated a statistically significant association between OXTR gene variants and autism spectrum disorder risk. - Intranasal oxytocin significantly increased eye gaze to the facial region and improved emotion recognition in individuals with high-functioning ASD in controlled crossover studies. - Prairie vole studies established that natural variation in oxytocin receptor distribution in brain reward centers determines species-specific differences in pair bonding behavior. - Oxytocin (Pitocin) is one of the most widely used peptide drugs in clinical medicine, with FDA approval for labor induction and postpartum hemorrhage management. **Frequently Asked Questions:** - Q: Is oxytocin FDA-approved for any conditions? A: Yes—synthetic oxytocin (Pitocin, Syntocinon) is FDA-approved for: (1) induction and augmentation of labor at term; (2) control of postpartum uterine bleeding; (3) incomplete or inevitable abortion management. It is among the most used medications in obstetric practice worldwide. For all psychiatric… - Q: How is oxytocin administered in behavioral research? A: Intranasal (IN) administration is standard for behavioral research: 24–40 IU in 1–2 puffs per nostril, administered 30–45 min before behavioral tasks. Intranasal delivery is preferred over IV for research because it provides partial CNS access without the cardiovascular effects of IV administration… - Q: What has research shown about oxytocin and autism? A: Oxytocin and ASD research has evolved considerably. Early studies (Andari 2010, Guastella 2010) showed improved emotion recognition and gaze toward faces with acute IN oxytocin. However, the large SOARS-B trial (NCT01944046; N=290 children; 24 weeks) did not find significant improvement in social w… - Q: What is oxytocin's role in pain and stress beyond social bonding? A: Oxytocin has established analgesic, anxiolytic, and anti-stress properties beyond its social bonding effects. Mechanistically: oxytocin inhibits the HPA axis (cortisol), activates descending pain inhibitory pathways in the periaqueductal gray, and modulates amygdala reactivity to threatening stimul… - Q: How does oxytocin exert its uterotonic effects in obstetrics? A: Oxytocin's uterotonic mechanism: oxytocin receptors (OXTR) are G-protein coupled receptors expressed on myometrial smooth muscle cells. Receptor density increases dramatically near term—driven by rising estrogen levels that upregulate OXTR expression 200-fold from early to late pregnancy. OXTR sign… ### [Pramlintide](https://peptpedia.org/peptide/pramlintide) Pramlintide is a synthetic analog of the pancreatic hormone amylin, originally FDA-approved in 2005 as adjunctive therapy to mealtime insulin for type 1 and type 2 diabetes. Note: All Symlin formulations were discontinued from the US market in 2025 (NDA 021332). **Key Findings:** - Pramlintide is FDA-approved for adjunctive use with mealtime insulin in type 1 and type 2 diabetes, addressing the amylin deficiency that accompanies beta-cell dysfunction through three complementary mechanisms. - Clinical trials demonstrated that pramlintide reduces HbA1c by 0.3-0.68% and achieves placebo-corrected weight loss of 1.8-3.6 kg, uniquely opposing the weight gain typically associated with insulin intensification. - Pramlintide was engineered from native human amylin with three proline substitutions at positions 25, 28, and 29 to prevent the amyloid fibril formation that makes native amylin unsuitable for pharmaceutical use. - The satiety-promoting effects of pramlintide extend beyond diabetic populations to obese non-diabetic individuals, reducing ad libitum food intake and meal duration through area postrema and hypothalamic signaling. **Frequently Asked Questions:** - Q: How does pramlintide differ from GLP-1 receptor agonists like semaglutide? A: Both improve glycemic control and reduce appetite but through entirely different mechanisms. Pramlintide (amylin receptor): requires mealtime dosing; reduces postprandial glucagon (but NOT insulin secretion—no insulinotropic effect); slows gastric emptying; must be used with insulin (cannot replace… - Q: Why was pramlintide engineered rather than using natural amylin? A: Native human amylin self-aggregates into amyloid fibrils through a process involving beta-sheet formation at positions 20–29 of the peptide sequence—the same fibril structure found in pancreatic islet amyloid deposits in T2D (where amyloid may contribute to beta-cell toxicity). Pharmaceutical use o… - Q: What are the main side effects of pramlintide? A: Nausea is the dominant side effect: affects 25–48% of patients during initiation; typically resolves within 4–8 weeks with gradual titration. The 50% insulin dose reduction protocol at initiation is critical—failure to reduce insulin is the primary cause of severe hypoglycemia with pramlintide (ins… - Q: Why has pramlintide had limited clinical adoption despite FDA approval? A: Despite approval since 2005, pramlintide has had modest commercial success for several reasons: (1) Dosing complexity—3× daily injections separate from insulin injections, cannot be mixed with insulin; (2) Hypoglycemia risk—the mandatory 50% insulin dose reduction protocol is complex to manage; (3)… - Q: What is the approved dosing protocol for pramlintide in type 1 vs. type 2 diabetes? A: Pramlintide dosing differs by diabetes type. Type 1 diabetes: start at 15 mcg SC immediately before each major meal (≥250 kcal or ≥30g carbohydrate); titrate by 15 mcg increments every 3 days as tolerated to target of 30–60 mcg per meal. Concurrent mealtime insulin must be reduced by 50% at initiat… ### [SS-31](https://peptpedia.org/peptide/ss-31) SS-31 (elamipretide) is a synthetic, cell-permeable tetrapeptide that targets the inner mitochondrial membrane and binds the phospholipid cardiolipin. It is studied as a mitochondrial bioenergetics agent and was approved by the FDA in 2025 for Barth syndrome under the brand name Forzinity. **Key Findings:** - SS-31 (elamipretide) concentrates in the inner mitochondrial membrane and binds cardiolipin, a phospholipid found almost exclusively in that membrane, which underlies its description as a cardiolipin-directed mitochondrial agent. - By binding cardiolipin, SS-31 favors the normal electron-carrier function of cytochrome c over its pathological peroxidase activity and, in preclinical work, helps preserve cristae structure, supports the electron transport chain, and improves the efficiency of ATP synthesis. - On September 19, 2025 the FDA granted accelerated approval to elamipretide hydrochloride (Forzinity) to improve muscle strength in adults and children with Barth syndrome weighing at least 30 kg, the first approved therapy for that disorder. - Multiple late-stage trials did not meet their primary endpoints, including PROGRESS-HF in heart failure, the MMPOWER-3 Phase 3 trial in primary mitochondrial myopathy, the randomized portion of the TAZPOWER Barth syndrome trial, and ReCLAIM-2 in age-related macular degeneration. - In preclinical and biochemical work, SS-31 reduces mitochondrial reactive oxygen species output by improving electron transport efficiency and limiting electron leak rather than by acting as a direct free-radical scavenger. **Frequently Asked Questions:** - Q: What is SS-31 (elamipretide)? A: SS-31 is a synthetic, cell-permeable tetrapeptide with the sequence D-Arg-2',6'-dimethyltyrosine-Lys-Phe-NH2. It is the same molecule as elamipretide, and it has also carried the development codes MTP-131 and Bendavia, plus the brand name Forzinity. In PubChem it is listed as CID 11764719, with mol… - Q: How does SS-31 work at the molecular level? A: SS-31 localizes to the inner mitochondrial membrane and binds selectively and reversibly to cardiolipin, a phospholipid found almost exclusively in that membrane. The interaction combines electrostatic attraction between the peptide's positively charged residues (D-Arg and Lys) and cardiolipin's ph… - Q: Which SS-31 clinical trials failed or missed their primary endpoint? A: Several did. PROGRESS-HF (NCT02788747), a Phase 2 trial in heart failure with reduced ejection fraction, did not meet its primary endpoint of change in left ventricular end-systolic volume at 4 weeks. MMPOWER-3 (NCT03323749), a Phase 3 trial of 40 mg daily subcutaneous elamipretide in 218 participa… - Q: If the main trials missed their endpoints, why did some studies still report positive signals? A: A trial can miss its pre-specified primary endpoint while secondary, exploratory, or open-label analyses suggest a possible effect. These signals do not carry the same weight as a met primary endpoint, because they are not the test the study was designed to pass and often lack a concurrent randomiz… - Q: Is SS-31 (elamipretide) FDA-approved? A: Yes, but only for one narrow indication. On September 19, 2025 the FDA granted accelerated approval to elamipretide under the brand name Forzinity (elamipretide hydrochloride injection, NDA 215244, sponsored by Stealth BioTherapeutics) to improve muscle strength in adult and pediatric patients with… ### [CagriSema](https://peptpedia.org/peptide/cagrisema) CagriSema is an investigational fixed-dose combination of cagrilintide, a long-acting amylin analog, and semaglutide, a GLP-1 receptor agonist, co-administered once weekly and studied in Phase 3 trials for obesity and type 2 diabetes. **Key Findings:** - CagriSema is a two-peptide combination product, not a single molecule: the amylin analog cagrilintide plus the GLP-1 agonist semaglutide, each dosed at 2.4 mg once weekly. - In the Phase 3 REDEFINE 1 trial of 3,417 adults with overweight or obesity, CagriSema produced 20.4 percent mean weight loss at 68 weeks versus 3.0 percent with placebo. - In REDEFINE 2 (1,206 participants with type 2 diabetes), CagriSema produced 13.7 percent weight loss and brought 73.5 percent of participants to an HbA1c of 6.5 percent or below, versus 15.9 percent on placebo. - Gastrointestinal adverse events are the dominant side effect, affecting roughly 72 to 80 percent of participants across Phase 3 trials, and were mainly transient and mild-to-moderate. **Frequently Asked Questions:** - Q: Is CagriSema a single peptide? A: No. CagriSema is a fixed-dose combination of two separate peptide drugs: cagrilintide, a long-acting amylin analog, and semaglutide, a GLP-1 receptor agonist. In the Phase 3 REDEFINE trials the two were co-administered as once-weekly subcutaneous injections of 2.4 mg each. This distinguishes it fro… - Q: How much weight loss did CagriSema produce in Phase 3 trials? A: In REDEFINE 1 (3,417 adults with overweight or obesity without diabetes), CagriSema produced an estimated mean weight change of -20.4% at 68 weeks versus -3.0% with placebo, a difference of -17.3 percentage points (P<0.001). In REDEFINE 2 (1,206 adults who also had type 2 diabetes), weight change w… - Q: Why combine an amylin analog with a GLP-1 agonist? A: Amylin and GLP-1 suppress appetite through different neural circuits. GLP-1 receptor activation primarily regulates homeostatic energy balance through hypothalamic centers, while amylin receptor activation in the area postrema reduces hedonic, reward-driven eating. The Phase 2 diabetes trial showed… - Q: What did REDEFINE 2 show for blood sugar control? A: In REDEFINE 2, adults with type 2 diabetes (baseline HbA1c 7-10%) treated with CagriSema for 68 weeks were far more likely to reach an HbA1c of 6.5% or below: 73.5% versus 15.9% on placebo, alongside the -13.7% versus -3.4% weight result. In the earlier Phase 2 diabetes trial, HbA1c fell 2.2 percen… - Q: What are the main side effects of CagriSema? A: Gastrointestinal adverse events dominate, as expected from both drug classes: nausea, vomiting, diarrhea, constipation, and abdominal pain affected 79.6% of CagriSema participants in REDEFINE 1 (versus 39.9% on placebo) and 72.5% in REDEFINE 2 (versus 34.4%). The events were mainly transient and mi… ### [MK-677 (Ibutamoren)](https://peptpedia.org/peptide/mk-677) MK-677 (ibutamoren) is an orally active, non-peptide small molecule agonist of the ghrelin receptor (GHSR-1a) that stimulates endogenous growth hormone and IGF-1 secretion, studied in randomized trials in older adults, obesity, and sleep research. **Key Findings:** - MK-677 is not a peptide but an orally active small-molecule ghrelin receptor (GHSR-1a) agonist, grouped with GHRPs because it drives the same pulsatile GH release pathway. - In adults aged 64-81, 25 mg daily increased mean 24-hour GH by 97 percent and restored IGF-1 to the young-adult range (141 to 265 µg/L at 4 weeks). - A 2-year randomized trial found 1.1 kg fat-free mass gain versus placebo in older adults, but no improvement in strength or function, alongside increased appetite, mild edema, and reduced insulin sensitivity. - MK-677 has no approved indication in any country and is named on the WADA Prohibited List under section S2, prohibited at all times. **Frequently Asked Questions:** - Q: Is MK-677 a peptide? A: No. MK-677 (ibutamoren) is a non-peptide, small-molecule spiropiperidine (formula C27H36N4O5S) that is orally active. It appears alongside growth hormone secretagogue peptides such as ipamorelin, GHRP-6, and hexarelin only because it targets the same receptor, GHSR-1a, and produces the same downstr… - Q: What did the 2-year MK-677 trial in older adults show? A: The Nass trial (Annals of Internal Medicine 2008) randomized 65 healthy adults aged 60-81 to MK-677 25 mg or placebo once daily. Over 12 months, MK-677 raised GH and IGF-1 into the young-adult range and increased fat-free mass by 1.1 kg versus a 0.5 kg loss on placebo, without serious adverse effec… - Q: How much does MK-677 raise GH and IGF-1? A: In the Chapman study (JCEM 1996) in adults aged 64-81, 25 mg/day increased mean 24-hour GH concentrations by 97 +/- 23% after 2 weeks, driven by higher GH pulse amplitude and nadir levels with unchanged pulse frequency. Serum IGF-1 rose from a baseline of 141 +/- 21 µg/L to 265 +/- 29 µg/L at 4 wee… - Q: Does MK-677 raise cortisol or prolactin? A: Modestly, with nuance by exposure length. Over 4 weeks in elderly subjects, Chapman and colleagues found no change in circulating cortisol and a 23% prolactin increase that stayed within the normal range. Over 12 months in the 2-year trial, cortisol increased by 47 nmol/L (P=0.020), a statistically… - Q: Does MK-677 build muscle? A: It increases measured fat-free mass, but that is not the same as proven functional muscle gain. In the 2-year elderly trial, fat-free mass increased 1.1 kg versus placebo, yet strength and physical function did not improve. Some of the fat-free mass increase likely reflects water and body cell mass… ### [Mod GRF 1-29](https://peptpedia.org/peptide/mod-grf-1-29) Mod GRF 1-29 is a tetrasubstituted analog of GRF(1-29), the shortest fully active fragment of growth hormone-releasing hormone, engineered for enzymatic stability; it is identical to the peptide core of CJC-1295 but lacks the Drug Affinity Complex (DAC) albumin-binding linker. **Key Findings:** - Mod GRF 1-29 is the tetrasubstituted GRF(1-29) peptide core of CJC-1295 without the DAC albumin-binding linker; the two share a molecule but not a duration of action. - The D-Ala2 substitution cut metabolic clearance roughly in half in normal men (21 versus 39.7 mL/kg/min) and lengthened the disappearance half-time from 4.3 to 6.7 minutes. - No human trial has tested the no-DAC peptide alone; human GH and safety data attributed to it come from CJC-1295 studies of the same core in albumin-conjugated form. - Continuous GHRH receptor stimulation by this peptide core raises trough GH 7.5-fold while preserving the frequency and magnitude of natural GH pulses. **Frequently Asked Questions:** - Q: What is the difference between Mod GRF 1-29 and CJC-1295? A: They share the identical bioactive peptide: a tetrasubstituted analog of GRF(1-29). CJC-1295 adds the Drug Affinity Complex (DAC), a maleimidopropionyl group on a C-terminal lysine that covalently binds the Cys34 residue of serum albumin after injection. That single modification changes the pharmac… - Q: Has Mod GRF 1-29 itself been tested in humans? A: No. There is no published human clinical trial of the no-DAC tetrasubstituted GRF(1-29) peptide as a standalone drug. The human data attached to this molecule come from two adjacent bodies of work: CJC-1295 trials (Teichman 2006; Ionescu and Frohman 2006), which used the same peptide core conjugate… - Q: Why is it called 'tetrasubstituted'? A: The peptide carries four amino acid substitutions relative to native GRF(1-29), introduced to resist enzymatic degradation and improve stability. The ConjuChem identification paper (Jetté 2005) describes CJC-1295 explicitly as a tetrasubstituted form of hGRF(1-29) with an added C-terminal lysine de… - Q: How does Mod GRF 1-29 differ from sermorelin? A: Sermorelin is unmodified GRF(1-29)NH2, the native 29-amino-acid GHRH fragment; it was FDA-approved as Geref for diagnostic and pediatric use before being withdrawn in 2009 for commercial, non-safety reasons. Mod GRF 1-29 is the same 29-residue scaffold carrying four stabilizing substitutions. Both… - Q: Why does the DAC linker matter so much? A: The DAC is the entire reason CJC-1295 exists. Jetté and colleagues showed that attaching a maleimidopropionyl group to the peptide lets it covalently bioconjugate to albumin within minutes of injection, creating a circulating drug reservoir detectable beyond 72 hours and a 4-fold greater GH respons… ### [Melanotan I (Afamelanotide)](https://peptpedia.org/peptide/melanotan-i) Melanotan I (afamelanotide) is a linear alpha-MSH analog with predominant melanocortin-1 receptor activity, FDA-approved in 2019 as Scenesse, a 16 mg subcutaneous implant, to increase pain-free light exposure in adults with erythropoietic protoporphyria. **Key Findings:** - Afamelanotide is the only melanocortin tanning peptide with regulatory approval: FDA-approved in 2019 as Scenesse, a 16 mg subcutaneous implant, for adults with erythropoietic protoporphyria. - In two Phase 3 trials, afamelanotide increased pain-free sun exposure (69.4 versus 40.8 hours in the US study; 6.0 versus 0.8 hours in the EU study) and reduced phototoxic reactions from 146 to 77. - Melanotan I is a linear alpha-MSH analog acting predominantly at MC1R, unlike the cyclic, non-selective Melanotan II, which activates all five melanocortin receptors. - The free peptide's half-life is under 2 hours, so the approved product is a slow-release implant dosed every 2 months; diffuse hyperpigmentation occurs in almost all treated patients. **Frequently Asked Questions:** - Q: What is the difference between Melanotan I and Melanotan II? A: Melanotan I (afamelanotide) is a linear 13-amino-acid alpha-MSH analog acting predominantly at MC1R, the melanocyte pigmentation receptor. Melanotan II is a smaller cyclic analog that non-selectively activates MC1R through MC5R, adding sexual arousal, appetite suppression, and nausea to the pigment… - Q: Is Melanotan I FDA-approved? A: Yes, in a specific form. The FDA approved afamelanotide in 2019 under the brand name Scenesse: a 16 mg subcutaneous implant indicated to increase pain-free light exposure in adult patients with a history of phototoxic reactions from erythropoietic protoporphyria. Approval applies only to that impla… - Q: How does afamelanotide help in erythropoietic protoporphyria? A: In EPP, defective ferrochelatase causes protoporphyrin IX to accumulate in skin and blood. Daylight excites the protoporphyrin, generating reactive oxygen species that produce immediate, severe burning pain. Afamelanotide activates MC1R on melanocytes to increase epidermal eumelanin, which absorbs… - Q: What is the afamelanotide implant and why is it needed? A: Scenesse is a rice-grain-sized solid rod containing 16 mg of afamelanotide, inserted subcutaneously, typically in the hip area, where it dissolves slowly. The implant exists because the free peptide's pharmacokinetics are poor for chronic therapy: subcutaneous afamelanotide has a beta-phase half-li… - Q: Does Melanotan I tan skin without sun exposure? A: Yes, pharmacologically. In the Ugwu pharmacokinetic study, significant tanning of the forehead, arms, and neck followed intravenous or subcutaneous dosing without any deliberate UV exposure, peaking a week after dosing. The Dorr Phase 1 studies then showed the peptide acts synergistically with UV:… ### [Eloralintide](https://peptpedia.org/peptide/eloralintide) Eloralintide (LY3841136) is a once-weekly, AMY1R-selective amylin receptor agonist developed by Eli Lilly for obesity, with Phase 2 weight loss of 9% to 20% at 48 weeks. **Key Findings:** - In a 48-week Phase 2 trial (263 participants), once-weekly eloralintide produced dose-dependent mean weight loss of 9-20% versus 0.4% with placebo, with trajectories not yet plateaued at trial end. - Eloralintide activates human AMY1R 12-fold more potently than the calcitonin receptor and 11-fold more potently than AMY3R, a selectivity engineered to improve gastrointestinal tolerability. - Terminal half-life of 310-366 hours (12.9-15.3 days) supports once-weekly subcutaneous dosing with low peak-to-trough variation. - In obese rats, fat mass accounted for the majority of eloralintide-induced weight loss, with significantly less lean mass loss than cagrilintide in head-to-head preclinical comparison (p = 0.0101). **Frequently Asked Questions:** - Q: How much weight loss did eloralintide produce in clinical trials? A: In the 48-week Phase 2 trial in 263 adults with obesity or overweight, once-weekly eloralintide produced mean body weight reductions of 9% (1 mg), 12% (3 mg), 18% (6 mg), and 20% (9 mg and the 6-9 mg escalation) versus 0.4% with placebo (PMID 41207310). Weight loss curves had not plateaued at week… - Q: How is eloralintide different from cagrilintide? A: Both are once-weekly amylin analogs, but they differ in receptor selectivity. Cagrilintide non-selectively activates amylin receptors and the calcitonin receptor (CTR). Eloralintide activates human AMY1R 12-fold more potently than CTR and 11-fold more potently than AMY3R. The design rationale is th… - Q: What are the side effects of eloralintide? A: In the 48-week Phase 2 trial, the most common adverse events were nausea (11-64% across dose arms versus 14% with placebo) and fatigue (up to 46% versus 12% with placebo). Both were dose-related and were substantially reduced with slower dose escalation. In Phase 1 studies, most adverse events were… - Q: Is eloralintide FDA approved? A: No. Eloralintide is investigational and not approved by the FDA or any other regulator. Its published evidence consists of Phase 1 studies and one 48-week Phase 2 trial; Phase 3 trials in obesity (with and without type 2 diabetes) are recruiting as of 2026. It is available only within Eli Lilly-spo… - Q: How does eloralintide work? A: Eloralintide mimics the hormone amylin, which is co-secreted with insulin after meals and promotes satiety through receptors in the hindbrain. It preferentially activates the AMY1R receptor, a heterodimer of the calcitonin receptor and RAMP1, reducing food intake. A C20 fatty diacid side chain bind… ### [Bioglutide](https://peptpedia.org/peptide/bioglutide) Bioglutide (NA-931) is an oral compound described by sponsor Biomed Industries as a quadruple receptor agonist (IGF-1, GLP-1, GIP, glucagon) for obesity. It has no peer-reviewed publications and no disclosed molecular structure. **Key Findings:** - PubMed contains zero publications mentioning NA-931 or bioglutide, and no molecular structure, formula, sequence, or CAS number has ever been publicly disclosed. - Three sponsor-run ClinicalTrials.gov registrations exist: a completed Phase 1 (74 participants), a completed Phase 2 (126 participants), and a not-yet-recruiting Phase 2 combination with tirzepatide. - No results have been posted or published for any registered trial, so no efficacy or safety claim can be independently verified. - The ClinicalTrials.gov records carry documented registration irregularities, including Phase 2 eligibility criteria virtually identical to Viking Therapeutics' earlier VK2735 trial registration. **Frequently Asked Questions:** - Q: Is bioglutide (NA-931) a real drug? A: NA-931 is a compound name associated with three sponsor-run ClinicalTrials.gov registrations by Biomed Industries, Inc. Beyond those registrations there is no verifiable scientific record: no peer-reviewed publications, no disclosed molecular structure, no CAS registry number, and no PubChem entry.… - Q: What receptors does bioglutide target? A: The sponsor describes NA-931 as a quadruple receptor agonist engaging IGF-1, GLP-1, GIP, and glucagon receptors. This is an unverified claim: no binding assays, signaling data, or pharmacology papers have been published, so the receptor profile cannot be independently confirmed. The IGF-1 component… - Q: Has bioglutide been tested in humans? A: The sponsor's registry listings show a completed Phase 1 study (74 participants) and a completed Phase 2 study (126 participants, listed as completed in April 2025). No results, adverse-event data, or publications have been posted for either. Registration of a trial is not evidence that results exi… - Q: Why is bioglutide's trial data flagged as unverified? A: The registry records themselves carry three irregularities: the Phase 1 study was registered retrospectively, first posted on 2024-09-27, nearly five months after its own recorded 2024-05-06 start date and two months after the Phase 2 trial began; the Phase 2 eligibility criteria are virtually word… - Q: Is bioglutide FDA approved or available for purchase? A: No. NA-931 is not approved anywhere and no verified supply chain exists. Because the molecular identity of NA-931 has never been publicly disclosed, any vendor selling material labeled 'bioglutide' or 'NA-931' cannot be selling a verifiable version of the sponsor's compound, and such material carri… ### [Adipotide](https://peptpedia.org/peptide/adipotide) Adipotide (FTPP, prohibitin-TP01) is a chimeric peptidomimetic that targets the blood vessels supplying white adipose tissue and triggers their apoptosis, producing rapid fat loss in obese primates but with dose-dependent renal effects. **Key Findings:** - Adipotide fuses a white-fat vascular homing peptide (CKGGRAKDC, binding prohibitin) to a proapoptotic domain (D-(KLAKLAK)2) that destroys the blood vessels supplying adipose tissue. - In obese rhesus macaques, 28 days of 0.43 mg/kg daily produced 7.4-14.7% body weight loss and a 38.7% average reduction in total body fat, with improved insulin resistance. - Glucose tolerance improved within 2-3 days of treatment in obese mice, independent of weight change or food intake, implicating adipose vasculature in metabolic control. - Dose-dependent, reversible renal proximal tubule changes appeared above 0.25 mg/kg in primates, and the only human trial (NCT01262664) was terminated after 4 participants. **Frequently Asked Questions:** - Q: What is adipotide and how does it work? A: Adipotide (FTPP, prohibitin-TP01) is a chimeric peptide with two parts: a homing sequence (CKGGRAKDC) that binds prohibitin on the blood vessels supplying white fat, and a proapoptotic sequence (D-(KLAKLAK)2) that kills those endothelial cells after internalization. Destroying the vasculature starv… - Q: Did adipotide work in monkeys? A: Yes. In the 2011 Science Translational Medicine study, obese rhesus macaques receiving 0.43 mg/kg daily for 4 weeks lost 7.4-14.7% of pretreatment body weight, with a 38.7% average reduction in total body fat on DEXA imaging, and showed improved insulin resistance. Effects partially reversed during… - Q: Why was adipotide's development discontinued? A: The only human trial, a Phase 1 study of prohibitin-TP01 in obese patients with metastatic prostate cancer at M.D. Anderson (NCT01262664), was terminated per the principal investigator's request after enrolling only 4 participants, and no results were published. Separately, the primate studies docu… - Q: What were the kidney side effects of adipotide? A: In rhesus monkeys, slight-to-moderate dose-dependent serum creatinine elevations appeared at doses above 0.25 mg/kg, reflecting reversible changes in renal proximal tubule function; concurrent blood urea nitrogen elevations were not observed, and most monkeys at the 0.43 mg/kg therapeutic dose main… - Q: Is adipotide FDA approved or available? A: No. Adipotide is not approved anywhere, and no active clinical program exists in the public record. Material sold by research chemical vendors has no regulatory oversight, and given the renal safety signal seen in primates plus the complete absence of human safety data, it carries substantial unkno… ### [ARA-290](https://peptpedia.org/peptide/ara-290) ARA-290 (cibinetide) is an 11-amino-acid peptide engineered from erythropoietin that activates the innate repair receptor, producing tissue-protective and anti-inflammatory effects without stimulating red blood cell production. **Key Findings:** - ARA-290 is an 11-amino-acid peptide from erythropoietin's helix B that activates the innate repair receptor (EPOR/CD131) without any erythropoietic activity. - The Phase 2b trial (64 patients) showed the 4 mg dose significantly increased corneal nerve fiber area in sarcoidosis small fiber neuropathy, objective evidence of nerve regrowth in humans. - A Phase 2 trial in type 2 diabetes showed improved HbA1c, lipid profiles, and neuropathic symptoms over 56 days of observation. - Plasma half-life is about 2 minutes, yet innate repair receptor engagement flips a sustained molecular switch producing effects lasting days to weeks. **Frequently Asked Questions:** - Q: What is ARA-290 (cibinetide)? A: ARA-290, also called cibinetide or pHBSP, is an 11-amino-acid peptide modeled on the helix B surface region of erythropoietin. It activates the innate repair receptor, a complex of the erythropoietin receptor and CD131, triggering tissue-protective and anti-inflammatory programs without stimulating… - Q: How is ARA-290 different from erythropoietin (EPO)? A: EPO signals through two receptor systems: the EPOR homodimer, which drives red blood cell production, and the innate repair receptor (EPOR plus CD131), which mediates tissue protection. Using EPO as a tissue-protective drug is limited by hematocrit rises, platelet activation, and thrombosis risk fr… - Q: What did the sarcoidosis small fiber neuropathy trials show? A: The Phase 2b trial in 64 patients found that 28 days of cibinetide at 4 mg daily significantly increased corneal nerve fiber area versus placebo (placebo-corrected +697 micrometers squared, P = 0.012) and increased regenerating nerve fibers in skin biopsies, with corneal changes tracking improved 6… - Q: Does ARA-290 help in diabetes? A: A Phase 2 trial in type 2 diabetes patients with neuropathy found 4 mg daily for 28 days improved HbA1c and lipid profiles over the 56-day observation period and significantly improved neuropathic symptoms; patients with reduced corneal nerve fiber density at baseline showed significant increases v… - Q: Is ARA-290 FDA approved or legal to use? A: ARA-290 is not approved for any indication by the FDA or any other regulator. Araim Pharmaceuticals received FDA orphan drug designation for sarcoidosis in 2016, which provides development incentives but is not an approval, and no Phase 3 program has been published. Anti-doping laboratories treat i… ### [Glutathione](https://peptpedia.org/peptide/glutathione) Glutathione is an endogenous tripeptide (gamma-Glu-Cys-Gly) that functions as the principal intracellular antioxidant in human cells, researched via oral, liposomal, intravenous, and intranasal routes. **Key Findings:** - A single 3 g oral dose of glutathione did not measurably raise plasma glutathione in healthy volunteers, establishing the gamma-glutamyltransferase degradation problem for oral delivery. - Six months of daily oral glutathione (250-1000 mg) raised body stores dose-dependently - up to 260% in buccal cells - and doubled natural killer cell cytotoxicity at 3 months in the high-dose arm. - IV glutathione has a plasma half-life of only 14.1 minutes and functions mainly as a delivery system for cysteine equivalents. - Intranasal glutathione failed to beat placebo in a 45-patient phase IIb Parkinson's disease trial, despite the established finding of nigral glutathione depletion in the disease. **Frequently Asked Questions:** - Q: Does oral glutathione actually get absorbed? A: The answer depends on the dosing pattern. A controlled study found that a single 3 g oral dose did not measurably raise plasma glutathione, cysteine, or glutamate over 4.5 hours, because intestinal and hepatic gamma-glutamyltransferase hydrolyzes the peptide (PMID: 1362956). Yet a 6-month randomize… - Q: Why do glutathione levels fall with age? A: Human work by Sekhar and colleagues showed that older adults synthesize glutathione more slowly than younger people, leaving them with lower glutathione and higher oxidative stress, and that the bottleneck is supply of the precursor amino acids cysteine and glycine (PMID: 21795440). Supplementing t… - Q: Is glutathione proven to help Parkinson's disease? A: No. The rationale is real - postmortem work found substantial glutathione loss in the Parkinson's substantia nigra (PMID: 8080242) - but the largest controlled test was negative. In a phase IIb double-blind trial, 45 patients received intranasal glutathione (100 or 200 mg three times daily) or plac… - Q: Does glutathione lighten skin, and is it safe for that use? A: A 2019 systematic review found only four clinical studies: oral glutathione at 500 mg/day and topical 2% oxidized glutathione brightened skin modestly in sun-exposed areas only, and the reviewers rated the overall evidence inconclusive because of study quality and inconsistency (PMID: 30895708). So… - Q: What is the difference between GSH and GSSG? A: GSH is the reduced, active form of glutathione; GSSG is the oxidized form produced when two GSH molecules link through a disulfide bond after neutralizing oxidants. The enzyme glutathione reductase converts GSSG back to GSH using NADPH. Healthy cells keep the GSH-to-GSSG ratio heavily tilted toward… ### [Humanin](https://peptpedia.org/peptide/humanin) Humanin is a 24-amino-acid peptide encoded in the mitochondrial genome (MT-RNR2) with cytoprotective, anti-apoptotic activity studied mainly in Alzheimer's disease and aging research. **Key Findings:** - Humanin is encoded in the mitochondrial genome (16S rRNA gene MT-RNR2), making it one of the first discovered mitochondrial-derived peptides. - Its core mechanism is direct binding to Bax, preventing Bax-driven mitochondrial apoptosis (Nature 2003). - Children of centenarians have markedly higher circulating humanin than age-matched controls; levels decline with age and are reduced in Alzheimer's disease and MELAS. - The only pharmacokinetic study (rodents) found a minutes-scale half-life and undetectable brain levels; no human has received humanin in a published trial. **Frequently Asked Questions:** - Q: Is humanin the same peptide as MOTS-c? A: No. Both are mitochondrial-derived peptides encoded by short open reading frames in mitochondrial DNA, which is why they are discussed together, but they come from different genes and act differently. Humanin is encoded in the 16S ribosomal RNA gene (MT-RNR2) and works mainly by suppressing apoptos… - Q: Has humanin been tested in humans? A: No human has received humanin in a published trial as of 2026. The human evidence is observational: circulating humanin is higher in children of centenarians and lower in Alzheimer's disease and MELAS (PMID: 32575074). Everything interventional - neuroprotection, cardioprotection, metabolic benefit… - Q: What is HNG, and how does it differ from native humanin? A: HNG is humanin with a single amino-acid substitution: glycine replacing serine at position 14 (S14G). Structure-activity mapping in the original characterization study showed this change makes the analog markedly more potent than native humanin in neuroprotection assays, which is why most animal st… - Q: Does injected humanin reach the brain? A: In the only pharmacokinetic study published, peripheral intraperitoneal injection of humanin analogs in rats produced measurable levels in plasma and liver but undetectable levels in brain (PMID: 23836030). Neuroprotection in animal models therefore likely reflects central administration in some pa… - Q: Why is humanin linked to longevity? A: Three findings converged: humanin overexpression extended lifespan in C. elegans through the daf-16/FOXO longevity pathway; circulating humanin declines with age in humans and several species but stays stable in the negligibly senescent naked mole-rat; and children of centenarians, who are themselv… ### [Klotho](https://peptpedia.org/peptide/klotho) Klotho is a 1012-amino-acid transmembrane protein encoded by an aging-suppressor gene; its shed extracellular domain circulates like a hormone and is studied in aging, cognition, and phosphate biology. **Key Findings:** - Disrupting the klotho gene in mice caused a syndrome resembling accelerated human aging; overexpressing it extended mouse lifespan by 20-30%. - A single low subcutaneous dose of recombinant klotho (10 mcg/kg) enhanced working memory in aged rhesus macaques; higher doses lost the effect. - Older adults in the lowest tertile of plasma klotho had a 78% higher six-year mortality risk than those in the highest tertile (InCHIANTI cohort). - Klotho is a 130 kDa glycoprotein requiring mammalian cell manufacturing - no consumer klotho peptide product can be verified as genuine. **Frequently Asked Questions:** - Q: Is klotho actually a peptide? A: No, and the distinction matters for buyers. Klotho is a 1012-amino-acid single-pass transmembrane glycoprotein of about 130 kDa - roughly 35 times larger than a typical research peptide. The circulating form is its shed extracellular domain, and the fragment studied for cognition (KL1) is still aro… - Q: Has klotho been tested in humans? A: No published study has administered exogenous klotho to a human as of 2026. Human evidence comes from genetics and observation: carriers of the KL-VS variant have higher circulating klotho and better cognitive scores (PMID: 24813892), and low plasma klotho independently predicted death over six yea… - Q: What did the 2023 monkey study actually find? A: Castner and colleagues gave aged rhesus macaques a single subcutaneous injection of recombinant rhesus klotho. A low dose of 10 mcg/kg enhanced working memory; higher doses did not help, an inverted-U dose response (PMID: 37400721). Serum klotho remained measurable to 52 hours. It is the strongest… - Q: Do low klotho levels predict death? A: In the InCHIANTI study of 804 community-dwelling adults aged 65 and older, those in the lowest tertile of plasma klotho (under 575 pg/mL) died at a 78% higher rate over six years than those in the highest tertile, after adjusting for a long list of health covariates (PMID: 21474560). This is a pros… - Q: What is the KL-VS variant? A: KL-VS is a common haplotype of the human klotho gene. People who carry one copy (roughly a quarter of many populations) have higher circulating klotho, and in a 2014 study they performed better on cognitive testing across three independent cohorts (PMID: 24813892). Mice engineered to model the vari… ### [Vasoactive Intestinal Peptide (VIP)](https://peptpedia.org/peptide/vip) Vasoactive intestinal peptide (VIP) is a 28-amino-acid neuropeptide that signals through VPAC1 and VPAC2 receptors; its synthetic form, aviptadil, has reached randomized human trials in lung disease and critical COVID-19. **Key Findings:** - VIP was isolated from small intestine in 1970 and reclassified from gut hormone to broadly distributed neuropeptide signaling through VPAC1/VPAC2 receptors. - Human pharmacokinetics show a disappearance half-time of about one minute after IV infusion, forcing multi-hour infusion or inhaled delivery in trials. - In a 196-patient critical COVID-19 RCT, aviptadil missed its primary endpoint but showed two-fold odds of 60-day survival in a secondary analysis, with no drug-related serious adverse events. - VIP both prevented and treated experimental arthritis by downregulating autoimmune and inflammatory components simultaneously (Nature Medicine 2001). **Frequently Asked Questions:** - Q: Is VIP the same thing as aviptadil? A: Aviptadil is the pharmaceutical name for synthetic human vasoactive intestinal peptide - the identical 28-amino-acid sequence made synthetically for clinical use. RLF-100 and Zyesami are development and brand names for the intravenous aviptadil program tested in critical COVID-19. When research ref… - Q: Did aviptadil actually work in COVID-19? A: The honest answer is unresolved. In the 196-patient randomized trial in critical COVID-19 respiratory failure, aviptadil missed its primary endpoint (alive and free of respiratory failure at day 60; OR 1.6, not significant). A prespecified secondary analysis showed two-fold odds of 60-day survival… - Q: Is VIP nasal spray proven for mold illness (CIRS)? A: No. Compounded intranasal VIP is used off-label in chronic inflammatory response syndrome protocols, but the key supporting study was published in a journal not indexed in PubMed, involves a small uncontrolled case series, and has never been tested in a randomized, placebo-controlled trial. The pro… - Q: What are VPAC1 and VPAC2? A: VPAC1 and VPAC2 are the two receptors that mediate VIP's effects. Both are Gs-coupled G-protein-coupled receptors that raise cAMP when activated, and both bind VIP and the related peptide PACAP with similar affinity, while a third receptor, PAC1, prefers PACAP. Their distribution - VPAC1 broadly ac… - Q: Why is VIP given by multi-hour infusion instead of a single injection? A: Human pharmacokinetic work showed that VIP disappears from plasma by first-order kinetics with an average half-time of about one minute after IV infusion, with a metabolic clearance rate of roughly 9 mL/kg/min (PMID: 730072). A bolus injection therefore produces only a brief pulse of exposure. Clin… ### [PEG-MGF](https://peptpedia.org/peptide/peg-mgf) PEG-MGF is a PEGylated form of mechano growth factor, the 24-amino acid E-peptide encoded by the IGF-1Ec splice variant of the IGF-1 gene, studied for its effects on muscle satellite cells. **Key Findings:** - The MGF E-peptide acts through a receptor distinct from the IGF-1 receptor: neutralizing IGF-1R antibodies block mature IGF-1 but not the E-peptide, which activates ERK1/2 without Akt in cardiomyocyte models. - In human muscle cell cultures, the 24-aa MGF E-peptide extended proliferative lifespan and delayed senescence in satellite cells from young but not elderly donors, while depleting the reserve cell pool in all age groups. - Systemic or intramuscular delivery of synthetic MGF E-peptide significantly improved engraftment of transplanted human muscle precursor cells in mice, linking the peptide to cell therapy research. - Sustained MGF overexpression in injured mouse muscle delayed resolution of pro-inflammatory macrophages without improving regeneration, a cautionary signal for chronic exposure. **Frequently Asked Questions:** - Q: What is the difference between MGF and PEG-MGF? A: MGF (mechano growth factor, IGF-1Ec) is a natural splice variant of the IGF-1 gene whose unique E domain is expressed in muscle after mechanical stress. The synthetic research peptide is the 24-amino acid C-terminal fragment of that E domain. Like most short peptides it degrades within minutes in b… - Q: Does PEG-MGF work through the IGF-1 receptor? A: Published evidence says no. In three separate studies (Yang 2002, Mills 2007, Stavropoulou 2009), neutralizing antibodies against the IGF-1 receptor completely blocked mature IGF-1 but did not block the MGF E-peptide's effects on proliferation. In rat cardiomyocytes the peptide activated ERK1/2 wit… - Q: Has PEG-MGF been tested in humans? A: No human clinical trial of MGF or PEG-MGF has been published as of 2026. The human evidence is limited to in vitro experiments on cultured human muscle cells, most notably the Kandalla 2011 study showing age-dependent activation of satellite cells. Safety, effective dosing, and pharmacokinetics in… - Q: Is PEG-MGF banned in sport? A: Yes. The World Anti-Doping Agency Prohibited List bans mechano growth factors by name under section S2 (peptide hormones, growth factors, related substances, and mimetics), alongside IGF-1. The prohibition applies at all times, in and out of competition, and covers MGF in any form including PEGylat… - Q: Does age affect how muscle cells respond to MGF? A: In the Kandalla 2011 human cell study, the MGF E-peptide extended the proliferative lifespan and delayed senescence of satellite cells from neonatal and young adult donors, but cells from a 73-year-old donor did not respond this way. Across all ages, treated cultures showed hypertrophy with depleti… ### [PNC-27](https://peptpedia.org/peptide/pnc-27) PNC-27 is a 32-amino acid chimeric peptide combining the HDM-2-binding domain of p53 with a cell-penetrating leader sequence, designed to lyse cancer cells by binding HDM-2 on their membranes. **Key Findings:** - PNC-27 kills cancer cells by binding HDM-2 displayed on their membranes and forming transmembrane pores; untransformed cells lack surface HDM-2 and are spared in every preclinical study. - Artificially expressing HDM-2 on the surface of resistant untransformed cells made them susceptible to PNC-27, directly proving the target (PNAS 2010). - The peptide kills p53-null K562 leukemia cells, confirming its mechanism is independent of cellular p53 status. - The FDA warned consumers in 2017 not to use PNC-27 products sold as cancer cures after finding bacterial contamination in sampled inhalation solutions. **Frequently Asked Questions:** - Q: How does PNC-27 distinguish cancer cells from normal cells? A: Cancer cells from many tumor types display the HDM-2 oncoprotein on their outer membrane, while untransformed cells do not. PNC-27 binds this surface HDM-2 and assembles transmembrane pores. In the PNAS 2010 study, untransformed MCF-10-2A cells resisted PNC-27 until researchers forced HDM-2 onto th… - Q: Does PNC-27 require p53 to work? A: No. Although PNC-27 is built from residues 12-26 of p53, it targets HDM-2 on the cell membrane rather than the nuclear p53 pathway. The 2014 study on K562 leukemia cells, which express no p53 at all, showed nearly complete killing with membrane colocalization of peptide and HDM-2. This makes the me… - Q: Has PNC-27 been tested in humans? A: No peer-reviewed human clinical trial results have been published as of 2026, and no registered trial with reported results could be identified. All efficacy evidence is from cell culture and mouse models, generated almost entirely by the inventor group and its affiliated company (NomoCan Pharmaceu… - Q: What did the FDA warn about PNC-27? A: In January 2017 the FDA warned consumers not to buy or use PNC-27, which was being sold online as a cancer treatment or cure. FDA laboratory testing found the bacterium Variovorax paradoxus in a PNC-27 solution intended for inhalation, and a March 2017 update reported Ralstonia insidiosa in another… - Q: What is poptosis? A: Poptosis is the term the research group uses for the death mechanism induced by PNC-27 and related peptides: peptide-induced formation of transmembrane pores leading to rapid necrotic lysis, as opposed to programmed apoptosis. A 2024 review in Biomedicines formalized the concept, describing pore fo… ### [PTD-DBM](https://peptpedia.org/peptide/ptd-dbm) PTD-DBM is a 25-amino acid fusion peptide designed to reactivate Wnt/beta-catenin signaling in hair follicles by competitively disrupting the CXXC5-Dishevelled interaction. **Key Findings:** - CXXC5, a negative regulator of Wnt signaling, is upregulated in balding human scalp dermal papilla cells; PTD-DBM competitively blocks the CXXC5-Dishevelled interaction to restore beta-catenin signaling. - Topical PTD-DBM restored hair regrowth in depilated mice and promoted wound-induced hair follicle neogenesis, with CXXC5 knockout mice phenocopying the effect. - The 2023 Cells study placed CXXC5 downstream of the DHT-prostaglandin D2 axis in androgenetic alopecia, positioning the peptide as a downstream intervention. - All primary data comes from a single laboratory whose principal investigator holds commercial rights; no human trial or independent replication has been published. **Frequently Asked Questions:** - Q: How does PTD-DBM promote hair growth? A: PTD-DBM blocks CXXC5, a protein that suppresses Wnt/beta-catenin signaling by binding Dishevelled. Releasing this brake reactivates Wnt signaling in dermal papilla cells, the cells that orchestrate follicle cycling, promoting re-entry into the growth (anagen) phase. In depilated mice the peptide re… - Q: What connects PTD-DBM to DHT and androgenetic alopecia? A: The 2023 Cells study showed that dihydrotestosterone drives prostaglandin D2 production in balding scalp dermal papilla cells, and PGD2 upregulates CXXC5, which suppresses Wnt signaling and hair growth. PTD-DBM acts downstream of this chain: it overcame both PGD2-induced and DHT-induced hair suppre… - Q: Has PTD-DBM been tested in humans? A: No human clinical trial or treatment study has been published as of 2026. Human evidence is limited to tissue and cell analysis: CXXC5 is upregulated in balding human scalp dermal papilla cells, and PTD-DBM reverses CXXC5-driven suppression in cultured human cells. Efficacy and safety in people are… - Q: Who developed PTD-DBM, and has the research been replicated? A: PTD-DBM was developed by Kang-Yell Choi's group at Yonsei University, Seoul, and essentially all primary data comes from that laboratory. The principal investigator is CEO of CK Regeon Inc., which holds the license to the technology - a conflict of interest declared in the 2023 paper. No independen… - Q: Can PTD-DBM penetrate skin when applied topically? A: Partially. The octaarginine protein transduction domain improves cellular uptake, but intact stratum corneum remains a major barrier: mouse studies that applied the peptide to depilated (disrupted) skin used 10 millimolar solutions, roughly 100 times the concentration used on open wounds. This conc… ### [AHK-Cu](https://peptpedia.org/peptide/ahk-cu) AHK-Cu (copper tripeptide-3) is the copper complex of the tripeptide Ala-His-Lys, a synthetic analog of GHK-Cu studied for hair follicle and skin applications. **Key Findings:** - AHK-Cu at 10^-12 to 10^-9 molar stimulated elongation of human hair follicles ex vivo and proliferation of cultured dermal papilla cells (Pyo 2007), the only direct human tissue study. - Nanomolar AHK-Cu shifted dermal papilla cells away from apoptosis, raising the Bcl-2/Bax ratio and lowering cleaved caspase-3 and PARP. - AHK-Cu is a single-residue analog of GHK-Cu (alanine for glycine); nearly all broader claims are extrapolated from GHK-Cu research, not measured for AHK-Cu. - No human clinical trial of AHK-Cu has been published; delivery studies show intact skin is a major barrier to copper tripeptides, addressable with microneedling. **Frequently Asked Questions:** - Q: What is the difference between AHK-Cu and GHK-Cu? A: Both are copper-carrying tripeptides that differ only in the first amino acid: GHK-Cu is glycine-histidine-lysine copper (copper tripeptide-1), a peptide naturally present in human plasma, while AHK-Cu is alanine-histidine-lysine copper (copper tripeptide-3), a synthetic analog. GHK-Cu has decades… - Q: Does AHK-Cu regrow hair? A: The direct evidence is one 2007 study: AHK-Cu at picomolar-to-nanomolar concentrations elongated human hair follicles in organ culture and stimulated dermal papilla cell proliferation with anti-apoptotic effects. There are no published human trials, animal hair-growth studies, or controlled cosmeti… - Q: Is AHK-Cu safe on skin? A: No AHK-Cu-specific human safety study has been published. Copper tripeptides as a class have been used in cosmetics for years, and a microneedle delivery study of the related GHK-Cu through human skin reported no obvious irritation, but formal sensitization, irritation, and long-term exposure data… - Q: Why does the peptide carry copper? A: Copper is a required cofactor for enzymes central to skin biology, including lysyl oxidase, which crosslinks collagen and elastin, and superoxide dismutase, a frontline antioxidant enzyme. Small histidine-containing peptides bind Cu2+ through the histidine residue and act as delivery vehicles that… - Q: How is AHK-Cu studied and formulated in research? A: The direct human tissue study used 10^-12 to 10^-9 molar in follicle organ culture and dermal papilla cell culture. Delivery research on the copper tripeptide class shows intact skin is a substantial barrier: Franz cell models show slow permeation, and microneedling or microemulsion systems increas… ### [Thymalin](https://peptpedia.org/peptide/thymalin) Thymalin is a polypeptide complex isolated from calf thymus, developed in the Khavinson bioregulator program and registered as an immunomodulatory drug in Russia. It is studied for T-cell restoration, cytokine modulation, and geroprotection. **Key Findings:** - Thymalin is a mixture of thymus-derived peptides rather than a single molecule; its characterized active components include the EW dipeptide (Glu-Trp), which became the separate drug Thymogen, and the KE dipeptide (Lys-Glu). - In cultured human hematopoietic stem cells, thymalin reduced progenitor markers CD44 and CD117 by 2 to 3 fold while increasing the mature T-cell marker CD28 by 6.8 fold, supporting a stem-cell differentiation mechanism. - An open-label randomized trial in 92 hospitalized COVID-19 patients found that adding thymalin (10 mg intramuscularly daily for 5 days) to standard therapy accelerated declines in IL-6, C-reactive protein, and D-dimer. - A 6 to 8 year observational study in 266 elderly subjects reported 2.0 to 2.1 fold lower mortality with thymalin and 4.1 fold lower with annual combined thymalin plus epithalamin, effect sizes that require independent replication. **Frequently Asked Questions:** - Q: What is the difference between Thymalin and Thymulin? A: They are different substances that are frequently confused. Thymalin is a multi-component polypeptide complex extracted from calf thymus, containing many short peptides; its characterized active components include the EW dipeptide (Glu-Trp, developed separately as Thymogen) and the KE dipeptide (Ly… - Q: What did the COVID-19 trial of Thymalin find? A: A single-center, open-label, randomized trial (PMID: 33575961) enrolled 92 hospitalized COVID-19 patients in St. Petersburg during April to July 2020. The 42-patient thymalin group received 10 mg intramuscularly once daily for 5 days in addition to standard therapy; 50 controls received standard th… - Q: Does Thymalin extend human lifespan? A: The only human lifespan data come from one open-label observational study (PMID: 14523363) that followed 266 elderly subjects for 6 to 8 years and reported 2.0 to 2.1 fold lower mortality with thymalin and 4.1 fold lower mortality with annual combined thymalin plus epithalamin, alongside a 2.0 to 2… - Q: What are the active components of Thymalin? A: Thymalin is a mixture rather than one molecule. The best-characterized components are two dipeptides: EW (Glu-Trp), which was isolated from the complex and developed as the standalone drug Thymogen, and KE (Lys-Glu), the basis of Vilon. A 2023 study (PMID: 37686182) showed that EW preferentially bi… - Q: Is Thymalin approved outside Russia? A: No. Thymalin is registered as a pharmaceutical in Russia (manufacturer Samson-Med) and has been used clinically there for decades, but it has never been approved by the FDA, the EMA, or any other Western regulatory agency. No application for Western approval is known to have been filed, and no inde… ### [Pinealon](https://peptpedia.org/peptide/pinealon) Pinealon is a synthetic tripeptide (Glu-Asp-Arg) from the Khavinson bioregulator program, studied as a neuroprotective agent that interacts directly with DNA and modulates gene expression in neuronal cells. **Key Findings:** - Pinealon (Glu-Asp-Arg) penetrates living cells and reaches the nucleus, where it binds DNA sequence-specifically, preferring CAG-containing sequences and responding to cytosine methylation status. - In an in vitro Alzheimer's model, pinealon at 200 ng/ml increased mushroom dendritic spines in hippocampal neurons by 71 percent, returning the parameter to normal levels. - In 5xFAD Alzheimer's-model mice, pinealon and the related KED peptide prevented dendritic spine loss, with computed binding sites in promoters of CASP3, NES, GAP43, APOE, SOD2, PPARA, and PPARG. - Pinealon dose-dependently limited reactive oxygen species accumulation and necrotic death in cerebellar granule cells, neutrophils, and PC12 cells, with effects on ERK1/2 signaling and the cell cycle. **Frequently Asked Questions:** - Q: What is Pinealon and how is it classified? A: Pinealon is a synthetic tripeptide with the sequence Glu-Asp-Arg (abbreviated EDR), developed in Vladimir Khavinson's bioregulator program in St. Petersburg. It belongs to the class of ultrashort peptides, compounds of 2 to 4 amino acids proposed to regulate gene expression by entering cells and in… - Q: Has Pinealon been studied in Alzheimer's disease models? A: Yes, in two complementary models. In an in vitro amyloid synaptotoxicity model, pinealon at 200 ng/ml increased mushroom dendritic spines in hippocampal neurons by 71 percent, restoring them to normal levels (PMID: 28853087). In 5xFAD transgenic Alzheimer's-model mice, pinealon and the related KED… - Q: How does Pinealon interact with DNA? A: Biophysical work showed that fluorescein-labeled pinealon penetrates HeLa cells and accumulates in the nucleus and nucleolus (PMID: 22117547). In vitro binding assays demonstrated that pinealon discriminates between nucleotide sequences, binding preferentially to CAG-containing oligonucleotides and… - Q: Has Pinealon been tested in humans? A: No controlled human trials have been published. A Russian-language review (PMID: 24738258) describes clinical application of pinealon and other peptide neuroprotectors in elderly patients, and a mechanism review from the developing group states it improved memory issues in elderly patients, but the… - Q: How does Pinealon differ from Semax or Cortexin? A: Pinealon is a single defined tripeptide (Glu-Asp-Arg) proposed to act through direct DNA interaction and epigenetic gene regulation. Semax is a defined synthetic heptapeptide (an ACTH fragment analog) that acts mainly through BDNF upregulation and melanocortin and serotonergic systems. Cortexin is… ### [Cardiogen](https://peptpedia.org/peptide/cardiogen) Cardiogen is a synthetic tetrapeptide (Ala-Glu-Asp-Arg) bioregulator from the Khavinson research program, investigated in preclinical models for effects on cardiac cell proliferation, apoptosis regulation, and age-related myocardial change. **Key Findings:** - Cardiogen (Ala-Glu-Asp-Arg) stimulated proliferation in myocardial tissue cultures from both young and old rats at 10^-12 M, while only 2 of 20 individual amino acids showed any activity in aged tissue. - The same organotypic culture work found cardiogen reduced p53 protein expression, interpreted as suppression of apoptosis in cardiac tissue. - In senescent rats with transplanted M-1 sarcoma, cardiogen produced dose-dependent tumor growth inhibition via hemorrhagic necrosis and stimulated tumor-cell apoptosis, acting through the tumor vascular network rather than direct cytotoxicity. - Molecular docking identified AEDR among the most efficient computed peptide ligands of the LAT1, LAT2, and PEPT1 transporters, a proposed cellular uptake route for ultrashort bioregulator peptides. **Frequently Asked Questions:** - Q: Has Cardiogen been studied in humans? A: No. As of 2026 there are no human studies of cardiogen of any kind: no clinical trials, no observational human data, and no published case reports. All published evidence is preclinical, consisting of organotypic tissue-culture experiments and rodent studies from the St. Petersburg research lineage… - Q: How does Cardiogen affect p53 and apoptosis? A: In myocardial explants from young and old rats, cardiogen at 10^-12 M reduced p53 protein expression, interpreted as suppression of apoptosis in cardiac tissue (PMID: 20210190). In contrast, in rats with transplanted M-1 sarcoma it increased tumor-cell apoptosis and produced hemorrhagic tumor necro… - Q: What is the evidence for Cardiogen's tissue specificity? A: The tissue-specificity claim rests on a 2006 organotypic culture study (PMID: 17152728) in which cardiogen, bronchogen, prostamax, and pancragen each stimulated growth only in explants of their corresponding organs (heart, lung, prostate, pancreas) from both young and aged rats, at 0.05 ng/ml. This… - Q: Is there a published Cardiogen dosing protocol? A: No. Published studies used cardiogen at 0.05 ng/ml and 10^-12 M in organotypic tissue cultures, and by injection in tumor-bearing rats without a translational dosing framework. No pharmacokinetic study exists in any species, so there is no basis for converting cell-culture concentrations into whole… - Q: How does Cardiogen relate to other Khavinson bioregulators? A: Cardiogen (Ala-Glu-Asp-Arg) belongs to the ultrashort-peptide panel developed at the St. Petersburg Institute of Bioregulation and Gerontology, the same program behind Epithalon, pinealon, and cartalax. Within the program's framework, each short peptide is assigned to a target tissue: cardiogen to… ### [Cartalax](https://peptpedia.org/peptide/cartalax) Cartalax is a synthetic tripeptide (Ala-Glu-Asp) from the Khavinson bioregulator program, assigned to cartilage and connective tissue and studied mainly in cell-culture models of aging and chondrogenic differentiation. **Key Findings:** - Cartalax (Ala-Glu-Asp, coded T-31) activated the chondrogenic markers SOX9, aggrecan, type II collagen, and COMP at 200 ng/ml in replicatively aging human mesenchymal stem cells, matching a cartilage polypeptide complex at one-tenth the concentration. - In marrow stromal stem-cell aging models, AED at nanomolar concentrations increased IGF1 expression 3.5 to 5.6 fold and stimulated NF-κB expression, with context-dependent effects on FOXO1, TERT, and TNKS2. - In aging skin fibroblasts, AED inhibited age-associated MMP-9 synthesis, enhanced Ki-67 and CD98hc expression, and suppressed caspase-dependent apoptosis. - All published cartalax evidence is in vitro or animal work; oral capsule products marketed in Russia have no PubMed-indexed clinical trial documentation. **Frequently Asked Questions:** - Q: Has Cartalax been studied in humans for osteoarthritis? A: No PubMed-indexed human trials exist for cartalax in osteoarthritis or any other condition. The cartilage-relevant evidence is a 2023 in vitro study (PMID: 37782646) in which AED at 200 ng/ml activated chondrogenic markers (SOX9, aggrecan, type II collagen, COMP) in replicatively aging human mesenc… - Q: What does the T-31 designation mean? A: T-31 is the code used for the AED tripeptide (Ala-Glu-Asp, cartalax) in the organotypic tissue-culture literature. In a 2015 study (PMID: 26033601), T-31 was tested alongside T-35 (EDL) and a calf-kidney polypeptide complex in kidney explants from young and old rats, where it stimulated proliferati… - Q: What did the chondrogenic differentiation study show? A: The 2023 study (PMID: 37782646) cultured human mesenchymal stem cells through replicative aging and measured the core cartilage-forming program: the transcription factor SOX9, the matrix proteins aggrecan and COMP, and type II collagen, the principal collagen of cartilage. AED at 200 ng/ml activate… - Q: Is oral Cartalax proven to work? A: No. The 100 mcg oral capsules sold in Russia for joint support have no published clinical trials documenting absorption, pharmacokinetics, or efficacy in PubMed-indexed journals. All published AED research used cell cultures or animal tissue explants at nanomolar concentrations. Whether an orally d… - Q: How does Cartalax relate to other Khavinson bioregulators? A: Cartalax (Ala-Glu-Asp) belongs to the ultrashort-peptide class from the St. Petersburg Institute of Bioregulation and Gerontology, alongside Epithalon (Ala-Glu-Asp-Gly), pinealon (Glu-Asp-Arg), and cardiogen (Ala-Glu-Asp-Arg). The class shares a proposed epigenetic mechanism, and AED differs from e… ### [Cortagen](https://peptpedia.org/peptide/cortagen) Cortagen is a synthetic tetrapeptide (Ala-Glu-Asp-Pro) built from amino acid analysis of the bovine brain cortex preparation Cortexin, studied in nerve regeneration and cerebral ischemia models. **Key Findings:** - Cortagen is a defined tetrapeptide (Ala-Glu-Asp-Pro) created by directed synthesis from the amino acid composition of Cortexin, replacing an inconsistently characterized bovine brain extract with a single molecule. - In rats with transected sciatic nerve, 10 mcg/kg intramuscular Cortagen for 10 days increased regenerating fiber growth rate by 27% and conduction velocity by 40%, the primary dose-response finding in its literature. - Five days of Cortagen dosing in mice altered expression of 234 cardiac transcripts on microarray, cited by the originating group as evidence that short peptides act through broad gene-expression modulation. - All Cortagen evidence originates from one research network; no independent laboratory replication, human trial, or pharmacokinetic study has been published. **Frequently Asked Questions:** - Q: What is Cortagen? A: Cortagen is a synthetic tetrapeptide with the sequence Ala-Glu-Asp-Pro (AEDP). It was created by directed chemical synthesis based on the amino acid composition of Cortexin, a natural polypeptide preparation from bovine brain cortex, and belongs to the Khavinson class of short peptide bioregulators… - Q: What did the Cortagen sciatic nerve study find? A: The primary Cortagen experiment (PMID: 11276314) transected and sutured the sciatic nerve in rats, then administered 10 mcg/kg intramuscularly once daily for 10 days. Regenerating nerve fiber growth rate increased by 27% and conduction velocity by 40% versus untreated controls. This is the only pub… - Q: How is Cortagen different from Cortexin? A: Cortexin is a mixture of polypeptides extracted from bovine brain cortex and carries its own clinical literature in Russia. Cortagen is a single defined molecule (Ala-Glu-Asp-Pro) synthesized to reproduce elements of the extract's activity. A 2011 rat study compared them directly in chronic cerebra… - Q: Has Cortagen been studied in humans? A: No peer-reviewed human clinical trial of Cortagen has been published. The introduction of a 2004 microarray paper from the developing laboratory states that Cortagen showed a therapeutic effect in human posttraumatic peripheral nerve recovery, but no citable clinical study is indexed in PubMed (PMI… - Q: Is Cortagen safe? A: Safety is unestablished. There is no toxicology study, no structured adverse-event reporting in the animal work, no pharmacokinetic study, and no human trial. Rat studies at 10 mcg/kg reported functional benefits without described toxicity, but small preclinical studies without safety endpoints can… ### [Livagen](https://peptpedia.org/peptide/livagen) Livagen is a synthetic tetrapeptide (Lys-Glu-Asp-Ala) developed as the liver-directed member of the Khavinson bioregulator family, studied in hepatocyte culture, digestive enzyme, and chromatin research. **Key Findings:** - Livagen (Lys-Glu-Asp-Ala) is the synthetic minimal peptide modeled on liver polypeptide preparations, developed by the Khavinson bioregulation group as the liver-directed family member. - In cultured rat hepatocytes, Livagen increased protein synthesis with the largest effect in cells from old animals; Epithalon tested in parallel showed no such effect. - Livagen inhibited enkephalin-degrading enzymes in human serum in vitro with an IC50 of about 20 micromolar, roughly 25-fold more potent than Epithalon in the same assay, without binding opioid receptors. - Ex vivo, Livagen decondensed age-condensed heterochromatin and reactivated ribosomal genes in lymphocytes from elderly donors; no human in vivo study exists. **Frequently Asked Questions:** - Q: What is Livagen? A: Livagen is a synthetic tetrapeptide, Lys-Glu-Asp-Ala (KEDA), created by directed chemical synthesis based on amino acid analysis of liver polypeptide preparations. It belongs to the Khavinson class of short peptide bioregulators and is positioned in that literature as the liver-directed member of t… - Q: Is Livagen the same peptide as Testagen? A: No. Livagen is Lys-Glu-Asp-Ala (KEDA), while Testagen is Lys-Glu-Asp-Gly (KEDG); they differ only in the fourth residue, alanine versus glycine. The sequences are documented in the primary literature, with Testagen's KEDG sequence shown explicitly in a 2011 Biochemistry (Moscow) study of fluorescen… - Q: What is the Livagen enkephalinase finding? A: A 2003 study found that Livagen inhibited enkephalin-degrading enzymes in human serum in vitro with an IC50 of about 20 micromolar, outperforming puromycin, leupeptin, and D-PAM in the same assay and running about 25-fold more potent than Epithalon. Radioreceptor assays showed no binding to mu or d… - Q: Has Livagen been studied in humans? A: No human clinical trial of Livagen has been published. Human-related data are ex vivo: lymphocytes from elderly donors exposed to Livagen showed ribosomal gene activation and decondensation of age-condensed heterochromatin (PMID: 12533768). Everything else is rat research, including hepatocyte cult… - Q: Is Livagen safe? A: Safety is uncharacterized. There is no toxicology study, no human trial, and no structured safety reporting in the animal work. The in vitro enkephalinase inhibition finding means an interaction with endogenous opioid tone cannot be excluded at sufficient exposure, although opioid receptor binding… ### [Ovagen](https://peptpedia.org/peptide/ovagen) Ovagen is a synthetic tripeptide (Glu-Asp-Leu) from the Khavinson bioregulator family. Marketed as a liver and GI peptide, its entire PubMed-indexed primary research record concerns kidney endpoints in rats. **Key Findings:** - Ovagen (Glu-Asp-Leu) is marketed as a liver and gastrointestinal bioregulator, yet every PubMed-indexed primary research paper on the EDL tripeptide studies kidney endpoints. - In rat cisplatin, gentamicin, and ischemia-reperfusion kidney injury models, EDL normalized diuresis, creatinine handling, and glomerular filtration while reducing proteinuria. - In aging renal cell culture, EDL reduced the senescence markers p16, p21, and p53 and increased SIRT-6, with DNA minor-groove binding proposed as the mechanism. - No human study, pharmacokinetic measurement, or formal safety assessment of Ovagen has been published. **Frequently Asked Questions:** - Q: What is Ovagen? A: Ovagen is a synthetic tripeptide, Glu-Asp-Leu (EDL), from the Khavinson short peptide bioregulator family. It is marketed in supplement channels as a liver and gastrointestinal bioregulator, but the PubMed-indexed primary research on EDL concerns the kidney: rat models of cisplatin, gentamicin, and… - Q: Is Ovagen really a liver peptide? A: The commercial positioning says liver and GI, but the indexed experimental literature says kidney. PubMed searches surface no primary experimental paper on EDL for liver or gastrointestinal endpoints; the hepatoprotective framing traces to review-level and monograph citations from the originating g… - Q: What did the Ovagen kidney studies show? A: In cisplatin-induced acute renal failure in rats, EDL normalized diuresis, creatinine handling, glomerular filtration rate, and sodium resorption while reducing proteinuria (PMID: 26515176). In gentamicin-induced nephropathy and ischemia-reperfusion injury, it prevented oliguria and retention azote… - Q: Has Ovagen been studied in humans? A: No. There is no human clinical trial, no human pharmacokinetic study, and no human observational report for the EDL tripeptide. The closest human-relevant data are rat renal cell culture experiments tracking senescence markers such as p16, p21, p53, and SIRT-6 (PMID: 25946838). Any human use report… - Q: Is Ovagen safe? A: There is no safety evidence in either direction. No toxicology study, no pharmacokinetic characterization, and no structured adverse-event reporting exist for EDL. Related Khavinson short peptides have been administered to animals at various doses without reported toxicity, but class-level reassura… ### [Prostamax](https://peptpedia.org/peptide/prostamax) Prostamax is a synthetic tetrapeptide (Lys-Glu-Asp-Pro) described as prostate-directed in the Khavinson bioregulator literature, with published evidence limited to organotypic culture and lymphocyte chromatin studies. **Key Findings:** - Prostamax (Lys-Glu-Asp-Pro) is a synthetic tetrapeptide positioned in the Khavinson literature as a prostate-directed bioregulator. - The only prostate-specific evidence is an organotypic culture study in which 0.05 ng/ml Prostamax stimulated rat prostate gland explants; no in vivo prostate study of the synthetic peptide is indexed in PubMed. - In lymphocytes from donors aged 75 to 86, Prostamax decondensed age-condensed chromatin and altered sister chromatid exchange frequency and nucleolar organizer activity. - Clinical papers about prostate bioregulator therapy concern bovine prostate extract drugs such as Vitaprost, which are chemically different from the synthetic KEDP tetrapeptide. **Frequently Asked Questions:** - Q: What is Prostamax? A: Prostamax is a synthetic tetrapeptide, Lys-Glu-Asp-Pro (KEDP), described in the Khavinson bioregulator literature as a prostate-directed peptide. Published research covers organotypic rat prostate culture and chromatin biophysics in lymphocytes from elderly donors. It should not be confused with bo… - Q: What prostate research exists on Prostamax? A: The only prostate-specific experiment indexed in PubMed is an organotypic tissue culture study in which Prostamax at 0.05 ng/ml stimulated growth of rat prostate gland explants from young and aged animals (PMID: 17152728). No in vivo animal prostate study and no human study of the synthetic KEDP te… - Q: Is Prostamax the same as Vitaprost or Samprost? A: No. Vitaprost is a bovine prostate extract drug studied in a randomized human trial for benign prostatic hyperplasia with chronic prostatitis (PMID: 34251104), and Samprost is a similar extract drug studied in a rat chronic aseptic prostate inflammation model (PMID: 22803042). Prostamax is a single… - Q: Has Prostamax been studied in humans? A: The synthetic peptide has no published human study. Human-related data are ex vivo chromatin experiments on lymphocytes from donors aged 75 to 86, where Prostamax produced deheterochromatinization and changed sister chromatid exchange frequency and nucleolar organizer activity (PMID: 23221144). The… - Q: Is Prostamax safe? A: No safety data exist: no toxicology study, no human trial, and no pharmacokinetic characterization. The organotypic culture finding of stimulated prostate tissue proliferation is the basis for a theoretical caution about use with undiagnosed or active prostate malignancy, since stimulating prostate… ### [Testagen](https://peptpedia.org/peptide/testagen) Testagen is a synthetic tetrapeptide (Lys-Glu-Asp-Gly) of the Khavinson bioregulator class, studied in hypophysectomized bird models for pituitary-thyroid axis effects. No human trials exist. **Key Findings:** - Testagen (KEDG, Lys-Glu-Asp-Gly) is modeled on anterior pituitary peptide composition; every indexed experimental study of it was performed in hypophysectomized birds, not mammals or humans. - Forty-day KEDG administration in hypophysectomized chickens and hens partially restored thyrotropin, thyroid hormones, thyroid morphology, and thymic structure, with weaker effects in old hens. - Vendor claims that Testagen supports testes or testosterone have no PubMed-indexed experimental support; no study has measured testosterone outcomes with KEDG. - A 2023 docking study proposed LAT1, LAT2, and PEPT1 transporters as a cellular uptake route for KEDG, the only molecular-level evidence in its literature. **Frequently Asked Questions:** - Q: What is Testagen? A: Testagen is the trade name for the synthetic tetrapeptide KEDG (Lys-Glu-Asp-Gly), designed from the amino acid composition of anterior pituitary peptide complexes. It belongs to the Khavinson school of short peptide bioregulators and is sold in Russia as a dietary supplement. Its indexed research b… - Q: Is Testagen a testosterone booster? A: No published evidence supports that claim. Vendor marketing often describes Testagen as a testicular or testosterone-supporting bioregulator, but the indexed literature on KEDG covers thyroid, thymus, immune, and coagulation endpoints in hypophysectomized birds. No PubMed-indexed study has tested K… - Q: What research has been done on Testagen? A: Four indexed experimental papers, all from the Kuznik group at Chita State Medical Academy, studied KEDG in hypophysectomized chickens and hens: 40-day administration partially restored thyrotropin and thyroid hormone levels, thyroid morphology, thymic structure, and immune and hemostatic parameter… - Q: Is Testagen safe? A: Human safety is uncharacterized: there are no human trials, no pharmacokinetic data, and no formal toxicology in indexed literature. The bird studies did not report toxicity during 40-day administration, but avian tolerance does not predict human safety. Products sold online as Testagen are researc… ### [Vilon](https://peptpedia.org/peptide/vilon) Vilon is a synthetic dipeptide (Lys-Glu, KE) identified as an active constituent of the thymus polypeptide complex Thymalin, studied for T-cell differentiation and cytokine modulation. **Key Findings:** - Vilon (Lys-Glu, KE) is the shortest Khavinson thymic bioregulator and one of the defined active substances of the registered Russian drug Thymalin. - Isolated KE reduced TNF-α, IL-1β, and IL-6 synthesis in inflamed human blood cells, outperforming the whole Thymalin complex at the TNF-α endpoint in the same assay. - Lifelong monthly KE dosing in CBA mice increased physical activity and reduced spontaneous lung adenomas but did not significantly extend survival. - Docking work from the developing group proposes KE binds GCGC motifs in nucleosomal DNA, the epigenetic mechanism claimed for the class; no receptor has been identified. **Frequently Asked Questions:** - Q: What is Vilon? A: Vilon is the synthetic dipeptide Lys-Glu (KE), developed at the St. Petersburg Institute of Bioregulation and Gerontology as a defined active substance of Thymalin, the calf thymus polypeptide complex. It is the shortest compound in the Khavinson thymic bioregulator family and is studied for T-cell… - Q: Is Vilon the same as Thymalin? A: No. Thymalin is a polypeptide extract of calf thymus registered as a drug in Russia; Vilon is one of its defined synthetic constituents, the KE dipeptide. A 2023 IJMS study compared them directly in LPS-stimulated human blood cells: isolated KE reduced TNF-α synthesis more strongly than the whole T… - Q: What does Vilon do to the immune system? A: In cell culture, KE increased the lymphocyte differentiation marker CD5 and pushed T-cell precursors toward CD4+ helper cells, and the parent complex Thymalin increased the mature T-cell marker CD28 by 6.8-fold in human hematopoietic stem cell cultures. In inflamed human blood cells and THP-1 macro… - Q: Does Vilon extend lifespan? A: The one long-term animal study says no for survival: female CBA mice treated lifelong with KE showed increased physical activity and fewer spontaneous lung adenomas, but no significant survival extension, while the pineal peptide epithalon in the same experiment did extend mean survival by 5.3%. Hu… - Q: Is Vilon safe? A: Human safety is uncharacterized: no Phase I trial, no pharmacokinetic study, and no controlled human exposure data exist for isolated KE. The mouse lifespan study reported no toxicity with lifelong monthly dosing. Because KE promotes T-cell activity, transplant recipients on immunosuppression and p… ### [Vesugen](https://peptpedia.org/peptide/vesugen) Vesugen is a synthetic tripeptide (Lys-Glu-Asp, KED) of the Khavinson bioregulator class, studied as a vascular endothelial regulator with mostly in vitro and animal evidence. **Key Findings:** - Vesugen is the tripeptide Lys-Glu-Asp (KED); its vascular claims rest on in vitro work showing normalized endothelin-1, restored connexin contacts, and increased sirtuin-1 in atherosclerotic endothelial models. - The 5xFAD mouse Alzheimer study (400 mcg/kg daily intraperitoneal) reported prevented dendritic spine loss but carries a January 2025 correction whose content is not specified in the public notice. - The two human studies (n=41 and n=32) are uncontrolled Russian-language reports; the n=32 study also detected prooxidant activity and reduced CD34+ progenitor cells. - No randomized trial, pharmacokinetic study, or independent replication outside the Khavinson network exists for Vesugen. **Frequently Asked Questions:** - Q: What is Vesugen? A: Vesugen (also spelled Vezugen) is the synthetic tripeptide Lys-Glu-Asp (KED), developed at the Saint Petersburg Institute of Bioregulation and Gerontology as a vascular endothelial bioregulator. It is sold in Russia as a dietary supplement. Its indexed literature is small, mostly in vitro and anima… - Q: What human evidence exists for Vesugen? A: Two small Russian-language studies, both uncontrolled: 41 patients with vasculogenic erectile dysfunction showed improved penile artery blood flow after KED monotherapy, and 32 elderly patients with polymorbidity showed favorable shifts in biological-age markers but also prooxidant activity and red… - Q: What is the correction on the Vesugen Alzheimer mouse study? A: The 2021 Pharmaceuticals paper reporting that KED prevented dendritic spine loss in 5xFAD Alzheimer mice received a formal correction published in January 2025 (PMID 39861198). The public correction notice does not specify what was changed. The findings remain on the record but should be cited with… - Q: Is Vesugen safe? A: Uncharacterized in humans. The two small human studies reported no adverse events but used no formal adverse-event protocols, and the 32-patient study detected prooxidant activity and a significant drop in circulating CD34+ hematopoietic progenitor cells, which the authors themselves flagged as inh… ### [Cyclic Glycine-Proline](https://peptpedia.org/peptide/cyclic-glycine-proline) Cyclic glycine-proline (cGP) is an endogenous diketopiperazine metabolite of IGF-1 that regulates IGF-1 bioavailability and is studied for neuroprotection and stroke recovery. **Key Findings:** - cGP is an endogenous diketopiperazine metabolite of IGF-1 that regulates IGF-1 bioavailability by competing with IGF-1 for IGF binding protein-3. - Unlike most peptides, cGP is orally available and reaches the human CNS: blackcurrant anthocyanin supplementation raised cerebrospinal fluid cGP in Parkinson patients within 28 days. - Intranasal cGP (20 mg/kg, 28 days) improved spatial memory and reduced amyloid plaque load in APP/PS1 Alzheimer mice, in a study independent of the group that built the cGP field. - The plasma cGP/IGF-1 ratio predicts 90-day neurological outcome after stroke, but as a biomarker association, not an intervention result. **Frequently Asked Questions:** - Q: What is cyclic glycine-proline? A: Cyclic glycine-proline (cGP) is a small cyclic dipeptide in the 2,5-diketopiperazine family, produced naturally when the N-terminal tripeptide of IGF-1 (glycine-proline-glutamate) is cleaved and cyclized. It circulates in human plasma and cerebrospinal fluid and acts as an endogenous regulator of I… - Q: How does cGP affect IGF-1? A: cGP retains the IGFBP-3 binding determinants of its parent IGF-1 N-terminal sequence, so it competes with IGF-1 for occupancy of IGF binding protein-3. By displacing IGF-1 from IGFBP-3, cGP increases free, bioavailable IGF-1; the cGP/IGF-1 molar ratio is used as a functional index of IGF-1 status.… - Q: Does cGP reach the brain when taken orally? A: Evidence says yes, indirectly: in 11 male Parkinson patients, 28 days of oral blackcurrant anthocyanin supplementation (a natural cGP source, 300 mg twice daily) significantly raised cerebrospinal fluid cGP, and CSF levels correlated with plasma levels (R=0.68). The CSF/plasma ratio was high for cG… - Q: What human evidence exists for cGP? A: Two lines: an observational stroke cohort (34 patients) in which a lower cGP/IGF-1 ratio at admission predicted worse 90-day neurological outcome, and a small open-label supplement study (11 Parkinson patients) showing oral blackcurrant anthocyanins raise CSF cGP. Neither is a controlled trial of i… - Q: Is cGP safe? A: cGP is an endogenous compound present in human plasma and cerebrospinal fluid, and the 28-day Parkinson supplement study reported no safety signal, but it involved only 11 patients and was not designed as a safety trial. No formal toxicology or controlled safety study of isolated cGP has been publi… ### [Adamax](https://peptpedia.org/peptide/adamax) Adamax is an unofficial, vendor-market derivative of the Russian nootropic peptide Semax with N-terminal acetylation and a C-terminal adamantane group. No peer-reviewed study of Adamax itself has been published. **Key Findings:** - Adamax has no peer-reviewed literature: no PubMed-indexed study and no PubChem record exists for the compound, so its structure is defined only by vendor specifications. - The molecule is a Semax core with N-terminal acetylation and a C-terminal adamantane cage, two standard modifications aimed at protease resistance and blood-brain barrier penetration. - The adamantane-for-brain-penetration strategy has one published proof of concept in a different peptide class (the CNTF mimetic P21, FEBS Letters 2010), not in any Semax analog. - All benefit claims trace to parent Semax: BDNF upregulation in rat brain, serotonergic modulation, and Russian stroke studies, none of which tested the Adamax conjugate. **Frequently Asked Questions:** - Q: Is Adamax the same as Semax? A: No. Adamax is an unofficial derivative of Semax with two structural changes: an acetyl group on the N-terminus and an adamantane cage on the C-terminus. Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is a registered drug in Russia with published clinical studies. Adamax is sold only as a research chemical, an… - Q: Has Adamax been studied in humans or animals? A: No. A PubMed search for Adamax returns no pharmacology, toxicology, or clinical literature for the peptide, and it has no PubChem record. Every claim made for it is extrapolated from two bodies of work: the Semax literature (Russian clinical stroke studies plus rodent BDNF and neurochemistry experi… - Q: What is the adamantane group supposed to do? A: Adamantane is a rigid, highly lipophilic hydrocarbon cage. Medicinal chemists attach it to peptides to increase resistance to enzymatic degradation and to improve passage across lipid membranes including the blood-brain barrier. The strategy has one published peptide proof of concept (the CNTF mime… - Q: How does Adamax compare to N-Acetyl Semax Amidate? A: Both are unofficial Semax derivatives sold as research chemicals. N-Acetyl Semax Amidate carries only the two end caps (N-acetyl and C-amide) and its structure is catalogued in PubChem (CID 172638603). Adamax adds the further adamantane modification and has no authoritative chemical registry entry.… - Q: Is Adamax approved or regulated anywhere? A: No. Adamax is not approved for human use in any country and is not on any regulator's review track. Its parent Semax is a registered prescription drug in Russia and Ukraine, but that registration covers only the unmodified peptide. Adamax is sold as a research chemical, and human use would be uncon… ### [Adalank](https://peptpedia.org/peptide/adalank) Adalank (N-acetyl Selank amidate) is a vendor-market derivative of the Russian anxiolytic peptide Selank with acetyl and amide end caps. No peer-reviewed study of Adalank itself has been published. **Key Findings:** - Adalank is exactly what its name says: Selank with N-terminal acetyl and C-terminal amide caps, a structure calculable at C35H60N12O9 (792.9 g/mol) but absent from PubChem and PubMed. - No experiment has tested the analog; all claims inherit from Selank, including the 62-patient GAD study showing anxiolysis comparable to medazepam. - Selank's distinctive mechanistic finding, restoration of serum leu-enkephalin stability in anxiety patients, has never been assayed for the end-capped analog. - Vendor claims of extended half-life are plausible class-level chemistry but remain unmeasured for this molecule. **Frequently Asked Questions:** - Q: What is Adalank? A: Adalank is the N-acetylated, C-amidated form of Selank (Ac-Thr-Lys-Pro-Arg-Pro-Gly-Pro-NH2), a vendor-market derivative of the Russian anxiolytic heptapeptide. The two end caps are meant to protect the peptide from exopeptidase degradation. It is sold only as a research chemical, and no peer-review… - Q: Has Adalank been studied? A: No. PubMed contains no pharmacology, toxicology, or clinical literature for Adalank or N-acetyl Selank amidate, and the compound has no PubChem entry. Its calculated formula (C35H60N12O9, 792.9 g/mol) follows unambiguously from the Selank structure plus the two caps, but every biological claim deri… - Q: What human evidence exists for the parent compound Selank? A: A 62-patient Russian study found Selank comparable to medazepam for generalized anxiety disorder and neurasthenia, with additional antiasthenic effects (PMID: 18454096); a clinical-immunological study documented cytokine changes over 14 days of treatment (PMID: 18577961); and an fMRI study in 52 he… - Q: What do the acetyl and amidate modifications do? A: N-terminal acetylation blocks aminopeptidases and C-terminal amidation blocks carboxypeptidases, the two enzyme classes that trim peptides from their ends. Together they generally extend serum survival and can improve membrane permeability. The trade-off is that end caps can also change receptor bi… - Q: Is Adalank approved anywhere? A: No. Parent Selank is registered as an anxiolytic drug in Russia, but that registration does not cover modified analogs. Adalank has no regulatory approval in any country and is sold as a research chemical; using it in humans would be self-experimentation with an untested compound. ### [N-Acetyl Semax Amidate](https://peptpedia.org/peptide/na-semax-amidate) N-Acetyl Semax Amidate is a doubly end-capped derivative of Semax (Ac-MEHFPGP-NH2) catalogued in PubChem but never tested in a published study. What is known about it is inferred from Semax pharmacology. **Key Findings:** - Unlike most grey-market analogs, N-Acetyl Semax Amidate has an authoritative identity: PubChem CID 172638603, C39H54N10O10S, 855.0 g/mol, CAS 2920938-90-3. - The analog has zero published studies; every biological claim is inherited from unmodified Semax. - Its design targets Semax's documented weakness, a 2-3 minute plasma half-life, but no stability or potency measurement of the analog exists. - Semax's bioactive C-terminal PGP fragment is exactly the region the amide cap modifies, an untested interaction flagged by the parent literature itself. **Frequently Asked Questions:** - Q: What is N-Acetyl Semax Amidate? A: It is Semax (Met-Glu-His-Phe-Pro-Gly-Pro) with an acetyl group capping the N-terminus and an amide capping the C-terminus, written Ac-MEHFPGP-NH2. The structure is authoritatively registered in PubChem (CID 172638603; C39H54N10O10S; 855.0 g/mol; CAS 2920938-90-3). It is sold as a research chemical… - Q: Is N-Acetyl Semax Amidate stronger or longer-lasting than Semax? A: Unknown. The end caps are designed to resist the exopeptidases that clear Semax from plasma in about 2-3 minutes, so longer molecular survival is a reasonable hypothesis, but no serum stability assay, half-life measurement, or potency comparison of the analog has been published. Claims of superior… - Q: Has N-Acetyl Semax Amidate been studied in humans? A: No. All human data in this space belongs to unmodified Semax: Russian stroke studies including a 110-patient series, and a placebo-controlled fMRI study in 24 healthy volunteers. None of it administered the acetyl-amidate, and results from the parent cannot be assumed to transfer to a chemically di… - Q: What is the difference between Adamax and N-Acetyl Semax Amidate? A: Both are unofficial Semax derivatives with the same N-acetyl cap. The amidate stops there, adding only the C-terminal amide, while Adamax attaches a bulky lipophilic adamantane cage at the C-terminus instead. The amidate's structure is registered in PubChem; Adamax has no authoritative registry ent… - Q: Is N-Acetyl Semax Amidate approved anywhere? A: No. Semax is a registered drug in Russia and Ukraine, but the registration covers only the unmodified peptide. The amidate is an unapproved research chemical in every jurisdiction, and human use would be uncontrolled self-experimentation with an untested analog. ### [Omberacetam](https://peptpedia.org/peptide/omberacetam) Omberacetam (Noopept, GVS-111) is a Russian-developed dipeptide mimetic of piracetam with nootropic and neuroprotective properties, studied in one comparative human trial and an extensive preclinical program. **Key Findings:** - Omberacetam is the INN for Noopept (GVS-111), a dipeptide-scaffold nootropic registered as a drug in Russia, with verified identity C17H22N2O4 (318.4 g/mol), CAS 157115-85-0. - It has the strongest human evidence in its class: a 56-day randomized trial in 53 patients where 20 mg/day matched piracetam 1200 mg/day with 1.8-fold fewer undesirable effects. - It is a prodrug: the ester hydrolyzes rapidly, releasing cycloprolylglycine, an endogenous IGF-1-related diketopiperazine that reaches the brain and carries its own pharmacology. - Preclinical work shows hippocampal NGF/BDNF upregulation, anti-excitotoxic protection, and attenuated tau hyperphosphorylation, but no human Alzheimer or Western replication trial exists. **Frequently Asked Questions:** - Q: Is omberacetam the same as Noopept? A: Yes. Omberacetam is the international nonproprietary name; Noopept is the Russian trade name; GVS-111 is the development code. All three refer to N-phenylacetyl-L-prolylglycine ethyl ester (C17H22N2O4, CAS 157115-85-0), the dipeptide-derived nootropic developed at the Zakusov Institute of Pharmacol… - Q: Is omberacetam a racetam? A: Not structurally. Racetams share a 2-oxopyrrolidine ring; omberacetam is an N-acylprolyl dipeptide ethyl ester designed with peptide logic as a piracetam analog. It is grouped with racetams functionally because it targets the same nootropic niche and was benchmarked against piracetam, but its chemi… - Q: What human evidence exists for omberacetam? A: One 56-day randomized comparative trial: 53 patients with mild cognitive disorders of vascular or post-traumatic origin received Noopept 20 mg/day or piracetam 1200 mg/day. Noopept matched piracetam's nootropic effect with 1.8-fold fewer undesirable effects and a more balanced anxiolytic profile (P… - Q: How does omberacetam relate to cycloprolylglycine? A: Omberacetam is an ethyl-ester prodrug that hydrolyzes rapidly in the body, releasing cycloprolylglycine (cPG), a cyclic dipeptide that is itself endogenous (it also forms during IGF-1 metabolism). Rat pharmacokinetics show the parent ester disappears quickly while cPG persists and reaches the brain… - Q: Is omberacetam approved anywhere? A: It is registered as a drug in Russia (sold as Noopept 10 mg tablets) and some neighboring states. It is not approved by the FDA or EMA. Outside those markets it is sold as a supplement or research compound, a regulatory gray zone with no quality-control guarantees. ### [P21](https://peptpedia.org/peptide/p21) P21 (P021) is an adamantane-containing CNTF mimetic peptide that promotes dentate gyrus neurogenesis and showed disease-modifying effects in transgenic Alzheimer mouse models. No human trials have been published. **Key Findings:** - P021 is a rationally designed CNTF mimetic: the CNTF(148-151) fragment DGGL with N-acetyl and a C-terminal adamantane-cage glycine amide, giving oral, brain-penetrant activity. - Chronic oral treatment of 3xTg-AD mice reduced tau hyperphosphorylation via the BDNF/TrkB/GSK3-beta axis and rescued cognition, neurogenesis, and synaptic plasticity; a prevention-start design also markedly reduced mortality. - In aged rats it normalized elevated CSF tau to young-adult levels without a detectable immune reaction, a notable tolerability signal for a peptide. - The entire evidence base is one research group's mouse and rat work; there is no human study and no independent replication, which caps confidence in the headline claims. **Frequently Asked Questions:** - Q: What is P21 and how is it related to CNTF? A: P21 (P021) is a synthetic mimetic of ciliary neurotrophic factor. It takes a 4-amino-acid active-region fragment of human CNTF (residues 148-151, Asp-Gly-Gly-Leu) and adds an N-terminal acetyl group and a C-terminal adamantane-cage glycine mimetic amide, written Ac-DGGL(A)G-NH2. The goal was to kee… - Q: Has P21 been tested in humans? A: No. Every published P021 study is preclinical, conducted in mice or rats, and all in vivo work comes from a single research group (the Iqbal group at the NYS Institute for Basic Research). There is no human pharmacokinetic, safety, or efficacy data, no registered clinical trial, and no independent… - Q: What did the Alzheimer mouse studies actually show? A: In 3xTg-AD mice, 12 months of oral P021 from 9-10 months of age reduced tau hyperphosphorylation and soluble amyloid, rescued cognition, neurogenesis, and synaptic plasticity (PMID: 25046994). Started at 3 months before pathology appeared, it prevented neurodegeneration, both pathologies, and memor… - Q: What is the adamantane group for? A: Adamantane is a rigid lipophilic hydrocarbon cage. Fusing it to the peptide's C-terminus (as an adamantane-glycine mimetic) increases resistance to proteolytic degradation and raises lipophilicity, which the design study credits for the compound's oral activity and blood-brain barrier permeability.… - Q: Does P21 clear amyloid plaques? A: No, and the primary data says so plainly. In 3xTg-AD mice, P021 significantly lowered soluble A-beta levels but produced only a nonsignificant trend toward reduced CA1 plaque load, which the authors interpreted as reduced A-beta generation rather than plaque clearance (PMID: 25046994). Its patholog… ### [PE-22-28](https://peptpedia.org/peptide/pe-22-28) PE-22-28 (mini-spadin) is a 7-amino-acid fragment of the sortilin-derived peptide spadin that blocks the TREK-1 potassium channel with sub-nanomolar affinity and shows rapid antidepressant-like effects in rodent models. **Key Findings:** - PE-22-28 (Gly-Val-Ser-Trp-Gly-Leu-Arg) is the minimal active fragment of spadin, designed from spadin's own serum degradation products; verified identity C35H55N11O9, 773.9 g/mol. - It blocks the TREK-1 potassium channel at IC50 0.12 nM (about 300x spadin) with no activity at TREK-2, TRAAK, TRESK, or TASK-1, and lasts about 23 hours in mice versus 7 for spadin. - Four-day treatment produced antidepressant-like behavior and near-doubled hippocampal neurogenesis in mice, with oral activity at 1 mg/kg. - The pharmacology is biphasic (very low doses activate TREK-1 and are neuroprotective), and no human study exists; vendor dosing is extrapolated from microgram-per-kilogram mouse protocols. **Frequently Asked Questions:** - Q: What is PE-22-28 and how does it relate to spadin? A: PE-22-28 is the shortest active fragment of spadin. Spadin is a 17-amino-acid peptide released from the propeptide of sortilin; by tracking spadin's degradation in mouse serum, researchers identified the 7-residue C-terminal piece (positions 22-28 of the propeptide, Gly-Val-Ser-Trp-Gly-Leu-Arg) as… - Q: How does blocking TREK-1 produce antidepressant effects? A: TREK-1 is a background potassium channel that keeps neurons electrically quiet. In the dorsal raphe, blocking it depolarizes serotonergic neurons and raises their firing rate, increasing serotonin output to mood circuits. SSRIs reach the same serotonergic endpoint indirectly through transporter inh… - Q: Has PE-22-28 been studied in humans? A: No. All PE-22-28 data is preclinical, from the French academic group that developed it and one independent electrophysiology study. The nearest human evidence is observational: serum levels of the endogenous parent propeptide rose after successful electroconvulsive therapy in treatment-resistant de… - Q: What is the biphasic dose effect? A: PE-22-28 does not act the same way at every dose. At very low doses (0.03 mcg/kg in mice) it increased TREK-1 channel activity and was neuroprotective after experimental stroke; at higher doses (3 mcg/kg) it blocked the channel and produced antidepressant-like effects (PMID: 31325429). The two regi… - Q: How fast does PE-22-28 act compared to SSRIs? A: In mouse models, antidepressant-like effects and hippocampal neurogenesis appear after 4 days of treatment, whereas SSRIs like fluoxetine require several weeks in the same paradigms (PMID: 28955242, 20405001). This is a rodent model comparison, not a human onset-of-action claim: no human has been d… --- ## Peptide Comparisons ### [Semaglutide vs Tirzepatide: Comparative Analysis of GLP-1 Receptor Agonist Efficacy for Weight Loss and Glycemic Control](https://peptpedia.org/compare/semaglutide-vs-tirzepatide) Research indicates that Tirzepatide, a dual GIP/GLP-1 receptor agonist, demonstrates superior weight loss efficacy compared to Semaglutide, a GLP-1-only agonist, in head-to-head clinical trials. The SURMOUNT-5 trial showed Tirzepatide achieved 20.2% average body weight reduction versus 13.7% for Semaglutide at 72 weeks—a 47% greater relative weight loss. Both compounds show comparable gastrointestinal tolerability profiles, but Tirzepatide's dual mechanism appears to provide synergistic metabolic benefits through simultaneous activation of glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 pathways. ### [Retatrutide vs Tirzepatide: Triple Agonist vs Dual Agonist Comparison for Metabolic Research](https://peptpedia.org/compare/retatrutide-vs-tirzepatide) Retatrutide, a first-in-class triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors, demonstrates unprecedented weight loss efficacy in clinical trials—up to 24.2% body weight reduction at 48 weeks. Compared to Tirzepatide's dual GIP/GLP-1 mechanism achieving 20.2% weight loss at 72 weeks, Retatrutide's addition of glucagon receptor agonism appears to enhance energy expenditure and hepatic lipid metabolism. While Tirzepatide has FDA approval and extensive real-world data, Retatrutide remains in Phase 3 trials with potential for superior metabolic outcomes. ### [Retatrutide vs Semaglutide: Triple Agonist vs GLP-1 Agonist for Next-Generation Obesity Research](https://peptpedia.org/compare/retatrutide-vs-semaglutide) Retatrutide's triple receptor mechanism (GLP-1/GIP/Glucagon) achieves significantly greater weight loss than Semaglutide's single GLP-1 pathway—24.2% vs 14.9% body weight reduction in clinical trials. While Semaglutide (Ozempic/Wegovy) represents the current gold standard with FDA approval and extensive real-world data, Retatrutide's Phase 2 results suggest it may nearly double the efficacy. The addition of GIP and glucagon agonism provides synergistic effects on insulin secretion, energy expenditure, and hepatic lipid metabolism not achievable with GLP-1 alone. ### [AOD-9604 vs Semaglutide: Non-Hormonal Fat Loss Peptide vs GLP-1 Agonist Comparison](https://peptpedia.org/compare/aod-9604-vs-semaglutide) AOD-9604, a modified fragment of human growth hormone (amino acids 176-191), and Semaglutide, a GLP-1 receptor agonist, represent fundamentally different approaches to fat metabolism research. AOD-9604 was designed to replicate GH's lipolytic effects without affecting blood glucose or promoting tissue growth, targeting fat breakdown directly. Semaglutide achieves weight loss primarily through appetite suppression and metabolic regulation via central nervous system pathways. While Semaglutide has robust FDA approval and clinical evidence for obesity treatment, AOD-9604's clinical development was discontinued after Phase 2b trials failed to demonstrate significant efficacy over placebo. ### [BPC-157 vs TB-500: Which Is Better? Gut, Tendon & Muscle Data](https://peptpedia.org/compare/bpc-157-vs-tb-500) BPC-157 is the better-supported choice in animal data for gut, tendon and ligament, and oral-stability research; TB-500 (and its parent thymosin β-4) is the better-supported choice for cell migration, muscle, and cardiac repair. They are not interchangeable. BPC-157's human evidence is thin but not zero — a phase II programme in ulcerative colitis (PL 14736, PMID 22300085) and small retrospective series, with no completed phase III. TB-500 itself has no published human data; the human trials used full-length Tβ4 (RGN-352), which is not the same molecule. ### [Semax vs Selank: Nootropic Peptide Comparison for Cognitive and Anxiolytic Research](https://peptpedia.org/compare/semax-vs-selank) Semax and Selank, both developed in Russia for clinical use, represent complementary approaches to cognitive and emotional regulation through peptide therapeutics. Semax, derived from ACTH (4-10), primarily enhances focus, learning, and cognitive performance through BDNF upregulation and dopaminergic modulation. Selank, a synthetic analog of the immunomodulatory peptide tuftsin, provides anxiolytic effects comparable to benzodiazepines without sedation or dependence. While both increase BDNF expression, their receptor profiles and downstream effects differ—Semax activates, while Selank calms. Researchers often combine them for balanced cognitive enhancement with mood stabilization. ### [CJC-1295 vs Ipamorelin: Pulse vs Sustained GH Release](https://peptpedia.org/compare/cjc-1295-vs-ipamorelin) Ipamorelin starts the GH pulse at the ghrelin receptor (~2-hour half-life); in the rat and swine study that introduced it (PMID 9849822) it released GH without the ACTH and cortisol rise seen with GHRP-6 and GHRP-2. CJC-1295 amplifies GH at the GHRH receptor (minutes without DAC, 6–8 days with DAC). They are complementary, not substitutes — a GHRP initiator plus a GHRH amplifier. Neither is FDA-approved; combination use rests on receptor pharmacology, not a published head-to-head trial. ### [Epithalon vs FOXO4-DRI: Telomerase Activation vs Senolytic Peptide Comparison for Longevity Research](https://peptpedia.org/compare/epithalon-vs-foxo4-dri) Epithalon and FOXO4-DRI represent two distinct approaches to cellular anti-aging research. Epithalon, a synthetic tetrapeptide based on pineal gland epithalamin, activates telomerase to maintain or extend telomeres—the protective caps on chromosomes that shorten with age. FOXO4-DRI is a senolytic peptide that selectively induces apoptosis in senescent ('zombie') cells that accumulate with age and secrete harmful inflammatory factors. While Epithalon aims to preserve cellular replicative capacity, FOXO4-DRI eliminates damaged cells that resist normal death. These represent complementary anti-aging strategies: maintaining healthy cells (Epithalon) versus removing harmful ones (FOXO4-DRI). ### [GHK-Cu vs BPC-157: Copper Peptide vs Gastric Peptide Comparison for Tissue Repair Research](https://peptpedia.org/compare/ghk-cu-vs-bpc-157) GHK-Cu and BPC-157 are two of the most researched peptides for tissue repair, with distinct but potentially complementary mechanisms. GHK-Cu, a naturally occurring copper-binding tripeptide, excels in skin rejuvenation, collagen remodeling, and topical wound healing through copper-dependent enzyme activation. BPC-157, a stable gastric pentadecapeptide, demonstrates broader systemic healing effects across multiple tissue types including tendons, muscles, and the gastrointestinal tract through angiogenic and growth factor pathways. GHK-Cu is well-suited for dermatological applications, while BPC-157 shows greater versatility for internal tissue repair. ### [GHRP-6 vs GHRP-2: Growth Hormone Secretagogue Peptide Comparison for Research](https://peptpedia.org/compare/ghrp-6-vs-ghrp-2) GHRP-6 and GHRP-2 are both hexapeptide growth hormone releasing peptides that stimulate GH release through the ghrelin receptor (GHS-R1a), but differ significantly in selectivity and side effect profiles. GHRP-6 is the original GHRP with potent but non-selective effects—producing intense hunger (ghrelin-like effect), cortisol elevation, and prolactin increase alongside GH release. GHRP-2 represents an improvement with greater GH potency and reduced off-target effects, though still less selective than the newer Ipamorelin. For pure GH research without confounding variables, Ipamorelin is preferred; for appetite stimulation research, GHRP-6 is unique. ### [Sermorelin vs CJC-1295: GHRH Analog Comparison for Growth Hormone Research](https://peptpedia.org/compare/sermorelin-vs-cjc-1295) Sermorelin and CJC-1295 are both GHRH analogs that stimulate pituitary GH release through the GHRH receptor, but differ dramatically in pharmacokinetics. Sermorelin is the natural GHRH (1-29) fragment with a short half-life (~10-20 minutes), requiring frequent dosing but producing physiological pulsatile GH patterns. CJC-1295, particularly with DAC (Drug Affinity Complex), has an extended half-life (~8 days), allowing weekly dosing but producing more sustained GH/IGF-1 elevation. Sermorelin has FDA approval history for pediatric GH deficiency, while CJC-1295 remains a research compound with more limited clinical data. ### [Hexarelin vs Ipamorelin: GHRP Potency vs Selectivity Comparison for Research](https://peptpedia.org/compare/hexarelin-vs-ipamorelin) Hexarelin and Ipamorelin represent opposite ends of the GHRP spectrum: maximum potency versus maximum selectivity. Hexarelin is the most potent GHRP for acute GH release but carries significant off-target effects including cortisol and prolactin elevation, rapid desensitization, and potential cardiac activity. Ipamorelin is the most selective GHRP, producing clean GH release without affecting cortisol, prolactin, or appetite, but with lower acute potency. For pure GH research, Ipamorelin is preferred; for studies requiring maximum GH spike or cardiac research, Hexarelin has unique properties. ### [BPC-157 vs KPV: Gastric Pentadecapeptide vs Anti-Inflammatory Tripeptide Comparison](https://peptpedia.org/compare/bpc-157-vs-kpv) BPC-157 and KPV represent different approaches to tissue healing and inflammation control, with overlapping applications in gastrointestinal research. BPC-157, a stable gastric pentadecapeptide, promotes healing through angiogenesis and growth factor modulation across multiple tissue types. KPV, a tripeptide derived from the C-terminus of alpha-MSH, provides potent anti-inflammatory effects through NF-κB inhibition independent of melanocortin receptor activation. While BPC-157 excels at structural tissue repair, KPV specializes in reducing inflammatory cascades. For inflammatory bowel disease research, both peptides show promise with complementary mechanisms. ### [Liraglutide vs Semaglutide: GLP-1 Agonist Comparison for Weight Loss and Diabetes | Peptpedia](https://peptpedia.org/compare/liraglutide-vs-semaglutide) Semaglutide demonstrates superior weight loss efficacy compared to Liraglutide in both clinical trial data and head-to-head comparisons, with once-weekly Semaglutide 2.4 mg (Wegovy) producing approximately 15% body weight reduction versus 5-8% for once-daily Liraglutide 3.0 mg (Saxenda). Both are FDA-approved GLP-1 receptor agonists with established cardiovascular safety profiles. Semaglutide's longer half-life (7 days vs ~13 hours for Liraglutide) enables once-weekly dosing, improving adherence. ### [Thymosin Alpha-1 vs LL-37: Immune-Modulating Peptide Comparison | Peptpedia](https://peptpedia.org/compare/thymosin-alpha-1-vs-ll-37) Thymosin Alpha-1 and LL-37 are two well-characterized immune-modulating peptides with complementary but distinct mechanisms. Thymosin Alpha-1 is a thymic hormone that primarily modulates adaptive immunity through T-cell maturation and Th1 cytokine enhancement, with regulatory approval in 35+ countries. LL-37 is an endogenous antimicrobial peptide from the cathelicidin family that bridges innate and adaptive immunity through direct microbial killing and immune cell signaling. ### [Ipamorelin vs Sermorelin: GHRP vs GHRH, Selectivity](https://peptpedia.org/compare/ipamorelin-vs-sermorelin) Ipamorelin is a selective GHRP (ghrelin receptor) with a ~2-hour half-life; in rats and swine it produced a GH pulse without the ACTH and cortisol rise seen with GHRP-6 and GHRP-2 (PMID 9849822). Sermorelin is a GHRH fragment: ~10–20-minute half-life, and the only one of the pair with prior FDA approval (Geref, withdrawn in 2008 for commercial reasons). They act on different receptors; Sermorelin has the larger human-use dataset, Ipamorelin the cleaner off-target profile in animal work. ### [Epithalon vs Thymosin Alpha-1: Anti-Aging vs Immune Peptide Comparison | Peptpedia](https://peptpedia.org/compare/epithalon-vs-thymosin-alpha-1) Epithalon and Thymosin Alpha-1 represent distinct but complementary approaches to age-associated decline. Epithalon is a pineal tetrapeptide studied for telomere elongation and telomerase activation; Thymosin Alpha-1 is a thymic peptide with regulatory approvals for immune modulation. Both are extensively researched in the context of aging, but Thymosin Alpha-1 has substantially stronger clinical evidence. ### [PT-141 vs Melanotan II: Melanocortin Peptide Comparison for Sexual Health Research | Peptpedia](https://peptpedia.org/compare/pt-141-vs-melanotan-ii) PT-141 (Bremelanotide) and Melanotan II are both cyclic heptapeptide analogs of alpha-MSH acting on melanocortin receptors, but with different selectivity profiles and regulatory status. PT-141 received FDA approval in 2019 (as Vyleesi) for hypoactive sexual desire disorder in premenopausal women—the only melanocortin peptide with this approval. Melanotan II has broader melanocortin receptor activation including MC1R (tanning) and more pronounced side effects. ### [Tirzepatide vs CagriSema: Next-Generation Weight Loss Peptide Comparison | Peptpedia](https://peptpedia.org/compare/tirzepatide-vs-cagrisema) Tirzepatide and CagriSema (cagrilintide + semaglutide) represent two distinct multi-receptor approaches to obesity pharmacotherapy. Tirzepatide's SURMOUNT-1 trial achieved 22.5% body weight loss at the highest dose; REDEFINE 1 demonstrated CagriSema achieving 20.4% weight loss. Both approaches demonstrate weight loss approaching the efficacy of bariatric surgery, but through different complementary receptor mechanisms. ### [Semax vs Dihexa: Cognitive Enhancement Peptide Comparison | Peptpedia](https://peptpedia.org/compare/semax-vs-dihexa) Semax and Dihexa are two of the most potent cognitive-enhancing peptides in preclinical research, though through entirely different mechanisms. Semax is an ACTH(4-7) analog registered in Russia that stimulates BDNF and NGF production; Dihexa is a small peptide with 10^7-fold greater potency than HGF at the MET receptor, driving synaptogenesis. Both have intriguing preclinical profiles but very limited human clinical data. ### [GHK-Cu vs Epithalon: Anti-Aging Peptide Comparison | Peptpedia](https://peptpedia.org/compare/ghk-cu-vs-epithalon) GHK-Cu and Epithalon are two well-characterized anti-aging peptides targeting different biological mechanisms. GHK-Cu is a naturally occurring copper tripeptide that modulates gene expression, promotes collagen synthesis, and has the most extensive human application through topical cosmeceuticals. Epithalon is a pineal tetrapeptide studied for telomerase activation and telomere elongation, primarily in Russian research contexts. ### [BPC-157 vs LL-37: Tissue Repair vs Antimicrobial Peptide Comparison | Peptpedia](https://peptpedia.org/compare/bpc-157-vs-ll-37) BPC-157 and LL-37 are both studied for wound healing but through distinct mechanisms: BPC-157 promotes tissue repair through angiogenesis, fibroblast activation, and nitric oxide modulation; LL-37 provides antimicrobial defense while simultaneously signaling keratinocyte migration and immune cell activation. They are complementary rather than competing, with BPC-157 addressing structural repair and LL-37 addressing infection defense and innate immune signaling during wound healing. ### [BPC-157 vs Ipamorelin: Healing Peptide vs GH Secretagogue Comparison | Peptpedia](https://peptpedia.org/compare/bpc-157-vs-ipamorelin) BPC-157 and Ipamorelin target entirely different physiological systems: BPC-157 is a tissue repair peptide derived from gastric juice that promotes healing through angiogenesis and fibroblast activation; Ipamorelin is a selective GHRP that stimulates pituitary GH release. They are frequently combined in research stacks because their non-overlapping mechanisms make them theoretically complementary—Ipamorelin's GH/IGF-1 axis stimulation supports muscle repair and recovery, while BPC-157 promotes direct tissue healing at injury sites. ### [Semax vs PT-141: ACTH Analog vs Melanocortin Peptide Comparison | Peptpedia](https://peptpedia.org/compare/semax-vs-pt-141) Semax and PT-141 share ACTH/alpha-MSH origin but represent pharmacologically distinct agents. Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is an ACTH(4-7) analog registered in Russia as a cognitive and neuroprotective agent; PT-141 (Bremelanotide) is an FDA-approved cyclic melanocortin peptide developed for sexual dysfunction. Both activate melanocortin receptor pathways, but with completely different clinical targets: Semax for CNS BDNF upregulation and neuroprotection; PT-141 for MC3R/MC4R-mediated sexual arousal. ### [Dihexa vs Cerebrolysin: Cognitive Enhancement Peptide Comparison for Neuroprotection Research](https://peptpedia.org/compare/dihexa-vs-cerebrolysin) Dihexa and Cerebrolysin both target cognitive enhancement and neuroprotection, but they occupy fundamentally different positions on the evidence spectrum. Dihexa is a small peptidomimetic reported to potentiate hepatocyte growth factor (HGF) signaling through the c-Met receptor and to promote synapse formation at picomolar concentrations in vitro. However, Dihexa remains entirely preclinical, and its foundational research has faced serious integrity concerns including an expression of concern and a retraction on key papers. Cerebrolysin is a porcine brain-derived peptide mixture with decades of clinical use outside the US, multiple randomized controlled trials and meta-analyses, and a Cochrane systematic review for vascular dementia that graded the evidence very low quality. This comparison illustrates the gap between novel molecular mechanism discovery and clinical translation — Dihexa represents frontier neuroscience with unresolved integrity questions, while Cerebrolysin represents a clinically studied but mechanistically imprecise neurotrophic therapy whose own evidence carries quality caveats. ### [FOXO4-DRI vs MOTS-c: Anti-Aging Peptide Comparison — Senolytic vs Mitochondrial Approaches](https://peptpedia.org/compare/foxo4-dri-vs-mots-c) FOXO4-DRI and MOTS-c represent two fundamentally different approaches to biological aging, targeting distinct hallmarks of the aging process. FOXO4-DRI is a senolytic peptide — a D-retro-inverso peptide engineered to selectively eliminate senescent "zombie" cells that accumulate with age and secrete inflammatory factors (the senescence-associated secretory phenotype, or SASP). It works by disrupting the FOXO4-p53 protein interaction that protects senescent cells from apoptosis. MOTS-c is a mitochondrial-derived peptide (MDP) encoded within the mitochondrial genome that improves cellular energy metabolism, insulin sensitivity, and exercise capacity through AMPK activation and metabolic regulation. One approach removes damaged cells; the other improves how remaining cells function. Both are preclinical, but their complementary mechanisms suggest different and potentially synergistic strategies for addressing the biology of aging. ### [CJC-1295 DAC vs No DAC: Same Peptide, Days vs Minutes](https://peptpedia.org/compare/cjc-1295-vs-mod-grf-1-29) CJC-1295 with DAC and Mod GRF 1-29 (sold as CJC-1295 no DAC) are the same tetrasubstituted GRF(1-29) core; the only difference is the DAC linker, which extends half-life from minutes to 5.8–8.1 days. Only the DAC form has human trial data; no published trial has tested Mod GRF 1-29 standalone, so human numbers attached to it are borrowed from CJC-1295. Removing the DAC removes the long action — it is not a shorter-acting version of the same drug. ### [Ipamorelin vs GHRP-2: Selectivity vs Potency in Ghrelin-Receptor GH Secretagogue Research](https://peptpedia.org/compare/ipamorelin-vs-ghrp-2) Ipamorelin and GHRP-2 (pralmorelin) are both growth hormone secretagogues acting through the ghrelin receptor (GHSR-1a), but they sit at opposite ends of the class's selectivity spectrum. Ipamorelin was characterized by its developer as the first selective GH secretagogue: in preclinical and clinical characterization it released GH dose-dependently without significantly affecting ACTH, cortisol, or prolactin. GHRP-2 produces a strong GH pulse — in human volunteers its GH response exceeded that of GHRH and matched hexarelin — but is not fully specific, raising prolactin, ACTH, and cortisol, and it significantly increases food intake through its ghrelin-mimetic action. The comparison is therefore not about which stimulates more GH, but about how much off-target endocrine activity a research design can tolerate. ### [TB-500 vs GHK-Cu: Cell Migration vs Gene Modulation in Regenerative Peptide Research](https://peptpedia.org/compare/tb-500-vs-ghk-cu) TB-500 and GHK-Cu are both studied for tissue repair, but they represent two different biological strategies. TB-500 is a synthetic fragment modeled on Thymosin Beta-4 (Tβ4), a 43-amino-acid G-actin-sequestering peptide that drives cell migration and activates the PINCH/ILK/Akt survival pathway — the mechanism behind its landmark cardiac repair data in a mouse myocardial infarction model. GHK-Cu is an endogenous copper-binding tripeptide whose plasma levels decline with age and which modulates the expression of hundreds of genes tied to extracellular matrix remodeling, antioxidant defense, and inflammation control. Tβ4's evidence runs deeper in cardiac and compromised-wound models, including two Phase 2 dermal trials of the full-length peptide; GHK-Cu's runs deepest in skin and matrix remodeling, supported by gene-profiling data but mostly cosmetic-grade human studies. Nearly all Tβ4 findings derive from the full-length protein, and how faithfully the TB-500 fragment reproduces them remains an open question. ### [Retatrutide vs CagriSema: Triple Agonist vs Amylin-GLP-1 Combination in Next-Generation Obesity Pharmacology](https://peptpedia.org/compare/retatrutide-vs-cagrisema) Retatrutide and CagriSema are the two leading candidates to succeed GLP-1 monotherapy in obesity pharmacology, built on opposing design philosophies. Retatrutide is a single engineered peptide activating GIP, GLP-1, and glucagon receptors — the glucagon component adding energy expenditure and hepatic fat effects — and produced 24.2% mean weight loss at 48 weeks in a 338-participant Phase 2 trial, the largest reduction reported for an obesity drug candidate at that duration. CagriSema is a fixed-dose combination of two validated peptides, the amylin analog cagrilintide plus semaglutide, which produced 20.4% weight loss at 68 weeks in the 3,417-participant Phase 3 REDEFINE 1 trial. Retatrutide holds the efficacy-ceiling claim but is still completing Phase 3 (the TRIUMPH program); CagriSema holds the more mature regulatory position with two completed and published Phase 3a trials. No head-to-head trial exists, and the different trial phases, durations, and populations make cross-trial ranking provisional. ### [Ipamorelin vs Tesamorelin: Growth Hormone Secretagogue Comparison](https://peptpedia.org/compare/ipamorelin-vs-tesamorelin) Tesamorelin is an FDA-approved GHRH analog (Egrifta) with Phase 3 evidence: in a pooled analysis of two 26-week trials in 806 antiretroviral-treated HIV patients with excess abdominal fat, 2 mg daily reduced visceral adipose tissue 15.4% versus placebo while sparing abdominal subcutaneous fat (PMID: 20554713). Ipamorelin is a GHSR-1a (ghrelin-receptor) agonist that, in swine, released GH without raising ACTH or cortisol (PMID: 9849822); published human data are a volunteer PK/PD infusion study (PMID: 10496658) and a Phase 2 postoperative-ileus trial that did not meet its primary endpoint (PMID: 25331030, NCT00672074). They act on different receptors, and no head-to-head trial exists. ### [AOD-9604 vs Tesamorelin: hGH Fragment versus GHRH Analog Comparison](https://peptpedia.org/compare/aod-9604-vs-tesamorelin) Tesamorelin is an FDA-approved GHRH analog with Phase 3 evidence that 2 mg daily reduced visceral adipose tissue 15.4% versus placebo at 26 weeks in 806 HIV-infected patients, sparing abdominal subcutaneous fat (PMID: 20554713). AOD-9604 is a synthetic C-terminal hGH fragment studied for lipolysis in rodents (PMID: 11146367, PMID: 11713213) and for cartilage histology in a rabbit osteoarthritis model (PMID: 26275694). PubMed does not index a randomized obesity trial of AOD-9604; a 2004 pipeline review reported Phase IIa work underway (PMID: 15134286). One is a GHRH analog with a labeled indication. The other is an unapproved fragment with preclinical metabolic and joint data. ### [MOTS-c vs SS-31: Mitochondrial Peptide Comparison](https://peptpedia.org/compare/mots-c-vs-ss-31) MOTS-c is a 16-amino-acid peptide encoded in mitochondrial 12S rRNA that, in mice, activates AMPK-linked metabolic programs and prevents diet-induced obesity and insulin resistance (PMID: 25738459). Human evidence is that exercise raises endogenous MOTS-c in muscle and blood (PMID: 33473109), not a completed interventional trial of the injected peptide. SS-31 (elamipretide) is a cardiolipin-binding tetrapeptide with several late-stage human trials: the randomized TAZPOWER crossover in Barth syndrome (n=12) did not meet either co-primary endpoint (PMID: 33077895), and MMPOWER-3 in primary mitochondrial myopathy missed both co-primaries (PMID: 37268435). FDA still granted accelerated approval of Forzinity in 2025 for Barth syndrome muscle strength. Both are mitochondrial, and their trial literature barely overlaps. ### [Oxytocin vs PT-141: Sexual Function and Neuropeptide Comparison](https://peptpedia.org/compare/oxytocin-vs-pt-141) PT-141 (bremelanotide, Vyleesi) is FDA-approved for acquired, generalized hypoactive sexual desire disorder in premenopausal women on the basis of two Phase 3 RECONNECT trials (1,267 randomized): subcutaneous 1.75 mg as needed improved FSFI desire-domain scores and reduced desire-related distress versus placebo (PMID: 31599840). Oxytocin is FDA-approved as Pitocin for labor induction and postpartum hemorrhage, not for sexual dysfunction. Intranasal oxytocin RCTs in sexual function are small and mixed: a 22-week crossover in 30 women found oxytocin and placebo both improved FSFI with no between-group effect (PMID: 26151620); a laboratory RCT in 27 healthy women found no effect on subjective or physiologic sexual parameters (PMID: 29596150). --- ## Research Articles ### [Wolverine Stack: A Scientific Analysis of BPC-157 and TB-500 Combination Research](https://peptpedia.org/research/wolverine-stack-bpc157-tb500-analysis) The Wolverine Stack refers to the combination of two peptides studied in preclinical research: BPC-157, a synthetic pentadecapeptide derived from human gastric juice that modulates the nitric oxide system and VEGFR2-mediated angiogenesis, and TB-500, a synthetic analog of thymosin beta-4 that regulates actin dynamics and cellular migration. While each peptide has an independent body of preclinical literature, no published peer-reviewed study has examined this specific combination, and the theoretical synergy between their complementary mechanisms remains unvalidated by controlled experimental evidence. ### [GLOW Stack: A Scientific Analysis of GHK-Cu, BPC-157, and TB-500 Combination Research](https://peptpedia.org/research/glow-stack-bpc157-tb500-ghkcu-analysis) The GLOW Stack is a three-peptide research combination consisting of GHK-Cu (glycyl-L-histidyl-L-lysine copper complex), BPC-157 (Body Protection Compound-157), and TB-500 (a synthetic fragment of Thymosin Beta-4), typically described in a 5:1:1 ratio by mass with GHK-Cu as the majority component. It extends the two-peptide Wolverine Stack (BPC-157 + TB-500) by adding GHK-Cu, a copper-binding tripeptide with documented effects on extracellular matrix gene expression. While each individual peptide has a body of preclinical research, no published study has evaluated the three-peptide GLOW combination together, and its purported synergistic benefits remain entirely theoretical. ### [KLOW Stack: A Scientific Analysis of GHK-Cu, BPC-157, TB-500, and KPV Combination Research](https://peptpedia.org/research/klow-stack-ghkcu-bpc157-tb500-kpv-analysis) The KLOW Stack is a four-peptide combination containing GHK-Cu, BPC-157, TB-500, and KPV in a reported 5:1:1:1 ratio. It extends the three-peptide GLOW Stack by adding KPV, a C-terminal tripeptide fragment of alpha-melanocyte-stimulating hormone with preclinical anti-inflammatory properties. The name derives from combining the K in KPV with the GLOW acronym. While each component has individual preclinical research, no published studies have examined this four-peptide combination together, and the theoretical synergistic rationale remains unvalidated in any controlled trial. ### [Mechanism of Action of Tirzepatide: A Technical Deep Dive into Dual GIP/GLP-1 Receptor Agonism](https://peptpedia.org/research/tirzepatide-mechanism) Tirzepatide is a first-in-class dual agonist that simultaneously activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual mechanism triggers complementary signaling cascades in pancreatic beta cells, adipose tissue, and the central nervous system, resulting in enhanced insulin secretion, improved lipid metabolism, reduced appetite, and delayed gastric emptying—producing superior glycemic control and weight loss compared to single-receptor agonists. ### [Semaglutide and the Gut-Brain Axis: How GLP-1 Signaling Controls Appetite and Satiety](https://peptpedia.org/research/semaglutide-gut-brain-axis) Semaglutide controls appetite through dual gut-brain axis pathways: peripheral GLP-1 receptors on vagal afferent neurons transmit satiety signals to the brainstem, while central GLP-1 receptors in the hypothalamus (arcuate nucleus, paraventricular nucleus) and brainstem (nucleus tractus solitarius, area postrema) directly regulate hunger, food reward, and energy homeostasis. This integrated signaling network produces profound and sustained appetite suppression, contributing to the significant weight loss observed with GLP-1 receptor agonist therapy. ### [BPC-157 Stability: Storage, Reconstitution, and Degradation Factors in Research Applications](https://peptpedia.org/research/bpc-157-stability) Lyophilized BPC-157 is highly stable when stored at -20°C, maintaining integrity for years. Once reconstituted in bacteriostatic water (BAC water), BPC-157 should be refrigerated at 2-8°C and used within 4-6 weeks for optimal activity. The peptide's unusual gastric stability—surviving extreme pH conditions—distinguishes it from most peptides, but in solution it remains susceptible to oxidation, hydrolysis, and bacterial contamination. Proper handling, including sterile technique and avoiding freeze-thaw cycles, is essential for research reproducibility. ### [Ipamorelin and Growth Hormone Secretagogue Signaling: GHS-R1a Pathway Deep Dive](https://peptpedia.org/research/ipamorelin-ghs-pathway) Ipamorelin selectively activates the growth hormone secretagogue receptor type 1a (GHS-R1a) to stimulate pituitary growth hormone release without the off-target effects of other GHRPs. Upon binding GHS-R1a—a G-protein coupled receptor—Ipamorelin triggers Gq/11-mediated phospholipase C activation, IP3 generation, and intracellular calcium release, culminating in GH granule exocytosis. Unlike GHRP-6 or Hexarelin, Ipamorelin does not activate cortisol or prolactin release, nor does it significantly stimulate appetite, making it the most selective growth hormone secretagogue for research applications. ### [MOTS-c: The Mitochondrial-Derived Peptide That Mimics Exercise](https://peptpedia.org/research/mots-c-mitochondrial) MOTS-c is a 16-amino acid peptide encoded within the mitochondrial genome's 12S rRNA gene, representing a novel class of 'mitokines'—signaling molecules derived from mitochondrial DNA. Upon cellular stress or metabolic demand, MOTS-c translocates to the nucleus and activates AMPK (AMP-activated protein kinase), the master metabolic sensor. This triggers metabolic reprogramming that mimics the effects of exercise: enhanced glucose uptake, improved insulin sensitivity, increased fatty acid oxidation, and stress resistance—without physical exertion. ### [How BPC-157 Triggers New Blood Vessels (VEGF)](https://peptpedia.org/research/bpc-157-angiogenesis) BPC-157 triggers new blood vessel formation mainly at the receptor end of the VEGF axis: in ischemic rat hind-limb muscle and human endothelial cells it raised VEGFR2 expression, promoted VEGFR2 internalization, and activated VEGFR2-Akt-eNOS signaling, while VEGF-A itself was not increased (PMID 27847966). Other injury models do report VEGF upregulation, and BPC-157 modulates the nitric oxide system (eNOS and iNOS). Improved perfusion is the proposed route to faster healing in muscle, tendon, bone, and gut — all of that evidence is preclinical. ### [FOXO4-DRI: Senolytic Peptide Mechanism and the p53-FOXO4 Axis](https://peptpedia.org/research/foxo4-dri-senolytics) FOXO4-DRI is a D-retro-inverso peptide that selectively kills senescent cells by disrupting the protective FOXO4-p53 interaction. In senescent cells, FOXO4 binds and sequesters p53, preventing it from triggering apoptosis—this is how damaged cells survive despite accumulating stress. FOXO4-DRI competes for this binding, releasing p53 to execute apoptosis specifically in senescent cells. Normal cells, which do not rely on FOXO4-p53 binding for survival, are unaffected. This selective senolytic action clears the aged, pro-inflammatory cells that drive tissue dysfunction with aging. ### [How GHK-Cu Binds Copper and Changes Gene Expression](https://peptpedia.org/research/ghk-cu-biochemistry) GHK-Cu binds copper(II) in a stable 1:1 complex (glycyl-L-histidyl-L-lysine:copper) and thereby modulates expression of over 4,000 genes — about 32% of the human genome. Downstream effects in published work include upregulation of collagen I, III, and IV, increased decorin and glycosaminoglycans, suppression of TGF-β, TNF-α, and IL-6, and TIMP-1/MMP rebalancing in wound-healing models. Most of that evidence is preclinical or from small cosmetic trials rather than large controlled studies. ### [Semax and BDNF: Neurotrophin Signaling and Cognitive Enhancement Mechanisms](https://peptpedia.org/research/semax-bdnf-pathway) Semax enhances cognitive function primarily through upregulation of BDNF (brain-derived neurotrophic factor) and activation of TrkB receptor signaling in the brain. This ACTH(4-10) analog increases BDNF gene expression in hippocampus and prefrontal cortex, triggering downstream cascades including MAPK/ERK, PI3K/Akt, and PLCγ pathways that promote neuronal survival, synaptic plasticity, long-term potentiation, and neurogenesis. These molecular effects translate to improved memory consolidation, learning capacity, and neuroprotection against various insults. ### [How TB-500 Moves Repair Cells: Actin and Migration](https://peptpedia.org/research/tb-500-thymosin-beta4-actin-polymerization) TB-500 moves repair cells toward injury by sequestering G-actin, maintaining the monomer pool that drives cell motility. One caution before the mechanism: the name covers two molecules. The chemical record TB-500 resolves to (PubChem CID 62707662, CAS 885340-08-9) is the acetylated WH2 heptapeptide Ac-LKKTETQ, C38H68N10O14, ~889 Da; some suppliers and papers use TB-500 to mean synthetic full-length thymosin beta-4 (43 residues, C212H350N56O78S, ~4,963 Da). Both carry the WH2 actin-binding motif and are reported to activate ILK/Akt signaling for migration, survival, and angiogenesis — but almost all of that literature is on full-length Tβ4, and no published PK study characterizes the heptapeptide in humans. ### [Does Epithalon Activate Telomerase?](https://peptpedia.org/research/epithalon-telomerase-activation-telomere-biology) In published cell-culture work from Khavinson's group, Epithalon induced telomerase (hTERT) activity and measurable telomere elongation in human fetal fibroblasts. Independent replication is limited: nearly all of this evidence comes from one research lineage. The tetrapeptide (Ala-Glu-Asp-Gly) is modeled on pineal epithalamin; rodent studies from the same program report melatonin, antioxidant, and lifespan effects. ### [Retatrutide: Mechanistic Basis of Triple GLP-1/GIP/Glucagon Receptor Agonism and Metabolic Outcomes](https://peptpedia.org/research/retatrutide-triple-agonism-glp1-gip-glucagon) Retatrutide (LY3437943) is a once-weekly injectable peptide that simultaneously activates three metabolic hormone receptors: GLP-1R (glucagon-like peptide-1 receptor), GIPR (glucose-dependent insulinotropic polypeptide receptor), and GCGR (glucagon receptor). This tripartite agonism combines GLP-1's appetite suppression and gastric emptying delay, GIP's complementary insulinotropic and adipose effects, and glucagon's thermogenic and hepatic energy expenditure elevation into a single molecule. A Phase 2 trial published in the New England Journal of Medicine (2023) reported up to 24.2% mean body weight reduction at 48 weeks — the highest weight loss reported for a once-weekly injectable agent at the time. ### [Sermorelin Pharmacology: GHRH Receptor Binding, Pituitary Signaling, and Physiological Growth Hormone Restoration](https://peptpedia.org/research/sermorelin-ghrh-receptor-pharmacology) Sermorelin is a synthetic 29-amino acid peptide corresponding to the N-terminal fragment of human growth hormone-releasing hormone (GHRH 1-44). It binds the GHRH receptor (GHRHR) on somatotroph cells in the anterior pituitary with high affinity, activating the Gαs/adenylate cyclase/cAMP/PKA cascade that drives growth hormone (GH) gene transcription and pulsatile GH secretion into the portal and systemic circulation. Unlike exogenous GH administration, sermorelin preserves hypothalamic-pituitary feedback regulation, resulting in physiological — rather than supraphysiological — GH pulses modulated by endogenous somatostatin and IGF-1 negative feedback. ### [Thymosin Alpha-1: Thymic Immunomodulatory Peptide and T-Cell–Mediated Immune Enhancement](https://peptpedia.org/research/thymosin-alpha1-t-cell-immunomodulation) Thymosin Alpha-1 (Tα1) is a 28-amino acid thymic peptide (derived by proteolytic cleavage of prothymosin alpha) that functions as a broad immunomodulatory signal, primarily by activating dendritic cells and polarizing T-helper responses toward Th1 immunity through TLR-9/MyD88/NF-κB signaling. It upregulates MHC class II and co-stimulatory molecule expression on antigen-presenting cells, enhances IFN-γ production from effector T cells, and augments NK cell cytotoxicity. Approved as Zadaxin (thymalfasin) in multiple countries for hepatitis B, hepatitis C (in combination), and as a cancer adjuvant, Tα1 is one of the most clinically validated immunomodulatory peptides derived from the thymus. ### [How CJC-1295 DAC Extends Half-Life to 6–8 Days](https://peptpedia.org/research/cjc-1295-dac-albumin-binding-mechanism) CJC-1295 (GRF[1-29]-C8 with Drug Affinity Complex) extends the 7–10 minute plasma half-life of native GHRH 1-29 to 6–8 days by incorporating a maleimido-propionic acid (MPA) linker at the C-terminus that covalently reacts with Cys34 of serum albumin immediately after subcutaneous injection. This albumin conjugation protects the peptide from dipeptidyl peptidase-IV (DPP-IV) cleavage and renal filtration. Crucially, GH pulsatility is preserved even under sustained GHRH stimulation because endogenous somatostatin continues to periodically brake pituitary GH release. Clinical studies document 2–10-fold elevations in GH and IGF-1 lasting the full week between injections. ### [PT-141 (Bremelanotide) and Melanocortin Receptor Signaling: MC4R Activation, Sexual Motivation Pathways, and FDA Approval Evidence](https://peptpedia.org/research/pt-141-bremelanotide-melanocortin-mc4r-sexual-function) PT-141 (bremelanotide; Vyleesi®) is a cyclic heptapeptide melanocortin receptor agonist that activates MC1R, MC3R, and MC4R receptors in the central nervous system and peripheral tissues. Unlike PDE5 inhibitors (sildenafil, tadalafil) that act on vascular smooth muscle, bremelanotide acts centrally in the medial preoptic area, paraventricular nucleus, and limbic circuits to increase sexual motivation and arousal independent of genital vascular physiology. FDA-approved in 2019 for hypoactive sexual desire disorder (HSDD) in premenopausal women, bremelanotide represents the first approved treatment acting through the CNS melanocortin pathway for sexual dysfunction. ### [IGF-1 LR3: Long-R3 Modification, IGFBP Resistance, and Anabolic Signaling Cascade](https://peptpedia.org/research/igf-1-lr3-igfbp-resistance-anabolic-signaling) IGF-1 LR3 (Long-R3 Insulin-Like Growth Factor-1) is a synthetic 83-amino acid analog of human IGF-1 modified at two positions: an Arg substitution at position 3 (replacing Glu3) and a 13-amino acid N-terminal extension sequence. These modifications reduce binding affinity to all six insulin-like growth factor binding proteins (IGFBPs 1–6) by approximately 100-fold, while preserving high-affinity binding to the IGF-1 receptor (IGF-1R). Since ~97% of endogenous IGF-1 in circulation is sequestered in ternary complexes with IGFBP-3 and the acid-labile subunit (ALS), IGF-1 LR3's near-complete IGFBP resistance makes it substantially more bioavailable, extending its effective plasma half-life from ~15 minutes (native IGF-1) to approximately 20–30 hours. ### [LL-37 Cathelicidin: Innate Immunity, Amphipathic Helix Antimicrobial Mechanism, and Vitamin D-Regulated Immunomodulation](https://peptpedia.org/research/ll-37-cathelicidin-innate-immunity-antimicrobial-mechanism) LL-37 is the sole human member of the cathelicidin antimicrobial peptide (AMP) family, produced by proteolytic cleavage of the 18 kDa precursor hCAP18 (encoded by the CAMP gene) by serine proteases in neutrophil granules and on epithelial surfaces. Its 37-amino acid sequence (beginning with two leucines — hence 'LL-37') adopts a cationic amphipathic alpha-helical conformation in the presence of bacterial membranes, enabling electrostatic targeting of negatively charged lipopolysaccharide (LPS)-rich gram-negative and teichoic acid-rich gram-positive bacterial membranes. Beyond direct antimicrobial activity, LL-37 modulates innate immune signaling by dampening excessive TLR4/LPS responses, stimulating chemokine release (IL-8, MCP-1) for neutrophil recruitment, and activating FPR2/FPRL-1 receptors on macrophages and epithelial cells to promote wound healing. ### [Kisspeptin and GPR54/KISS1R Signaling: Hypothalamic Control of the GnRH Pulse Generator and Reproductive Endocrine Axis](https://peptpedia.org/research/kisspeptin-gpr54-gnrh-reproductive-axis) Kisspeptin is a family of hypothalamic neuropeptides (kisspeptin-54, -14, -13, -10) encoded by the KISS1 gene and processed from a 145-amino acid precursor. All kisspeptin isoforms share a C-terminal decapeptide (kisspeptin-10) that is fully sufficient for GPR54/KISS1R receptor activation. GPR54 is a Gq/11-coupled GPCR expressed on GnRH (gonadotropin-releasing hormone) neurons, and kisspeptin binding activates the PLC/IP3/DAG/calcium signaling cascade, depolarizing GnRH neurons and triggering pulsatile GnRH release into the hypothalamo-hypophyseal portal circulation. This kisspeptin-GPR54-GnRH axis is the indispensable 'gate' for puberty initiation, gonadal steroid feedback integration, and fertility — established by two landmark 2003 studies showing that loss-of-function GPR54 mutations cause idiopathic hypogonadotropic hypogonadism (IHH) in humans. ### [Dihexa and the HGF/c-Met Synaptogenesis Pathway: Mechanism, Evidence, and Limitations](https://peptpedia.org/research/dihexa-hgf-cmet-synaptogenesis) Dihexa is a peptidomimetic that enhances cognitive function by allosterically potentiating hepatocyte growth factor (HGF) binding to the c-Met receptor, promoting synaptogenesis at picomolar concentrations. Unlike direct receptor agonists, Dihexa amplifies endogenous HGF signaling rather than replacing it. Preclinical studies show improvements in spatial learning and memory in aged and cognitively impaired rodents. However, the foundational evidence base has significant integrity concerns — the landmark McCoy 2013 paper has an Expression of Concern, and the Benoist 2014 follow-up was retracted in 2025. An independent 2021 replication by Sun et al. provides supporting evidence from outside the original research group. ### [FOXO4-DRI Preclinical Evidence and Translational Challenges: From Mouse Models to Clinical Reality](https://peptpedia.org/research/foxo4-dri-preclinical-translation) FOXO4-DRI demonstrated selective senolytic activity in the landmark Baar et al. 2017 Cell study, with subsequent independent confirmations in human chondrocytes (Huang 2021), mouse Leydig cells (Zhang 2020; Li 2024), pulmonary fibrosis models (Han 2022; Liu 2023), keloid fibroblasts (Kong 2025), and endothelial cells (Hu 2025). However, significant translational barriers remain: no human pharmacokinetic data, high synthesis cost, unknown long-term safety, and the absence of clinical trials. Meanwhile, the broader senolytic field has advanced — dasatinib+quercetin has completed multiple human trials including Phase 2 in Nature Medicine (Farr 2024). FOXO4-DRI's theoretical selectivity advantage over small-molecule senolytics has not been tested in humans. ### [FOXO4-DRI Research Dosing: Every Published Protocol (2026)](https://peptpedia.org/research/foxo4-dri-dosage-protocol) There is no human FOXO4-DRI dose, because the peptide has never been tested in people. The animal literature is unusually consistent, though: nearly every published in vivo study used 5 mg/kg per injection, given three times on alternate days (days 1, 3, and 5, or days 14, 16, and 18 in the pulmonary fibrosis model), with effects tracked over the following three to four weeks. In cell culture, 25 μM applied for three to five days is the standard working concentration. Everything below is drawn from the published studies themselves; anything you read elsewhere that goes further is extrapolation, not evidence. ### [FOXO4-DRI Human Trials: Status, Evidence Gaps, and What to Watch (2026)](https://peptpedia.org/research/foxo4-dri-human-trials) As of July 2026, no human trial of FOXO4-DRI has ever been registered or published. ClinicalTrials.gov, the registry where any legitimate trial must appear before enrollment, returns zero studies for the compound, and no trial report exists in the PubMed literature. Everything currently claimed about FOXO4-DRI rests on roughly a dozen animal and cell-culture studies. This article walks through what that evidence actually is, why no trial has started, and what would count as real progress. ### [FOXO4-DRI Safety and Side Effects: What the Evidence Shows (2026)](https://peptpedia.org/research/foxo4-dri-safety) In the published mouse studies, FOXO4-DRI caused no reported side effects: treated animals kept their weight, blood counts, and organ markers while senescent cells were cleared, and the peptide spared healthy cells in culture. But that entire safety dataset is three small animal studies with no formal toxicology arm, no dose escalation, no repeat dosing, no long-term follow-up, and nothing in humans. One 2023 study in Circulation even found that clearing senescent cells, including with FOXO4-DRI, worsened pulmonary hypertension in rodents. This page separates what is documented from what is merely assumed. ### [Liraglutide Pharmacology: GLP-1 Receptor Binding, C16 Palmitate Albumin Anchoring, and the Pharmacokinetic Basis of Once-Daily Incretin Therapy](https://peptpedia.org/research/liraglutide-glp1-receptor-pharmacology) Liraglutide is a 31-amino acid GLP-1 analog sharing 97% sequence identity with human GLP-1, modified by a Lys³⁴Arg substitution and a C16 palmitoyl chain attached to Lys²⁶ via a γ-glutamate spacer. The fatty acid anchors the peptide to serum albumin, slowing subcutaneous absorption, shielding it from DPP-4 degradation, and extending its half-life to 13 hours — sufficient for once-daily administration. ### [Melanotan II Pharmacology: A Non-Selective Cyclic Melanocortin Agonist at MC1R, MC3R, and MC4R](https://peptpedia.org/research/melanotan-ii-melanocortin-receptor-pharmacology) Melanotan II is a synthetic lactam-bridged cyclic heptapeptide analog of α-MSH(4-10) that non-selectively activates melanocortin receptors. MC1R activation on melanocytes drives eumelanin synthesis and tanning; MC3R/MC4R activation in the hypothalamus produces pro-erectile and anorexigenic effects. Its unapproved status and case reports of eruptive atypical nevi define a significant unresolved safety profile. ### [Tesamorelin Pharmacology: A Stabilized GHRH(1-44) Analog for Endogenous GH Axis Stimulation and Visceral Adipose Reduction](https://peptpedia.org/research/tesamorelin-ghrh-analog-pharmacology) Tesamorelin is a synthetic 44-amino acid analog of human growth hormone-releasing hormone, stabilized by a trans-3-hexenoyl group attached to Tyr¹ that confers resistance to DPP-IV cleavage. It activates pituitary GHRH receptors, stimulating pulsatile endogenous GH secretion and raising IGF-1. In phase 3 trials, 2 mg daily reduced visceral adipose tissue by 15–18% over 26–52 weeks in HIV-associated lipodystrophy. ### [Cerebrolysin Pharmacology: A Porcine Brain-Derived Peptide Mixture with Neurotrophic-Like Activity](https://peptpedia.org/research/cerebrolysin-neurotrophic-peptide-mixture-pharmacology) Cerebrolysin is an enzymatically prepared mixture of low-molecular-weight peptides and free amino acids derived from porcine brain, pharmacologically standardized for neurotrophic-like activity rather than defined as a single molecule. It modulates neurotrophin systems — normalizing pro-NGF/NGF balance and protecting cholinergic neurons in transgenic models — with mixed clinical evidence: positive Alzheimer's meta-analyses but a neutral pivotal stroke trial.